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Abstract

NEUROPROTECTIVE EFFECTS OF POSTINJURY LITHIUM TREATMENT:
DETERMINING THE OPTIMAL DOSING PARADIGM AND ASSESSING POTENTIAL
MECHANISMS OF ACTION
By Katharine Coryell Eakin, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Robert J. Hamm, Ph.D.,
Professor Emeritus
Department of Psychology
Traumatic brain injury (TBI) has a dramatic impact on our society in terms of mortality,
morbidity, and inherently high financial costs. Formidable research efforts are being addressed
to the identification of neuroprotective agents capable of ameliorating the neurological outcome
after TBI. Preclinical studies have recently demonstrated lithium to be a promising
neuroprotective agent for both acute ischemic brain injury and chronic neurodegenerative
disease. In light of these encouraging data, we designed a lateral fluid-percussion injury (FPI)
study aimed at investigating the role of early post-traumatic administration of lithium as a
strategy for reducing TBI-induced motor and cognitive deficits. The optimal dose of this agent
and the time window for its administration have been determined on the basis of data derived
from the assessment of motor and cognitive functioning in experimental animals, as well as from

xxv

the stereological quantification of neuronal survival (PID 7) within the CA3 and hilar regions of
the hippocampus ipsilateral to the FPI. In addition, we attempted to elucidate the
mechanisms underlying the neuroprotective properties of this drug via western blot analysis of
levels of the pro-apoptotic marker caspase-3 (PID 1, 7) and two neuroplasticity markers, growth
associated protein-43 (GAP-43) and brain-derived neurotrophic factor (BDNF) (PID 1, 7, 21).
Our findings indicate that low-dose lithium chloride (0.125 or 0.25 mmol/kg), given
either 30 min or 8 hr after lateral FPI significantly ameliorates injury-induced cognitive and
motor impairment. Specifically, cell survival in the CA3 region of the hippocampus of the
injured lithium-treated animals (but not in the hilus) was significantly increased compared to
injured vehicle-treated animals. Western blot analyses revealed a significant increase in GAP-43
levels on PID 7 in injured animals when treated with lithium, indicating a possible mechanism
for lithium-induced neuroprotection. In contrast, BDNF levels were relatively unchanged until
PID 21, and caspase-3 activation was not observed at all, suggesting that these proteins play less
significant roles in the observed neuroprotective effects of lithium treatment after lateral FPI.
Early administration of lithium, within 8 hours after TBI, holds promise as an effective therapy
to ameliorate postinjury neurobehavioral deficits and warrants further investigation in clinical
TBI studies.
Keywords: lithium, traumatic brain injury, TBI, cognitive function, vestibulomotor
function, depression, forced swim test, beam walk, neuroprotection, hippocampus, CA3, hilus,
BDNF, GAP-43, caspase-3, preclinical, translational research, Morris water maze, MWM.

Neuroprotective Effects of Postinjury Lithium Treatment: Determining the Optimal Dosing
Paradigm and Assessing Potential Mechanisms of Action

Traumatic Brain Injury
Epidemiology. TBI represents a major public health problem in the United States. TBI
is one of the leading causes of preventable mortality and morbidity among children, young adults
and the elderly (Langlois, Rutland-Brown, & Thomas, 2004; Sosin, Sniezek, & Thurman, 1996;
Thurman et al., 1999).
According to the Centers for Disease Control and Prevention (CDC), approximately 1.4
million Americans sustain a TBI each year. To put the magnitude of this number into
perspective, there are more new cases of TBI each year than breast cancer (212,920) (American
Cancer Society) and HIV/AIDS (43,700) combined. Of these 1.4 million, approximately 1.1
million will receive care from an emergency department (ED), 230,000 will require
hospitalization, and 50,000 will die. The most common causes of TBI are falls (28%), motor
vehicle accidents (20%), “struck by/against” events (19%), and assault (11%) (Langlois et al.,
2004).
Incidence of TBI is highest in children (0-4 years), young adults (15-19 years), and older
adults (>75 years). In almost every age group, males are about 1.5 times more likely than
females to incur TBI, possibly due to a higher incidence of motor vehicle accidents, use of
firearms, and risk-taking behavior among males (Langlois et al., 2004). Additionally, in the
young adult population (15-24 years), mortality rates for males are 3.6 times higher than for
females.
TBI survivors may suffer enduring physical, emotional, cognitive and behavioral changes
that significantly interfere with daily functioning. Recent epidemiologic data from the CDC
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indicate that 80,000-90,000 individuals become disabled from TBI each year. A conservative
estimate is that 5.3 million Americans currently live with long-term disabilities due to TBI,
accounting for 2% of the total population (Langlois et al., 2004; Thurman, Alverson, Dunn,
Guerrero, & Sniezek, 1999). Functional impairment may also occur following mild brain injury,
and it is estimated that 25% to 35% of individuals will continue to present cognitive and
emotional difficulties when re-evaluated at 3 and 6 months from the time of injury.
In addition to the physical, psychosocial and vocational disabilities caused by TBI, the
related long-term morbidity may place a dramatic financial burden on the individual, his or her
family, workplace, and society. The direct and indirect costs associated with TBI in the U.S. are
estimated to be $60 billion annually (Finkelstein E, Corso P, Miller T and associates. The
Incidence and Economic Burden of Injuries in the United States. New York (NY): Oxford
University Press; 2006.), and the lifetime cost for one person surviving a severe TBI can reach
$4 million (Langlois et al., 2004).
Biomechanics of TBI. TBI can result from rapid acceleration or deceleration of the head
and neck, blunt trauma to the head caused by an object striking the head, or an object penetrating
the skull (McIntosh et al., 1996; Povlishock & Christman, 1994). Holbourn (1943) was the first
to describe the effects of shearing strains, specifically rotational acceleration forces, as a primary
cause of predictable injury in the brain. The effect of acceleration or deceleration forces on the
brain is varied and largely depends on the presence of rotational forces applied to the head and
neck. Individuals who sustain a sagittal (front to back) injury have the greatest likelihood of
recovery, lateral (side to side) injuries have the worst percentage for recovery, and oblique injury
outcomes are somewhere in between (McIntosh et al., 1996). These forces are sufficient to
produce brain injury without any accompanying contact injury.
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The mechanical forces that produce TBI can be attributed to either static or dynamic
loading. In order to assess the severity of a TBI resulting from dynamic loading, it is important
to account for inertial, acceleration and impact forces. The greater the force acting on the head
and neck, the more damage is inflicted (Gaetz, 2004; Ommaya & Gennarelli, 1974). By
understanding the biomechanical events associated with TBI, researchers are better able to
replicate injuries in animal models, and this might ultimately lead to the development of new
treatments for TBI.
Static loading. Static loading occurs when forces are applied to an unmoving head over
an extended time course (greater than 200 ms) and generally produces multiple, comminuted, or
eggshell fractures of the skull. This type of mechanical force does not normally produce the
characteristic symptoms commonly associated with TBI, and neurological signs such as coma
are not generally seen unless the force is sufficient to cause deformation of the skull and brain
tissue (Graham, McIntosh, Maxwell, & Nicoll, 2000).
Dynamic loading. Dynamic loading is the mechanical force that is most commonly
associated with the typical sequelae of TBI. Dynamic loading generally occurs in a much faster
timeframe compared to static loading (less than 50 ms). Dynamic loading can be further
classified as either impact or impulsive (Graham et al., 2000; McIntosh et al., 1996).
Impact loading. Impact loading occurs when a blunt object strikes the head, typically
producing both contact- and inertial-related injuries. The amount of damage produced is directly
related to the amount of force applied to the skull. Contact forces can generate stress waves that
radiate through the skull and can cause additional skull fractures distant from the point of impact
(Graham et al., 2000; McIntosh et al., 1996).
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Impulsive loading. Impulsive loading occurs when the head is set into motion or when a
moving head is suddenly stopped, either without striking anything or by contact with an object.
This type of injury can be produced when the head moves indirectly as a result of impact to
another part of the body (McIntosh et al., 1996). Primary damage to the brain parenchyma is
caused by non-uniform distribution of pressure and strain (Graham et al., 2000; McIntosh et al.,
1996). Biological tissue is more resilient to slower strains as compared to fast strains (Graham et
al., 2000).
Primary and secondary brain injury. Historically, the pathophysiology of TBI has
been characterized by two distinct phases: primary and secondary injury. Primary injury consists
of the immediate craniocerebral damage (i.e., injury to the skull, brain or both) that occurs at the
moment of the initial impact, and is classically distinguished into two components, focal
(cerebral contusion, laceration, rupture of intracranial vessels) and diffuse (traumatic axonal
injury (TAI), diffuse microvascular injury) (Graham et al., 2000; McIntosh et al., 1996;
Povlishock & Becker, 1985), although both may coexist to varying degrees (Graham et al., 2000;
Povlishock & Katz, 2005).
Secondary injury can be described as a dynamic process of neuronal dysfunction
eventually culminating in cell death, triggered by the activation of a cascade of complex and
interrelated neurochemical events that initiate in the immediate post-traumatic period. This
process, which evolves in the hours and days following the initial traumatic event, is responsible
for progressive neurological impairment and may significantly alter prognosis. Therefore, an
understanding of the biomolecular mechanisms underlying this secondary process of neuronal
demise and the development of effective therapeutic strategies capable of arresting it has become
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a focus of intense research activity over the last two decades, both in the clinical and preclinical
setting.
One of the most important concepts emerging from this research is that a lack of oxygen
supply to the brain (i.e., hypoxia) is the key factor initiating the cascade associated with the
development of the secondary brain injury. Therefore, prevention or prompt recognition and
treatment of factors such as hypotension and increased intracranial pressure (ICP) that lead to
decreased oxygen delivery to the injured brain appear to be crucial to a good neurological
outcome. Increase in intracranial pressure is related to several factors such as brain edema (both
cytotoxic and vasogenic), hydrocephalus, and intracranial mass (brain contusion or
intraparenchymal hematoma). Hypoxic events lead to the production of free radicals, disruption
of intracellular calcium, release of cytochrome c from mitochondria, and initiation of apoptotic
cascades(Gaetz, 2004; McIntosh et al., 1996; Merenda & Bullock, 2006).
Focal injury. Primary focal injury such as a missile (e.g., gunshot wound) or penetrating
wound is characterized by the presence of contusions or direct disruption of brain tissue and can
include hemorrhage and hematomas in the epidural, subdural, subarachnoid, and
intraparenchymal areas (Gaetz, 2004; Gennarelli, 1993). Secondary damage from focal injuries
includes delayed neuronal injury to neighboring regions, microvascular injury, focal ischemichypoxic injury, herniation, and regional and diffuse hypometabolism. Focal injuries produce
regions of significantly reduced cerebral blood flow creating ischemic conditions that promote
inflammation and cytotoxicity in addition to neuronal necrosis (Bullock, Maxwell, Graham,
Teasdale, & Adams, 1991; Gaetz, 2004).
Contusions. The presence of a contusion is extremely common in patients with focal
TBI; however, TBI can occur without contusion. Contusions cannot be used as an explanation
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for loss of consciousness at the time of injury or as a factor in the maintenance of a comatose
state, but they are linked to focal seizures and/or functional deficits in the language centers of the
brain (Povlishock & Christman, 1994; Ribas & Jane, 1992). In most cases, contusions are the
byproduct of hemorrhagic lesions within the gray matter or at the gray-white interface and
contribute to neuronal damage and ischemia (Povlishock & Katz, 2005). Contusions are most
commonly located on the frontal and temporal poles, the lateral and inferior surfaces of the
frontal and temporal lobes, and above the Sylvian fissure (Gaetz, 2004; Gennarelli & Graham,
1998; Gurdjian, 1976; McIntosh et al., 1996; Povlishock & Christman, 1994). They are
commonly seen at the apex of gyri and can appear as punctate hemorrhages or streaks of
hemorrhage usually accompanied by progressive bleeding into adjoining white matter
(Gennarelli & Graham, 1998).
There are several types of contusions, including coup contusions that occur directly
beneath skull fractures, contracoup contusions that occur some distance (not always directly
opposite) from the fracture, and gliding contusions. Gliding contusions are most likely to be
associated with diffuse brain injury and are produced by cortical gray matter moving in
opposition to the underlying white matter causing shearing strains that damage the penetrating
vessels located at the gray/white interface, producing hemorrhagic lesions in the parasagittal
cortex (Adams, Doyle, Graham, Lawrence, & McLellan, 1986; Povlishock & Christman, 1994).
In addition, nonhemorrhagic contusions may be identified using MRI. These lesions are not
associated with hemorrhage but are located on the cortical surface where one would expect to see
“traditional” contusions. Another type of nonhemorrhagic contusion is identified within the
subcortical white matter, leaving the superficial cortex unharmed. These lesions are associated
with shearing forces and diffuse axonal injury (Povlishock & Christman, 1994).
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Hematomas. There are several kinds of hematomas, including intraparenchymal
hematoma, epidural hematoma, and acute subdural hematoma (Gaetz, 2004; Gennarelli &
Graham, 1998; Povlishock & Christman, 1994). One possible explanation for the formation of
hematomas is the rupturing of cerebral arterioles caused by the shearing and tensile forces
generated by the injury (Povlishock & Christman, 1994). Intraparenchymal hematomas are
located deep within the parenchyma and are associated with rupture of a blood vessel. Epidural
hematomas are most commonly associated with a skull fracture. Acute subdural hematomas are
caused by the rupturing of bridging veins beneath the dura or cortical arteries (Gennarelli &
Graham, 1998). Cerebral hematomas are usually formed at the time of injury; however, there is
evidence that delayed hematoma formation may occur in patients with injuries ranging from mild
to severe (Povlishock & Christman, 1994; Soloniuk, Pitts, Lovely, & Bartkowski, 1986).
Hematoma and contusion are associated with secondary ischemic damage and subsequent
necrosis from mass effect from blood that affects the adjacent tissue (Gennarelli & Graham,
1998).
Diffuse injury. Primary diffuse injury consists of diffuse axonal injury (DAI) and
petechial white matter hemorrhage. Secondary diffuse injury is associated with delayed neuronal
injury, microvascular injury, diffuse hypoxic-ischemic injury (HII), and diffuse hypometabolism
(Povlishock & Katz, 2005). In addition to secondary injuries, delayed pathology resulting from
brain injury can lead to DAI, which is characterized by axonal swelling and degradation
followed by axonal separation from its downstream segment and characteristic formation of a
retraction bulb (Povlishock & Christman, 1995). Diffuse cell death is among the sequelae
commonly observed following TBI and can be attributed to one of two morphologically distinct
processes: apoptotic and necrotic.
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Necrosis. Necrotic cell death occurs following degradation of the cell membrane and
disruption of ionic homeostasis leading to the rapid destruction of the cytoskeleton and
cytoplasmic components (Povlishock & Katz, 2005). Rapid cell death is linked to the activation
of the cysteine proteases calpain and caspase, causing degeneration and increased porosity of the
plasma membrane and leakage of cell contents into the extracellular space (Rowe & Chuang,
2004).
Apoptosis. Apoptosis is programmed cell death from internal mechanisms. Unlike
necrosis, apoptosis does not require disruption of the cell membrane. Apoptotic events are
mediated by internucleosomal DNA strand breaks with nuclear condensation that cause the cell
to slowly die (Povlishock & Katz, 2005). Apoptotic cells are characterized by dense packing of
cellular material into apoptotic bodies that are subsequently phagocytized (Rowe & Chuang,
2004). Trauma-induced apoptosis has many mitigating factors, including excessive
neuroexcitation via excitatory amino acids (EAA) (e.g., glutamate, aspartate, NMDA, AMPA),
decreased ATP level, radical-mediated injury, ionic imbalance (e.g., dysregulation of calcium
homeostasis), aberrant proteolytic enzyme activity, dysregulation of pro-apoptotic genes (e.g.,
Bcl-2), and traumatic axonal injury (Ansari, Roberts, & Scheff, 2008; Povlishock & Katz, 2005;
Raghupathi, 2004; Raghupathi, Graham, & McIntosh, 2000; Yakovlev & Faden, 2004).
Traumatic axonal injury / diffuse axonal injury. DAI was first described by Strich in
1956. Originally, the pathogenesis was assumed to be tearing of axons throughout the brain
caused by shearing forces generated at the time of injury. This hypothesis was based on the
observation that the injured axons appear reactive and swollen when visualized postmortem
using histological techniques (Adams, Graham, Murray, & Scott, 1982; Strich.S.J., 1956).
However, subsequent research has shown that DAI is not the result of immediate shearing of
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axons, since reactive axons are undetectable using histological techniques unless the patient
survives for a minimum of 12 hours postinjury (Pilz, 1983). Instead, DAI is a dynamic and
evolving process that can continue for months postinjury. DAI is characterized by disruption of
the neurofilament and cytoskeletal network allowing accumulation of typically excluded ions
and neurofilament compaction, in addition to damaged mitochondria within the axon. All of this
leads to Wallerian degeneration, the reactive swelling and detachment of the axon segment
downstream from the point of injury forming characteristic retraction bulbs. Damaged axons can
be found throughout the subcortical white matter, basal ganglia, diencephalon, and all areas of
the brainstem. Interestingly, these damaged neurons are typically observed next to healthy axons
and can also be found running along healthy microvessels. However, damaged axons can also be
found in foci of petechial hemorrhaging or in the area surrounding a hematoma (Povlishock &
Christman, 1994). Other aspects commonly associated with DAI are edema, petechial
hemorrhages, non-hemorrhagic macroscopic white matter lesions, and small subarachnoid and
intraventricular hemorrhages (Povlishock & Katz, 2005).
Generalized changes. In addition to the characteristic changes of focal and diffuse brain
injury, there a number of generalized changes that occur following TBI, including alterations in
the permeability of the blood brain barrier (BBB), neurotransmitter responses, carbon dioxide
(CO2) levels, and cerebral blood flow (Povlishock & Christman, 1994).
Findings from clinical studies have found elevated neurotransmitter levels in the cerebral
spinal fluid (CSF) of brain-injured patients. Studies have also shown that increases in the levels
of EAAs such as glutamate and aspartate in the extracellular fluid surrounding the contusion area
can remain elevated for as many as four days after injury (Povlishock & Christman, 1994). EAA
release is determined by the severity of the initial injury combined with any secondary events
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that may have occurred prior to stabilization at a hospital (Zauner & Bullock, 1995). Most of the
research supporting the presence of generalized changes comes from preclinical studies and will
be discussed in greater detail in the experimental TBI section.
Neurotransmitters involved in TBI pathology. Following TBI, multiple
neurotransmitter systems are affected and changes can persist for years following the insult. A
brief discussion of each of the neurotransmitters involved in TBI pathology follows, as well as a
description of the effects of lithium treatment. The neurotransmitters that are affected by both
TBI and lithium include: serotonin (5-HT), glutamate, γ-aminobutyric acid (GABA),
norepinephrine (NE), dopamine (DA), and acetylcholine (ACh) (Faden, Demediuk, Panter, &
Vink, 1989; Fonseca, Sierra, Geraldes, Cerdan, & Castro, 2009; Hamill, Woolf, McDonald, Lee,
& Kelly, 1987; Hayes, Jenkins, & Lyeth, 1992; O'Dell, Gibson, Wilson, DeFord, & Hamm,
2000; Rowe & Chuang, 2004; Shaldubina, Agam, & Belmaker, 2001; Verbois, Sullivan, Scheff,
& Pauly, 2000).
Serotonin. 5-HT is released by presynaptic serotonergic neurons and activates specific
postsynaptic receptors, mostly affecting the 5-HT2 subgroup of 5-HT receptors. 5-HT also
activates presynaptic autoreceptors. These subgroups of receptors are known as 5-HT1A or 5HT1B and they decrease the amount of 5-HT released per nerve impulse via an inhibitory
feedback loop. 5-HT1A autoreceptors are localized on the soma and dendrites of serotonergic
neurons and 5-HT1B autoreceptors are located on the terminal boutons of presynaptic
serotonergic neurons. Levels of this neurotransmitter can be modulated by preventing the
breakdown of 5-HT via monoamine oxidase inhibition or by preventing the reuptake of 5-HT
from the synaptic cleft via blockade of autoreceptors on the presynaptic neuron. The discovery
of the therapeutic benefits of 5-HT modulation in the treatment of mental illness has lead to
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intensive study and subsequent discovery of its involvement in brain activity for sleep regulation,
sexual activity, depression, and anxiety, as well as the perception of hunger and satiety (Zafonte,
Cullen, & Lexell, 2002).
There is substantial evidence that 5-HT plays a significant role in the pathogenesis of
TBI. Pharmacological treatments that target 5-HT have been shown to significantly improve
outcome following TBI. Reduction in the metabolites of 5-HT have been found in the CSF of
patients with TBI (Markianos, Seretis, Kotsou, & Christopoulos, 1996; Zafonte et al., 2002).
Major depression is one of the most prevalent co-morbid conditions reported by individuals
following TBI (Rosenthal, Christensen, & Ross, 1998). A study by Kreutzer, Seel, and Gourley
(2001) investigating the prevalence of depression following TBI reported that 42% of individuals
met the American Psychiatric Association’s requirements for diagnosis with depression, as
outlined in the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV, 1994) (4th
ed.; DSM–IV; American Psychiatric Association, 1994). In clinical studies, selective
serotonergic reuptake inhibitors (SSRI) were administered to patients diagnosed with depression
resulting from a TBI, and improvements were found in neuropsychological assessment of
psychomotor speed, recent verbal memory, recent visual memory, and general cognitive
efficiency (Fann, Uomoto, & Katon, 2001; Zafonte et al., 2002), as well as normalization of
mood swings (e.g., crying or laughing spells) (Nahas, Arlinghaus, Kotrla, Clearman, & George,
1998; Zafonte et al., 2002).
Glutamate. Glutamate is the primary excitatory neurotransmitter in the brain. It is
important in synaptic plasticity, neuronal migration during development, neuronal viability, and
long-term potentiation (LTP) (Lu, Roder, Davidow, & Salter, 1998; Schumann, Alexandrovich,
Biegon, & Yaka, 2008). In the acute phase following TBI, increases in extracellular glutamate
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have been observed both in animal models and in human patients (Bullock et al., 1995;
Schumann et al., 2008). Release of glutamate activates ionotropic and metabotropic receptors,
particularly the ionotropic N-methyl-D-aspartate (NMDA) receptor with its NR2A and NR2B
subunits. In non-injured brains, the NMDA receptor is crucial for the initiation of LTP in both
the hippocampus and the cortex (Lu et al., 1998; Rosenblum, Dudai, & Richter-Levin, 1996;
Schumann et al., 2008). Injury-induced hyperactivation of NMDA receptors allows calcium
levels to reach toxic levels, and calcium is among the key mediators of cell death initiated by
secondary injury.
γ-Aminobutyric acid (GABA). GABA is the primary inhibitory neurotransmitter in the
brain and is responsible for maintaining control over excitatory feedback loops. Following TBI,
modulation of GABA receptors can produce markedly different outcomes depending on the time
point and duration of postinjury treatment. In a rat weight-drop model of diffuse brain injury,
levels of GABA metabolites were significantly increased at 24 and 48 hours postinjury (Pascual
et al., 2007), corresponding to the timeframe of the hypofunctional state in the biphasic
hypothesis of secondary brain injury. The drug diazepam, a benzodiazepine and indirect
GABAA agonist, has been found to significantly impair motor recovery following daily shortterm administration beginning 12 hours post-lesion (Schallert, Hernandez, & Barth, 1986).
However, administration of diazepam either 15 min prior to or 15 min after central fluid
percussion injury was found to reduce mortality rates and improve performance in the Morris
water maze (MWM) compared to untreated injured animals (O’Dell, Gibson, Wilson, DeFord, &
Hamm, 2000). Likewise, administration of the GABAA antagonist bicuculline 15 min after TBI
significantly increased the latency to reach the goal platform as compared to injured saline-
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treated animals (O'Dell et al., 2000). These studies show that increasing the activity of inhibitory
pathways may be neuroprotective in the acute phase of secondary injury.
Norepinephrine. Catecholamines are important in the normal functioning of the
prefrontal cortex (PFC), particularly in the case of working memory (Goldman-Rakic, Muly, III,
& Williams, 2000). In clinical studies, serum levels of NE have been correlated with injury
severity, with higher concentration of NE corresponding to a greater severity of injury (Clifton,
Ziegler, & Grossman, 1981; Hamill et al., 1987). NE levels were found to be increased in the
hypothalamus at 1 hr and 1 week after fluid-percussion injury (FPI) (McIntosh, Yu, &
Gennarelli, 1994). Additionally, using the CCI impact model, NE levels were increased in the
medial PFC (MPFC) at 7 and 14 days postinjury (Kobori, Clifton, & Dash, 2006).
Dopamine. DA is a key mediator in neurological functioning following TBI. DA
agonists administered in the hypofunctional chronic phase postinjury have been shown to
improve cognitive outcome following TBI in experimental and clinical settings (Gualtieri, 1988;
Kline, Yan, Bao, Marion, & Dixon, 2000; Whyte, Vaccaro, Grieb-Neff, & Hart, 2002). Both the
D1-R and D2-R subtypes are involved in memory dysfunction following brain injury. Longterm memory dysfunction has been attributed to depleted dopamine levels in the hippocampus
(Tang, Noda, Hasegawa, & Nabeshima, 1997). Catecholamines in the PFC are necessary for
regulating aspects of cognitive functioning such as working memory and attention (GoldmanRakic et al., 2000). The PFC is known to be particularly vulnerable to TBI and injury-induced
disturbances to the DA system are related to impaired cognitive functioning (Massucci, Kline,
Ma, Zafonte, & Dixon, 2004; Mattson & Levin, 1990; McDowell, Whyte, & D'Esposito, 1997;
Sawaguchi & Goldman-Rakic, 1991).
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Acetylcholine. The medial PFC and hippocampus are innervated by the cholinergic
basal forebrain complex and are involved in cortical arousal, consciousness, memory and
learning (Brand, Groenewald, Stein, Wegener, & Harvey, 2008; Picciotto, Brunzell, &
Caldarone, 2002; Sarter & Bruno, 2000). The involvement of ACh in TBI has been well
established. Regional and temporal changes in ACh levels and its synthesizing enzyme choline
acetyltransferase (ChAT) have been reported following TBI (Donat et al., 2008; Saija et al.,
1988). Fluctuations in ACh levels of up to 50% have been reported immediately postinjury. In
the hippocampus there is a significant decline in cholinergic activation at 1 hour, persisting for
up to 21 days postinjury (Verbois et al., 2000).
Human TBI outcome. Individuals who have sustained a TBI are likely to suffer
cognitive and/or behavioral impairments following the injury. In minor head injuries, accounting
for 75% of the total number of TBI’s per year, the most common clinical syndrome seen after
injury is brain concussion. Many patients with mild TBI develop what is known as postconcussion syndrome, marked by disabilities due to cognitive impairment or psychological
sequelae for variable periods of time. TBI patients who suffer a moderate to severe injury
usually experience unconsciousness and/or post-traumatic amnesia (PTA) following TBI
(Povlishock & Katz, 2005). PTA is commonly observed following moderate and severe injury,
but individuals with mild injury may also experience PTA. PTA is associated with two types of
memory impairment: retrograde and anterograde amnesia. Permanent memory loss is associated
with severe head injuries.
Retrograde amnesia. Retrograde amnesia is the inability to recall events prior to the
traumatic event. Most retrograde amnesia cases follow Ribot’s law, which states that the closer
temporally a memory is to the traumatic event, the more susceptible it is to disruption by TBI.
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Recovery from retrograde memory loss begins with more remote memories and typically only
the moments immediately prior to injury remain lost. Usually the period of permanent memory
loss can be measured in minutes, although in rare cases memory loss of 2 or more days prior to
the traumatic event can occur (Capruso & Levin, 1992).
Anterograde amnesia. Anterograde amnesia is the inability to form new memories
following the traumatic event. In severe head injury, typically following recovery from coma,
individuals may experience a confusional state accompanied by anterograde amnesia. The
hallmark of anterograde amnesia is disorientation. Individuals with this type of memory loss can
also exhibit other symptoms of confusion such as deficits in attention, agitation, combativeness,
hypokinetic or hyperkinetic behavior, inappropriateness, disinhibition, and severe perseveration.
Recovery from anterograde amnesia typically follows a set sequence: first, orientation to person;
second, orientation to place; and third, orientation to time (Capruso & Levin, 1992).
The frontal cortex is highly susceptible to TBI-induced pathology. Executive functioning
(e.g., information processing, memory, and attention), controlled by the dorsolateral PFC
(DLPFC) is frequently impaired, even following mild injury (Lipton et al., 2009). In a recent
study, diffusion-tensor imaging was used to evaluate the relationship between post-TBI structural
changes and performance on neuropsychological assessment in the continuous performance and
executive maze tasks. Patients with mTBI performed worse compared to healthy controls in
overall performance on both tests. Additionally, lower fractional anisotrophy, an indicator of
axonal injury, was predictive of poorer performance on measures of executive functioning
(increased errors of omission in the continuous performance task and increased number of trials
and errors in the executive maze) in mTBI patients (Lipton et al., 2009). The frontal cortex
oversees and regulates many important aspects of life such as motivation for self-initiated
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behavior and the regulation, initiation, and planning of behavior. Long-term attentional deficits
after TBI are reported to be a significant problem by both individuals with TBI and their families
as a significant problem. TBI patients have difficulty in tasks requiring vigilance and focused
attention. They generally can perform untimed tasks of immediate attentional span (e.g., digit
span) as well as uninjured individuals, but if a task requires switching focus, decision making, or
speed of processing, TBI patients are often significantly impaired.
Psychological disease. An individual’s outcome following TBI is related to several
factors, including age, preinjury abilities, personality, and injury severity (Capruso & Levin,
1992). Acute confusional states are most commonly observed during the first few weeks
following a TBI (Jorge, 2005). Post-traumatic agitation is another common symptom and
typically resolves within 10 days (Jorge, 2005; Kadyan et al., 2004). Patients frequently report
slowed or diminished cognitive abilities after TBI. Memory is the most susceptible of cognitive
functions following TBI. TBI can also bring about psychiatric conditions, and the frequency of
mood disorders such as major depression, bipolar disorder, and anxiety are significantly greater
in TBI populations. Post-traumatic stress disorder (PTSD) is commonly associated with TBI as
well, and there is a correlation between the presence of neuropsychiatric disorders and difficulty
with psychosocial adjustment and ability to return to work following TBI (Jorge & Robinson,
2002). Given the profound impact of TBI on the individual as well as his or her family, coworkers and friends, it is important to evaluate therapeutic measures that may be able to prevent
these cognitive sequelae from occurring.
Experimental Traumatic Brain Injury. Experimental brain injury models must
generate similar injuries to those observed following human TBI. Regardless of the
physiological, behavioral, or anatomical outcome measure, it is important that the results be
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reproducible and quantifiable, clinically relevant, and produce a continuum of injury severities
(Lighthall, Dixon, & Anderson, 1989). No single model can replicate the complex mechanisms
that occur following human TBI, but several preclinical models of TBI have been developed and
implemented to properly characterize its underlying pathology.
Models and mechanics of experimental TBI. There are four models that have been used
to investigate the effects of TBI: physical, computational, cell culture, and animal. All of these
models have provided important data for the understanding and treatment of TBI. However, to
date, only animal models are able to fully represent how a living organism responds to trauma.
There are a number of animal models that reliably reproduce the sequelae associated with human
TBI. Animal models of injury include dynamic closed head injury, penetration, ablation,
lesioning, and quasistatic injury. Since the present study utilizes a closed head model of head
injury, other models of TBI will not be discussed further. One aspect that must be taken into
consideration when evaluating experimental data is the time course of events following trauma.
The pathophysiological mechanisms that occur following experimental injury in animal models
occur over a faster timeframe than that which is observed following human TBI (Zauner &
Bullock, 1995). This is also important when evaluating the effects of pharmacological
treatments in animal models of injury, such as the rate of metabolism of the selected drug.
Fluid-percussion injury. FPI is the most commonly used rodent model of TBI. The
model requires a small-diameter (4.8 mm) craniotomy to expose the dura mater, and the injury is
produced by applying a brief fluid pulse directly to the surface of the dura. The injury can be
delivered either centrally or laterally. Central FPI delivers the fluid pulse along the central suture
midway between bregma and lambda. Lateral FPI delivers the injury to the parietal lobe midway
between the coronal and lambdoid sutures. The FPI model is able to replicate the cognitive and
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histological changes seen in human head injury (Dixon et al., 1987). In rodent models, FPI has
been shown to produce cognitive deficits that can last for weeks or months postinjury (Hamm,
Lyeth, Jenkins, O'Dell, & Pike, 1993). Other aspects of human TBI are also generated following
FPI, such as hemorrhage at the gray/white interface, acute hypertension, bradycardia, increased
plasma glucose levels, and suppression of electroencephalogram amplitude that is related to the
magnitude of the head injury (Cortez, McIntosh, & Noble, 1989; Dixon, Lighthall, & Anderson,
1988).
Both central and lateral FPI models are capable of producing cognitive deficits via
damage to the hippocampus, a region of the brain known to be selectively vulnerable in human
TBI. The two models differ in the type of damage inflicted on the hippocampus. Central FP
does not produce the same magnitude of cell loss that is typically seen following lateral FP, but it
does produce hippocampal damage (Hamm et al., 1993; Lyeth et al., 1990). The memory
impairment observed following central FPI is not believed to be due to cell death but instead due
to neuronal dysfunction in the hippocampus (Hayes et al., 1992; Lyeth et al., 1990). Lateral FPI
is known to cause significant cell death in the CA3 region of the hippocampus as well as bilateral
cell loss in the hilus (Cortez et al., 1989; Hicks, Smith, Lowenstein, Saint, & McIntosh, 1993;
Smith, Okiyama, Thomas, Claussen, & McIntosh, 1991). Memory dysfunction observed
following lateral FPI is directly related to the amount of cell death in the dentate hilar region
(Smith, Lowenstein, Gennarelli, & McIntosh, 1994).
The lateral FPI model of TBI was selected for use in the present study because it reliably
produces aspects of both focal (cortical contusion) and diffuse (impaired functioning of
subcortical structures) brain injury, resulting in motor and cognitive deficits typical of human
TBI (Hallam et al., 2004; Hicks, Soares, Smith, & McIntosh, 1996; Nahas et al., 1998; Nolan et
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al., 1997). Lateral FPI produces alterations in regional cerebral blood flow, BBB permeability
(Cortez et al., 1989; Yamakami & McIntosh, 1991), metabolic functioning, and
electroencephalographic activity (Hovda et al., 1995; Kokiko-Cochran, Michaels, & Hamm,
2008; McIntosh et al., 1989), all of which are known to occur following human head trauma.
Neurochemical changes detected in human patients have been reported in animal models using
lateral FPI, including neurotoxicity from glutamate over-expression, alteration in the expression
of neurotrophic factors and stress-induced proteins, and compromised integrity of cytoskeletal
architecture (Di, Gordon, & Bullock, 1999; Hallam et al., 2004; Hicks, Martin, Zhang, &
Seroogy, 1999; Huh, Raghupathi, Laurer, Helfaer, & Saatman, 2003; Raghupathi, McIntosh, &
Smith, 1995). Because it is able to closely approximate the injuries observed following human
TBI, the lateral FPI model was selected for use in the present study.
Controlled cortical impact. Controlled cortical impact (CCI) uses either a pneumatic or
magnetically driven piston to strike exposed brain tissue. The advantage of this model is that the
biomechanical events contributing to the injury can be precisely quantified, and force, velocity,
and tissue deformation can be correlated to the amount of tissue damage and/or functional
impairment. The CCI model has been shown to produce cognitive deficits similar to those
observed following human TBI (Hamm et al., 1992). Moreover, CCI is able to simulate the
neuropathology of severe human head injury more effectively than FP injury (Dixon, Clifton,
Lighthall, Yaghmai, & Hayes, 1991). Hoffman and colleagues developed a bilateral model of
frontal cortical contusion that was able to reproduce deficits typically observed after frontal lobe
damage in humans (Hoffman, Fulop, & Stein, 1994). This model uses a pneumaticallycontrolled cortical impactor to create bilateral contusions of the medial prefrontal cortex in male
Sprague-Dawley rats. Both CCI models were able to produce cognitive deficits as measured by
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the Morris water maze (MWM) in addition to producing neurological, histological, and
physiological deficits (Hamm et al., 1992; Hoffman et al., 1994). CCI can also cause direct
hemorrhage within the cortical gray matter and produce significant edema and damage to the
BBB (Beaumont et al., 2000).
Weight drop model. First described by Foda and Marmarou (1994), this model induces
diffuse TBI using a free-falling brass weight dropped from a predetermined distance onto a
stainless steel disk cemented onto the animal’s skull. The stainless steel disk prevents skull
fractures, allowing for greater impact-acceleration levels and increased range of brain injury
severity (Foda & Marmarou, 1994). Postinjury apnea, convulsions, subarachnoid hemorrhage,
and intraventricular hemorrhage are common after this type of injury. In severely injured
animals, there is also evidence of petechial hemorrhage. Foda and Marmarou (1994) used this
model to show that brainstem damage is not a necessary component of severe head injury as
previously thought. Irrespective of the severity of the brain injury (mild, moderate, severe), this
model produces microscopic damage to neurons, axons, astrocytes, and small blood vessels.
However, the extent of these changes is directly proportional to the severity of the TBI.
Pathobiology of experimental TBI.
Focal. The FPI (Dixon et al., 1987) and CCI (Lighthall et al., 1989) mechanisms of
injury are capable of eliciting focal contusion and hemorrhage in various animal models
including primates, rodent and non-rodent models. In the most severe injuries, hemorrhage can
lead to further destruction of the cortical gray matter followed by the formation of a cystic cavity
surrounded by glial cells. Precontusional changes observed in animal models of TBI correlate
with nonhemorrhagic contusions observed in human TBI. Hemorrhage in injured cortical areas
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can expand over time and produce a larger hemorrhagic mass that can facilitate secondary
ischemia and infarction (Povlishock & Christman, 1994).
Intraparenchymal hemorrhage can be generated following FPI and is typically seen only
following severe injury. As in human TBI, the presence of a contusion is not always associated
with mortality, nor does the presence of a contusion necessarily have a direct correlation with
behavioral pathologies. Only when the contusion spans a large area of nervous tissue and/or
involves a discrete functional area does it have a direct relationship to behavioral outcome
(Povlishock & Christman, 1994).
Diffuse. Not all animal models of TBI are able to mimic the pathology of diffuse axonal
injury. FPI and CCI models are only able to produce focally confined axonal damage, but these
models have nevertheless been used to obtain the majority of data regarding traumaticallyinduced DAI (Povlishock & Katz, 2005). The model that most closely replicates the pathology
associated with DAI was described in a study by Gennarelli et al. (1982). In this study,
nonhuman primates sustained DAI as a result of rapid acceleration of the head in one of three
directions (sagittal, oblique, or lateral) without impact (Gennarelli et al., 1982). Due to the
difficulty and expense associated with nonhuman primate studies, new models utilizing optic
nerve stretch have been developed to study DAI (Maxwell, Povlishock, & Graham, 1997).
The nature of DAI was not fully investigated until adequate animal models were
developed. Povlishock and colleagues used anterograde tracers in the major conducting
pathways prior to applying varying levels of experimental injury to determine if the axons were
disconnecting at the time of injury or if there was another process occurring within the axon that
was facilitating axonal degradation. These experiments showed that there was a change in axon
length within 1-2 hours postinjury and an accumulation of the anterogradely transported tracer,
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which caused local swelling of the axon. Within 3- to 6-hours postinjury, the axonal swelling
increased to form a retraction bulb and ultimately resulted in axonal separation (Cheng &
Povlishock, 1988; Povlishock & Becker, 1985; Povlishock & Kontos, 1985). This demonstrated
that axonal injury is not caused by tearing of the axon by external forces at the time of injury, but
rather is the result of injury-induced changes within the axon. In their 2005 review article,
Povlishock and Katz noted that while previous research had focused on investigating the effects
of injury on large caliber myelinated axons, more recent findings have shed light on the
importance of injury to myelinated and unmyelinated fine caliber fibers. This aspect of injury
may be more important to outcome following TBI (Reeves, Phillips, & Povlishock, 2005).
Generalized. FPI produces an immediate increase in extracellular release of
neurotransmitters, including catecholamines, acetylcholine, and glutamate (Faden et al., 1989;
Hayes et al., 1992; Zauner & Bullock, 1995). Shearing injuries can initiate widespread changes
in neurotransmitter functioning and ionic homeostasis. These changes set off widespread
depolarization of cells allowing influx of sodium and calcium ions into the cell and efflux of
potassium ions to the extracellular space (Katayama, Becker, Tamura, & Hovda, 1990). These
cellular changes are related to neuronal and glial swelling that can lead to edema and increases in
intracranial pressure (ICP) (Zauner & Bullock, 1995). A hallmark feature of experimental brain
injury is excessive release of EAA’s (Katayama et al., 1990; McIntosh et al., 1989). Although
there are several excitatory neurotransmitters that are associated with TBI-induced neurotoxicity,
glutamate appears to be the most important (Rothman & Olney, 1986). Increased release of
EAA’s such as glutamate and aspartate from the hippocampus is seen following moderate to
severe TBI, and amount of neurotransmitter release seems to correlate with injury severity
(Hayes & Dixon, 1994). Animal studies have confirmed that multiple agonist-receptor
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interactions are involved in TBI pathologies, and this is the basis of the strategy of treatment
with receptor antagonists as a method of neuroprotection after TBI. Povlishock and Christman
(1994) discuss several studies that have used EAA antagonists to elicit a neuroprotective effect.
When multiple EAA antagonists are combined they offer even greater neuroprotection than when
used individually (Jenkins et al., 1988).
In brain tissues affected by moderately reduced regional cerebral blood flow (rCBF),
glutamate excitotoxicity may be responsible for secondary ischemic damage. Hypoxia-related
neuronal depolarization is caused by increased extracellular levels of glutamate due to increased
release and decreased reuptake of glutamate. High levels of glutamate can cause depolarization
of cell membranes and activation of voltage-gated calcium channels that in turn activates the
release of more glutamate via a positive feedback loop, resulting in glutamate neurotoxicity and
ultimately cell death (Gennarelli, 1993). Other amino acid neurotransmitters such as glycine are
reported to be involved in seizure activity and toxicity from secondary damage (Nilsson et al.,
1994). Glutamate antagonists have been found to be effective in reducing intracranial pressure
produced by edema (Schroder, Muizelaar, Bullock, Salvant, & Povlishock, 1995).
Edema is the accumulation of serous fluid within a body cavity or tissue and is a
significant factor related to secondary injury. Edema can be caused by a multitude of events and
is the endpoint of several pathological processes. There are two primary types of edema:
vasogenic and cytotoxic. Vasogenic edema is a common element in clinical and experimental
TBI. The breakdown of the BBB occurs at the tight junctions of endothelial cells, resulting in
vascular permeability to water and plasma proteins (Tanno, Nockels, Pitts, & Noble, 1992b)
allowing passage of neurotoxic vascular components into the parenchyma (McIntosh et al.,
1996). Cytotoxic edema is produced by acute ischemic events and characterized by swelling of
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neurons, glia, and endothelial cells. Lack of oxygen prevents adenosine triphosphate (ATP)dependent sodium and potassium ion transport. ATP levels can be disrupted by ischemic
reduction in cerebral blood flow or mitochondrial dysfunction. Sodium accumulates within cells,
disrupting osmotic equilibrium and allowing excessive amounts of water into the cell.
Intracellular calcium levels are also increased and lead to the activation of phospholipases and
the subsequent release of arachidonic acid followed by the release of oxygen-derived free
radicals and infarction (Kandel, 2000).
Disruption of the BBB may be exacerbated by the occurrence of a secondary insult such
as hypoxia or ischemia (Tanno, Nockels, Pitts, & Noble, 1992a; Tanno et al., 1992b). Mild and
moderate focal TBI have been linked to alterations in the permeability of the BBB that has been
shown to persist for up to 15 hours postinjury (Cortez et al., 1989). In another study, lateral FPI
was combined with a secondary ischemic insult, and the combined injuries were associated with
transient breakdowns of the BBB that spanned from 1-72 hr post-TBI. The re-establishment of
the BBB occurred in stages; brain regions farther away from the injury site recovered more
quickly, some within 1 hr, while the region directly below the injury site demonstrated BBB
disruption that lasted up to 72 hr after injury (Tanno et al., 1992a; Tanno et al., 1992b).
Hypertensive responses following moderate or severe injury are also known to disrupt the BBB
(Hayes & Dixon, 1994).
Vascular abnormalities in preclinical research are very similar to those seen following
human TBI and include impairment or loss of autoregulation (Lewelt, Jenkins, & Miller, 1980),
impaired physiologic cerebral vascular responsiveness to changes in arterial blood gases (Wei,
Dietrich, Povlishock, Navari, & Kontos, 1980), and altered cerebral blood flow (DeWitt et al.,
1986; Povlishock & Christman, 1994). Abnormally low levels of carbon dioxide in the blood
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stream have been found following experimental TBI. It is hypothesized that shear and tensile
strains may produce functional and structural changes in cerebral blood vessels (Povlishock &
Christman, 1994).
Biphasic Hypothesis
Remote Functional Depression (RFD) is a hypothesis proposed by Feeney (1991) to
explain the apparent biphasic condition associated with the brain’s response to trauma-induced
injury. RFD is derived from the idea of diaschisis, first proposed by von Monakow in 1914
which postulates that a focal injury to one area of the brain can produce damage to a
morphologically separate area via common neural pathways. Von Monakow attributed the
remote damage to a loss of excitatory input from the injured area. It was speculated that
spontaneous recovery from this state was due to the resolution of the dysfunctional signaling
pathway (von Monakow, 1914, translated to English in 1969).
The biphasic model of brain injury deals with the sequelae associated with secondary
injuries and is divided into acute and chronic phases. In the acute phase, marked cerebral
hypermetabolism leads to increases in the extracellular release of several neurotransmitters
leading to neurotoxicity. The chronic phase is characterized by a hypofunctional state with
delayed cell loss in selectively vulnerable brain regions, leading to cerebral atrophy on
neuroimaging and decreased cerebral metabolism. These are associated with neuronal loss and
inflammation that is observed via magnetic resonance spectroscopy (MRS) and which can persist
for months following TBI in humans. Experimental therapies to treat TBI are designed to target
either the acute or chronic phase. It is within these two time points that treatments can be
implemented. Typically, treatments that are effective in the excitotoxic acute phase are
ineffective when administered during the hypofunctional chronic phase, and vice versa. The
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time-sensitive nature of treatment intervention can make the translation from acute treatments in
preclinical models to clinical use extremely difficult.
In the proposed study, postinjury treatment with lithium is theorized to be beneficial in
ameliorating the pathobiology associated with both the acute and chronic phases following TBI.
Due to the known mechanisms of lithium’s action, it is hypothesized that lithium will be able to
attenuate the excitotoxic processes associated with the acute postinjury phase and prevent
apoptotic events as well as enhance neuronal regeneration in the chronic postinjury phase (Ren,
Senatorov, Chen, & Chuang, 2003).
Lithium
Background. Lithium is the third element on the periodic table and a member of the
alkali metal group. Lithium has many remarkable therapeutic applications, most notably its
ability to treat both the manic and depressive phases of bipolar affective disorder (BAD)
(Shaldubina et al., 2001). This drug has been also used to alleviate aggressive behavior,
migraines, cluster headaches, the inappropriate secretion of anti-diuretic hormone, and
chemotherapy-induced leucopoenia (Shaldubina et al., 2001). More recently, the evidence that
this simple cation may exert beneficial effects in various models of brain injury has brought
renewed interest in the therapeutic potential of this drug. The following sections will outline the
general effects of the clinically relevant doses of lithium in the brain that are related to lithium’s
effectiveness as a therapy for BAD and factors related to learning and memory, followed by an
in-depth review of lithium’s role in neuroprotection, neuroplasticity, and neurogenesis.
Lithium has a multitude of effects in the brain, not all of which are relevant to this thesis.
In the following section, a short synopsis of some of the prominent aforementioned effects
produced by clinically relevant doses of lithium will be discussed. These lithium-induced effects
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include inositol monophosphatase (IMPase), glucose metabolism, enzymes, and the
neurotransmitters 5-HT, ACh, and NE.
Inositol monophosphatase (IMPase). Lithium is speculated to inhibit IMPase and
thereby hinder the functioning of the cycle of the second-messenger phosphatidylinositol (PI)
(Shaldubina et al., 2001). Allison and Stewart (1971) showed that lithium decreases free inositol
concentration and increased inositol monophosphate (IP) concentration in the brain (Allison &
Stewart, 1971; Shaldubina et al., 2001). Allison and Bilsner, using a rat model, found that
therapeutic doses of lithium inhibited brain inositol monophosphatase, providing an explanation
for the reduction in inositol and accumulation of inositol monophosphate (Allison & Blisner,
1976). Lithium inhibits the dephosphorylation of IP by inositol monophosphatase, thus
preventing the release of inositol. Other mood stabilizers (e.g., valproic acid and carbamazepine)
also inhibit inositol. A common mechanism of action for these drugs is the depletion of inositol,
thereby suggesting that it may have a role in the clinical effectiveness of these therapies (Teo et
al., 2009).
Glucose metabolism. Regional cerebral metabolic rate for glucose (rCMRglc) is an
imaging technique that can be utilized to determine areas of brain activity in vivo (Basselin,
Chang, & Rapoport, 2006). It was determined that chronic (6-week) lithium treatment, within
the therapeutic range used to treat BAD, produced an increase in regional brain glucose
metabolism in 30 of 81 brain regions examined. The increased activity was observed in auditory
and visual areas as well as in the frontal cortex, amygdala, hippocampus, nucleus accumbens,
caudate-putamen, interpeduncular nucleus, and substantia nigra (Basselin et al., 2006).
Serotonin. Lithium treatment downregulates the expression of 5-HT1B autoreceptors and
thereby increases 5-HT levels in the brain (Odagaki, Koyama, Matsubara, Matsubara, &
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Yamashita, 1990; Redrobe & Bourin, 1999). In vitro studies report that administration of
therapeutic levels of lithium caused specific inhibition of 5-HT1B receptor binding in membrane
preparations (Massot et al., 1999; Shaldubina et al., 2001). In support of this effect, in vivo
studies revealed that lithium is able to prevent behaviors mediated by 5-HT1B (Massot et al.,
1999; Shaldubina et al., 2001). Lithium-induced actions at 5-HT neurons were correlated with
management of hyperactive behavior in rats (Grahame-Smith & Green, 1974; Redrobe & Bourin,
1999). Short-term, two-day, treatment with lithium was found to increase 5-HT levels without
altering 5-HT firing rate or alteration in the number of spontaneously active neurons, which
indicates that short-term lithium treatment inhibits presynaptic 5-HT receptors (Blier & De
Montigny, 1985; Redrobe & Bourin, 1999).
Lithium’s observed effect of inhibiting 5-HT1B may have beneficial effects in learning
and memory. Research indicates that antagonists of 5-HT1B receptors can prevent memory
impairment and facilitate learning during tasks that require a high cognitive demand (Zafonte et
al., 2002). In support of this finding, agonists of 5-HT1B receptors produced deficits in learning
(Zafonte et al., 2002). Additionally, lithium’s actions may help to reduce aggressive behavior in
TBI patients. However, due to potential lithium-induced toxicity, it is recommended that less
toxic treatment options be considered first (Levy et al., 2005).
Acetylcholine. Some of lithium’s effects on memory may be related to its effects on
ACh. ACh is known to be involved in memory formation in both humans and animals (Hogg,
Raggenbass, & Bertrand, 2003; McNamara & Skelton, 1993). Lithium was found to increase the
synthesis and release of ACh in the hippocampus, mediated by 5-HT1A receptor-mediated
pathways (Fujii, Nakai, Nakajima, & Kawashima, 2000). A time- and concentration-dependent
increase in the expression of the muscarinic ACh receptor was reported following lithium
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administration. Additionally, lithium prevented agonist-induced downregulation of the
muscarinic receptor (Liles & Nathanson, 1988). ChAT activity was also reported to be
influenced by lithium administration (Giovanni, Scali, Prosperi, Bellucci et al., 2002). Lithium
was found to reduce memory deficits related to the drug, H-89, a PKAII agonist, in part by
increasing the activation of cholinergic markers (Sharifzadeh et al., 2007).
Norepinephrine. Lithium is reported to enhance the reuptake of NE in both
synaptosomes and brain slices. The ability of lithium to decrease the activity of NE is reported
to likely contribute to the acute antimanic and prophylactic effects of the drug. In a study by
Katz and Kopin (1969), lithium administration decreased the amount of the [3H]NT released
following electrical stimulation of brain slices but did not affect the spontaneous release of NE.
Another study reported that lithium treatment reduced yohimbine-induced increases in NE levels
in the cerebral cortex, possibly by reducing NE release (Swann, 1988).
Enzymes. Numerous enzymes are affected by lithium; however, only few are
significantly inhibited at therapeutic serum concentrations. Clinically relevant serum levels of
lithium (0.5 – 1 1.2 mM) are known to have direct effects on the metabolic enzyme
phosphoglucomutase and on a superfamily of structurally related phosphomonoesterases. Of this
family, the enzymes IMPase, polyphosphate 1-phosphatase (IPPase), fructose 1,6biophosphatase (FBPase), and bisphosphate nucleotidase (BPNase) have been shown to have a
magnesium ion binding site within the active site of the enzyme (Atack, Broughton, & Pollack,
1995b; Gould, Quiroz, Singh, Zarate, & Manji, 2004; Harwood & Agam, 2003). Lithium has an
ionic radius similar to magnesium and as such can substitute for magnesium through
uncompetitive inhibition, binding to the active site and preventing product release and trapping
products in the active site (Atack, Broughton, & Pollack, 1995a; Harwood & Agam, 2003).
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Pharmacokinetics of lithium. Lithium has the narrowest therapeutic window of any
drug routinely prescribed in psychiatric medicine (Kilts, 1998). The therapeutic range for
human serum concentrations of lithium was determined to be 0.6 – 1.2 mEq/L (Feldman, Meyer,
& Quenzer, 1997; Kilts, 1998; Komoroski & Pearce, 2004). Serum levels that fall below 0.6
mEq/L have been associated with increased rates of relapse of symptoms and poorer
psychosocial functioning in BAD patients (Gelenberg et al., 1989; Kilts, 1998; Solomon et al.,
1996). Serum levels above 1.5 mEq/L are associated with adverse side effects and levels above
3.5 mEq/L are associated with life-threatening lithium intoxication. It is very important for
individuals prescribed lithium to have routine monitoring of serum lithium concentrations to
prevent aversive effects. If serum levels go beyond 2.0 mEq/L, lithium is known to have toxic
effects that include vomiting, diarrhea, nephrogenic diabetes insipidus (including polyuria and
polydipsia), bone loss, hypercalcaemia, ataxia, tremor, fatigue, irritability, seizures, coma, and
death (Feldman et al., 1997; Schou, 2001). Due to the side effects of lithium it is estimated that
over one third of patients are poorly able to tolerate its effects. Lithium also has reported
teratogenic effects. In humans, there is an increased risk for cardiovascular malformations,
particularly Ebstein’s anomaly, a congenital heart defect, when lithium is taken during the first
trimester of pregnancy (De Santis et al., 2008).
Lithium is the smallest of the alkali cations, with an ionic radius of 0.60 Å. The
structural similarity of lithium to sodium (0.95 Å) and potassium (1.4 Å), all members of group
1A in the periodic table, allows lithium to substitute for these cations in various cellular
processes. However, the differences in ionic radii alter the effectiveness of lithium to carry out
these processes to the same degree as the other cations (Ehrlich & Diamond, 1980). For
example, in the brain, lithium can replace sodium in extracellular fluid and is easily drawn into
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neurons during an action potential. However, it is not easily removed by the sodium-potassium
pump, and thereby prevents potassium from reentering the cell. The resulting imbalance in
electrolytes prevents the cell from repolarizing properly and inhibits conduction and thereby
neuronal excitability (Grafe, Reddy, Emmert, & ten, 1983). Lithium can also substitute for the
divalent cations, calcium and magnesium. Calcium and lithium have a similar charge density,
and magnesium and lithium have a very similar ionic radius, 0.65 and 0.60 Å respectively. It is
the similarity between lithium and the afore mentioned divalent cations that is physiologically
relevant because of their regulatory actions in cellular functioning (e.g., enzymes, kinetics, and
synaptic events) (Ehrlich & Diamond, 1980).
Lithium negligibly binds to plasma proteins and it is not metabolized or biotransformed
in any appreciable way. Lithium is excreted by the kidneys in its intact form and is reabsorbed
in the proximal renal tubules (Feldman et al., 1997; Janicak & Munson, 1998; Kilts, 1998).
Lithium has high energy of hydration and its hydrated ionic radius (310 pm) is similar to sodium
with its hydration coat (340 pm). Because of this ionic radius, lithium can substitute for sodium
in many of the active sodium transport mechanisms. In periods of dehydration or sodium
depletion, both sodium and lithium retention is increased, necessitating adequate hydration prior
to initiating lithium treatment to prevent excessive build-up of lithium in the body (Janicak &
Munson, 1998).
As previously mentioned, the similarities between sodium and lithium allow for lithium
to replace it in sodium transport mechanisms, such as: the sodium-potassium pump, sodiumlithium countertransport, bicarbonate-sensitive pathway, voltage-dependent sodium channel, and
leak (i.e., passive diffusion). However, under physiological conditions, the affinity of lithium
relative to other cations in the various transport mechanisms precludes the likelihood for certain
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mechanisms to be important in the transport of lithium across a particular membrane. For
example, the transport of lithium across the membrane of a red blood cell (RBC) occurs through
leak and bicarbonate-sensitive pathways, whereas sodium-lithium countertransport is important
for the removal of lithium from the cell. The influx of lithium into excitable cells (i.e., nerve and
muscle cells) is primarily through via voltage-dependent sodium channels and to a lesser extent,
passive diffusion. Similar to RBCs, the removal of lithium from excitable cells is largely via
sodium-lithium countertransport (Ehrlich & Diamond, 1980).
Lithium enters the brain via the blood-CSF barrier (Ehrlich & Wright, 1982). The
authors reported that lithium is passively transported across tight junctions formed by the
epithelial cells of the choroid plexus via sodium-lithium countertransport (Ehrlich & Wright,
1982). In this mechanism, one lithium ion is transported out of the cell in exchange for one
external sodium ion, which goes into the cell. Once across the choroid plexus, lithium enters the
brain through the CSF, which is continuous with the interstitial fluid that surrounds the cells of
the brain.
In humans, lithium (typically lithium carbonate) is easily absorbed and reaches peak
plasma levels in 1 – 2 hours for standard release formulations and 4 – 5 hours for sustained
release formulations (Grandjean & Aubry, 2009). The effect of lithium administration on serum
levels can vary greatly among human subjects depending on factors like weight and age. The
half-life of lithium is 18 – 20 hours in healthy young adults and up to 36 hours in elderly patients
(Janicak & Munson, 1998). The elimination half-life of lithium is between 18 – 36 hours. In
humans, the difference between brain and plasma lithium concentrations is significant. Brain
concentrations are approximately half of serum levels (Komoroski & Pearce, 2004; Pearce,
Lyon, & Komoroski, 2004). In one study, it was reported that brain concentrations of lithium are
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better correlated with effective treatment of mania as compared to serum concentrations (Kilts,
1998). Similarly, (Gould et al., 2008), using a mouse model of depression, found that the
observed antidepressant-like effects of lithium were due to its action in the brain, and not to any
peripheral effects of the drug (Gould et al., 2008). However, MRI studies show that among
animals there is less variability between brain and serum concentrations of lithium (Komoroski
& Pearce, 2004; Pearce et al., 2004). Indeed, in rodents, following long-term treatment with
lithium, whole brain and serum lithium concentrations were found to be equivalent
(Ghoshdastidar, Dutta, & Poddar, 1989; Gould et al., 2008; Gould, O'Donnell, Picchini, &
Manji, 2007).
The distribution and retention of lithium in the blood and brain of male mice was
evaluated following single-dose and chronic (21 day) lithium treatment. A single-dose of lithium
(0.5 mmol/kg) produced peak plasma levels at 8 hours post-injection and peak brain
concentration at 12 hours post-injection. Chronic daily administration of this dose showed no
change in overall lithium concentration in the whole brain or the following brain regions:
cerebral cortex, striatum, hippocampus, diencephalon, brain stem and cerebellum (Messiha,
1976). Lambert and colleagues also reported steady brain levels of lithium following both acute
and chronic lithium dosing (Lambert, McGirr, Ely, Kilts, & Kuhar, 1999).
Serum lithium levels in rats were assessed after acute (single-dose) and chronic (30 day)
dosing with 2.0 mmol/kg lithium chloride, administered via intraperitoneal injection (Tsaltas,
Kyriazi, Poulopoulou, Kontis, & Maillis, 2007). The serum concentrations were evaluated to
ensure that daily lithium administration did not result in accumulation of the drug, which might
cause increased serum levels over days and possibly affect the health of the animals. Serum
concentrations were assessed at 1, 12, or 24 hours following the last lithium injection. The
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findings from this study show that there was no difference in the serum lithium levels of
chronically or acutely treated rats at any of the time points. Thus, the authors concluded that
daily intraperitoneal injections of lithium are not likely to produce excess lithium accumulation
over time (Tsaltas et al., 2007). However, there was a significant difference in the serum levels
of lithium over the three post-injection time points (1, 12, and 24 hours), irrespective of the
duration of treatment. The 2.0 mmol/kg (84.7 mg/kg, ip) dose of lithium produced peak serum
concentrations (1.7 ± 0.4 mEq/L) at 1 hour post-injection. Serum concentrations decreased at 12
hours (0.5 ± 0.4 mEq/L) and were almost absent by 24 hours (0.4 ± 0.4 mEq/L) post-injection
(Tsaltas et al., 2007). In another study, single dose of 5.0 mmol/kg administered to rats produced
a maximum brain concentration of 1.5 mmol/kg between 9 and 24 hours, and the half-life was
determined to be 12 hours (Wraae, 1978). These animal findings are in accord with the decline
in serum concentrations observed in human pharmacokinetic studies (Tsaltas et al., 2007).
Lithium is neuroprotective. There is compelling evidence to state that lithium is
neuroprotective. Supporting data comes from in vitro, in vivo and clinical studies employing
vastly diverse methodologies and parameters (Rowe & Chuang, 2004).
In vitro. In studies using both rodent and human cell lines, (e.g., cerebellar granule cells
(CGC), cerebral cortical cells, hippocampal neurons, PC12 cells, and neuroblastoma cells)
lithium has been found to be neuroprotective against a variety of insults (e.g., β-amyloid peptide
(Aβ), potassium deprivation, staurosporine and heat shock, oubain, β-bungarotoxin, and
glutamate excitotoxicity (Alvarez et al., 1999; Bijur, De Sarno, & Jope, 2000; Bournat, Brown,
& Soler, 2000; Hennion, el-Masri, Huff, & el-Mailakh, 2002; Mora et al., 2001; Nonaka, Hough,
& Chuang, 1998; Nonaka, Katsube, & Chuang, 1998; Rowe & Chuang, 2004; Wei et al., 2000).
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In an animal model of Alzheimer’s disease, primary cultures of rat cortical neurons were
treated with Aβ, known to induce cell death in cultured neurons. Lithium treatment (10 mM and
2 mM), was found to prevent Aβ-induced tau hyperphosphorylation in addition to providing
significant neuroprotection to cortical neurons (Alvarez et al., 1999). These effects are
hypothesized to involve lithium-induced inhibition of GSK-3β, a kinase known to phosphorylate
a wide range of substrates including tau. The 10 mM dose of lithium was protective against Aβ;
however, this dose resulted in lithium-induced toxicity and cell death after 4 days of treatment.
The lower dose of lithium did not have the same toxic effects. Therefore, it was speculated by
the authors that low doses of lithium, similar to those used in the treatment of BAD, may be
beneficial in treating Alzheimer’s disease, as well as other neurodegenerative disorders (Alvarez
et al., 1999).
When cells in culture are deprived of potassium, the result is increased activated caspase3 levels, in addition to promoting the phosphorylation of PKB and GSK-3. Granule cells
subjected to potassium deprivation, in the presence of 5 mM lithium chloride, were completely
protected against potassium-induced apoptosis. Additionally, the protective effect was observed
for up to 48 hours after lithium treatment. These findings indicate that the neuroprotective
actions of lithium are effective for a period of time after lithium treatment has ended (D'Mello,
Anelli, & Calissano, 1994). In another study, Mora and colleagues also examined the effects of
potassium deprivation in cerebellar granule cells, with the aim to elucidate a potential
mechanism of action for lithium-induced neuroprotection (Mora, Gonzalez-Polo, Fuentes, Soler,
& Centeno, 1999). Caspase-3 is an effector caspase and has been established as a biochemical
marker of apoptosis (Bijur et al., 2000). In CGC’s, 5 mM lithium, co-incubated with low
potassium, significantly decreased the levels of activated caspase-3 protein. Lithium was found
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to prevent the cleavage of procaspase-3, and not the activity of the active form of capase-3 (Mora
et al., 2001). The authors speculate that the phosphorylation state of PKB and GSK-3β are
related to lithium’s effects.
Staurosporine is used to experimentally induce apoptosis in all cell types and thereby
increase activation of caspases-3 and -9 (Bijur et al., 2000). Human neuroblastoma SH-SY5Y
cells were subjected to staurosporine or heat shock in the presence of GSK-3β over-expression.
GSK-3β alone was not sufficient to induce apoptosis. However, over-expression did confer
greater vulnerability to caspases-3 activation and apoptosis when combined with staurosporine or
heat shock (Bijur et al., 2000). Lithium treatment was able to significantly reduce the apoptotic
effect. It was proposed that lithium’s activation of the phosphoinositide 3-kinase/Akt (PI3k/Akt)
pathway may partially contribute to these protective effects via PI3-K inhibition of GSK-3β.
Additionally, lithium-induced inhibition of GSK-3β prevents degradation of β-catenin.
Decreased β-catenin has been linked to increased cell death (Bijur & Jope, 2000). Contrary to
these findings, another study, using CGCs exposed to staurosporine, and then treated with
lithium, failed to find neuroprotection (Nonaka et al., 1998). Because lithium’s neuroprotective
effects against other insults in cerebellar granule cells has been well documented in the literature,
these findings indicate that lithium neuroprotection may be specific to particular initiators of
apoptosis, i.e., GSK-3β (Bijur & Jope, 2000; Nonaka et al., 1998).
Oubain is a toxic agent used to experimentally mimic the neurochemical changes
observed following manic episodes in individuals with BAD. Mania is associated with increased
sodium retention, increases in intracellular sodium and calcium, and decreased activity of the
sodium-potassium pump (Hennion et al., 2002). Low dose lithium treatment for 72 hours prior
to oubain exposure was protective against oubain-induced toxicity. However, if lithium was
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administered 24 or 48 hours prior to exposure, the protective effect was not observed. This
finding indicates that for some of the beneficial effects of lithium, a loading period is required.
Indeed, in the treatment of BAD, the mood stabilizing effects are not observed for a period of
time following initiation of treatment (Hennion et al., 2002).
Cultured cerebellar granule cells exposed to the neurotoxin β-bungarotoxin, a NMDA
receptor and L-type calcium channel agonist, results in increased neuronal calcium influx.
Lithium pre-treatment, ranging from 2 – 7 days, was found to be dose and time-dependent.
Maximum effectiveness was observed following pretreatment with 1.2 mM lithium for 3 days.
This dose and duration of pre-treatment attenuated the β-bungarotoxin-induced increase in
reactive oxygen species (ROS) and superoxide anion. However, pre-incubation for 6 – 7 days
using the same dose (1.2 mM) of lithium resulted in suboptimal levels of neuroprotection. A
higher concentration of lithium (3.0 mM) was also found ineffective in preventing βbungarotoxin neurotoxicity, in addition to being slightly toxic to the cells (Tseng & Lin-Shiau,
2002). The dose of lithium found to be most effective against this neurotoxin is in accordance
with the therapeutic serum levels of lithium used in human patients (between 0.5 and 1.2 mM)
(Hopkins & Gelenberg, 2000; Tseng & Lin-Shiau, 2002).
Several studies have reported on lithium’s neuroprotective effects against glutamateinduced neurotoxicity in cultured CGCs (Chen & Chuang, 1999; Kopnisky, Chalecka-Franaszek,
Gonzalez-Zulueta, & Chuang, 2003; Manji, Moore, & Chen, 1999; Nonaka et al., 1998).
Glutamate excitotoxicity leads to initiation of pro-apoptotic pathways and is known to play a role
in TBI pathology. Cerebellar granule cells pre-treated (7 – 9 days) with lithium (0.5 – 5.0 mM)
showed significant protection against glutamate-induced neurotoxicity by modulation of NMDA
receptor mediated calcium influx (Nonaka et al., 1998). Lithium is able to protect against not
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only NMDA receptors mediated calcium influx, but also suppresses apoptotic mechanisms
initiated by excitotoxic calcium influx.
Lithium’s involvement in preventing apoptosis was assessed via examination of gene
expression and protein levels of pro-apoptotic (p53 and Bax), and cytoprotective (Bcl-2) (Chen
& Chuang, 1999; Manji et al., 1999). CGCs pre-treated with lithium (3 mM) for 7-days
prevented glutamate-induced increases in p53 and Bax mRNA levels, and at the same time,
sustained lithium-induced increases in Bcl-2 mRNA (Chen & Chuang, 1999). Indeed, lithium
also increased the ratio of Bcl-2 protein levels over Bax protein. These findings are further
supported by both in vitro and in vivo studies, where chronic lithium treatment increased the
expression of Bcl-2 and decreased the expression of p53 and Bax (Manji et al., 1999). Bax and
Bcl-2 are both involved in modulating cytochrome c release by mitochondria. Pre-treatment
with lithium for 7 days was found to block glutamate-induced cytochrome c release by
mitochondria, thereby preventing the release of cytochrome c into the cytosol (Chen & Chuang,
1999).
Cyclic AMP-responsive element binding protein (CREB) is a signaling system involved
in cell survival and increases in CREB are associated with synaptic plasticity and neuronal
reorganization in hippocampal mossy fiber cells following TBI (Finkbeiner, 2000; Hu et al.,
2004). Additional supporting evidence for its beneficial effects in cell survival is from data
showing phosphorylated CREB (pCREB) directly regulates the CRE-dependent transcription of
the BDNF and Bcl-2 (Kopnisky et al., 2003; Tao, Finkbeiner, Arnold, Shaywitz, & Greenberg,
1998). CGCs exposed to glutamate for 8 days revealed a dose- and time-dependent change in
pCREB at Ser133. Decreases in pCREB due to glutamate exposure were completely blocked by
treatment with MK-801 (a potent NMDA receptor antagonist), indicating that the glutamate-
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induced changes in pCREB are related to the activation of NMDA receptors (Kopnisky et al.,
2003). Lithium pre-treatment for 7 days prior to glutamate exposure suppressed glutamateinduced decreases in pCREB, whereas lithium treatment for 30 minutes, 4 hour and 24 hours did
not affect pCREB levels. Increased protein phosphatase-1 (PP-1) activity is reported to be
involved in glutamate-induced decreases in pCREB. It was found that lithium treatment
prevented glutamate-induced increases in PP-1 activity (Kopnisky et al., 2003). In addition to
PP1, the MEK/ERK pathway also regulates pCREB and is increased following lithium
administration (Kopnisky et al., 2003).
Cerebral cortical neurons exposed to toxic levels of glutamate can be protected by
NMDA receptor antagonists (e.g., MK-801). However, non-NMDA receptor antagonists were
not effective. Again, this indicates that glutamate toxicity in these neurons is mediated by
NMDA receptors (Hashimoto, Hough, Nakazawa, Yamamoto, & Chuang, 2002). Lithium
treatment, at therapeutic levels, generates plasma levels within the range of 0.6 – 1.2 mM
(Hashimoto et al., 2002; Hopkins & Gelenberg, 2000). Doses of lithium between 0.1 mM – 1.0
mM showed significant neuroprotective effects when administered 6 days prior to excitotoxicity.
These data indicate that lithium at therapeutic and sub-therapeutic concentrations is
neuroprotective in cerebral cortical neurons (Hashimoto et al., 2002). Additionally, the duration
of lithium pre-treatment was critical for its neuroprotective effects. The minimum duration for
pre-treatment to achieve neuroprotection was at least 2 days. Maximum neuroprotection was
attained after 5 – 6 days (Hashimoto et al., 2002).
In vivo. In vivo studies have also demonstrated the neuroprotective effects of lithium
in several animal models (e.g., transient and focal ischemia-induced brain damage, striatial
infusion of quinolinic acid to produce an excitotoxic model of Huntington’s disease, excitotoxic
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lesions of the cholinergic system, kainic-acid-induced brain lesions, and irradiation) (Inouye et
al., 1995; Rowe & Chuang, 2004). Manji, Moore, & Chen, (1999), reported that in both in vitro
and in vivo studies, chronic lithium treatment increased the expression of the anti-apoptotic
protein Bcl-2 and decreased the expression of pro-apoptotic proteins p53 and Bax.
Compelling evidence for lithium’s efficacy as a treatment against secondary injuries
associated with TBI comes from an experimental model of stroke that produces transient focal
cerebral ischemia via middle cerebral artery occlusion (MCAO) (Ren et al., 2003; Xu, Culman,
Blume, Brecht, & Gohlke, 2003; Yan, Wang, Hou, Ji, & Zhou, 2007). MCAO is characterized
by ischemia-induced infarct, damage to the basal ganglia (i.e., striatum, subthalamic nucleus, and
substantia nigra), in addition to sensory, motor and behavioral deficits (Borlongan, Cahill, &
Sanberg, 1995).
Heat shock proteins (HSP) (e.g., HSP-70 & HSP-71) are molecular chaperones that
protect the cell from thermal and oxidative stress. Additionally, HSPs protect neurons by
antagonizing apoptosis-inducing factor (AIF) (Ravagnan et al., 2001). HSP-70 is a stressinduced protein that acts to protect unfolded or malfolded proteins by binding to them, ensuring
proper folding and preventing intracellular protein aggregation (Hendrick & Hartl, 1993; Ren et
al., 2003). This cellular protector also participates in the disposal of damaged or defective
proteins. Heat shock factor-1 (HSF1) is a cytoplasmic transcription factor that when activated is
converted to a nuclear protein that regulates gene transcription of HSPs. HSF-1 is negatively
regulated by serial phosphorylation at Ser307 by MAPK, allowing GSK-3β to phosphorylate the
adjacent Ser303 (Chu, Soncin, Price, Stevenson, & Calderwood, 1996).
Lithium treatment following transient MCAO has been shown to significantly increase
HSF-1 and HSP-70 levels as compared to saline controls (Ren et al., 2003). The upregulation of
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HSF-1 and HSP-70 induced by lithium occurs rapidly and is temporally allied to lithium’s
neuroprotective effects against MCAO / reperfusion-induced brain injury (Ren et al., 2003).
Lithium-induced neuroprotective effects resulting from increased HSP-70 are thought to be due
to either direct inhibition of GSK-3β or activation of the phosphoinositide 3-kinase/Akt signaling
pathway. Both are related to disinhibition of HSF-1, thereby allowing increased transcription
and expression of HSP-70. Indeed, over-expression of HSP-70 was found to protect neurons
from ischemic brain damage (Hoehn et al., 2001; Ren et al., 2003). Additionally, activation of
HSP-70 inhibited ischemia-induced activation of NF-κB (a pro-apoptotic factor) and subsequent
increases in apoptotic cell death (Feinstein et al., 1996; Ren et al., 2003; Schneider et al., 1999).
The study by Ren (2003), showed that increases in HSF-70 following MCAO were observed
only in the ipsilateral side. The contralateral side revealed increases in HSF-1 binding, but not in
HSP-70. Sham animals exhibited the same effects observed in the contralateral hemisphere.
These data indicated that a further stimulus may be necessary to induce HSP-70 transcription
(Pirkkala, Nykanen, & Sistonen, 2001; Ren et al., 2003).
Chronic (2 week) treatment with lithium was evaluated for its neuroprotective effects in a
rodent model of stroke (Xu et al., 2003). Ischemic brain damage was produced by MCAO
lasting 90 min followed by reperfusion. Rats were administered 1 mmol/kg lithium (sc) each
day, for 12 days prior to the ischemic insult, with the dose of lithium on day 12 administered 2
hours prior to MCAO. Treatment with lithium was continued for two additional days following
the insult. During these days, two hours post-injection, animals underwent neurological
assessment. Data from these assessments show that lithium-treated rats had significantly better
scores on measures of neurological function, derived from two previous studies, Garcia et al.
(1995) and Bederson et al. (1986). The neurological functions assessed were: spontaneous
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activity, symmetry in moving all four limbs, forepaw outstretching, climbing, body
proprioception, response to vibrissae touch (Garcia, Wagner, Liu, & Hu, 1995), forelimb flexion,
decreased resistance to lateral push, and circling behavior (Bederson et al., 1986). In addition to
improvements in the neurological functioning score, Xu and colleagues (2003) found significant
reductions in total infarct volume (32.7%) as compared to vehicle-treated injured rats. Edema
formation, however, was not affected by lithium treatment. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL), an assay used to detect DNA fragmentation
resulting from apoptotic cascades, revealed a significant reduction in TUNEL-positive cells of
lithium-treated injured rats as compared to vehicle-treated injured rats. Analysis of the apoptotic
marker, caspase-3, revealed significantly fewer caspases-3 positive-cells in the ischemic
penumbra of the occluded area of lithium treated rats (Xu et al., 2003). Levels of the AP-1
transcription factor c-Jun were increased in the ipsilateral cortex following ischemic injury
resulting from MCAO. Proteins modulated by AP-1 are generally increased in surviving cortical
regions. Lithium has been shown to indirectly reduce AP-1 levels via inhibition of NMDA
receptor-mediated increases in pro-apoptotic p38 and JNK (Rowe & Chuang, 2004). Indeed, Xu
and colleagues found that c-Jun levels were significantly lower in the ischemic penumbra of
lithium-treated rats. The authors purport the observed neuroprotective effects of lithium are due
to reduced apoptotic events in the cortex, as determined by inhibition of caspase-3 and decreased
fragmentation of DNA. Additionally, the lithium-induced alteration in c-Jun levels suggests that
reduced AP-1 protein expression may be involved in the neuroprotective effects of lithium in
ischemic brain injury (Xu et al., 2003).
Extracellular signal-regulating kinase 1 and 2 (ERK1/ERK2) is a member of the mitogenactivated protein kinase superfamily and is activated via phosphorylation on threonine and
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tyrosine residues as a reaction to extracellular stimuli including growth factors.
Neurotransmitters and neurotrophins can also be activated by brain injury. ERK1/ERK2 is
known to be involved in cell growth, proliferation, differentiation, apoptosis, synaptic plasticity,
and learning and memory via involvement in LTP (Atkins, Selcher, Petraitis, Trzaskos, &
Sweatt, 1998; Liou, Clark, Henshall, Yin, & Chen, 2003; Ménard et al., 2002; Schaeffer &
Weber, 1999). Lithium’s influence on signaling cascades, specifically, mitogen-activated protein
kinase (MAPK) and ERK1/ERK2, was evaluated following transient global cerebral ischemia
(Yan, Hou, Wu, Liu, & Zhou, 2007). At 6 hours postinjury, lithium treatment was found to upregulate ERK1/ERK2 in the CA3 and DG of the hippocampus in both the sham and ischemicinjured groups. Cognitive assessment using the MWM (PID 19-21) revealed a trend towards
shorter latencies for the lithium-treated ischemic rats as compared to ischemic rats (Yan et al.,
2007).
Another study by Yan and colleagues (2007), evaluated preinjury lithium treatment on
several behavioral outcome measures (beam balance, elevated plus maze, open field task, and
MWM) following transient global ischemia (Yan et al., 2007). Rats were pre-treated with
lithium (1.0 mmol/kg, ip) daily for 2 weeks prior to ischemic brain injury, with treatment
continuing for the duration of the behavioral assessments (i.e., 9 days post-insult). Beam
balance, elevated plus maze, and open field tasks were administered on PID 3. The MWM task
was performed on PID 7 – 9. Performance in the beam balance task was significantly improved
on PID 7 only. The behavioral assessments revealed that untreated ischemic rats were more
likely to engage in hyperactive behavior, as measured by the open field task, and exhibited
greater risk taking behavior, as measured by increased open arm exploration in the elevated plus
maze. The MWM protocol employed two sets of four trials on the first day of testing, followed
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by a single set of four trials for the remaining two days. On the first day of testing the ischemic
rats and the lithium-treated ischemic rats did not differ significantly; however, the lithium-treated
rats did show a trend toward shorter latencies. On the second and third days tested in the MWM,
the lithium-treated ischemic rats performed significantly better as compared to the ischemic rats
(Yan et al., 2007). Histological analysis and quantification of pyramidal neurons within CA1 of
the hippocampus was performed 9 days after reperfusion. Significant cell death was observed
within the CA1 region of ischemic rats. Lithium treatment significantly reduced cell death, with
no significant difference observed between lithium-treated and sham rats (Yan et al., 2007).
Clinical studies. Clinical research provides the final pieces of supporting evidence for
lithium’s neuroprotective ability. However, in clinical studies it is difficult to determine to what
extent the beneficial effects of lithium are due to neuroprotection or to neurotrophic effects
(Rowe & Chuang, 2004). Neuroimaging techniques and post-mortem morphology studies have
revealed decreases in brain volume and cell number in patients with mood disorders (Drevets et
al., 1999). These changes could be due to developmental abnormalities, disease progression, or
alterations in neurochemistry resulting from changes in neurotransmitter levels in chronic
affective disorders (Duman, Heninger, & Nestler, 1997).
MRI studies have shown increased gray matter volume within several brain structures of
individuals diagnosed with BAD and treated with lithium as compared to individuals with BAD
not undergoing lithium treatment (Bearden et al., 2007a; Bearden et al., 2007b; Manji, Moore, &
Chen, 2000a; Monkul et al., 2007; Moore, Bebchuk, Wilds, Chen, & Manji, 2000). Levels of Nacetyl-aspartate (NAA), a marker of neuronal viability, were increased following 4 weeks of
lithium treatment. It is difficult to determine if these effects are due to neuroprotective or
neurotrophic effects.
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Moore and colleagues (2000), using three-dimension magnetic resonance imaging (3DMRI) and quantitative brain-tissue segmentation, investigated the neuroprotective/neurotrophic
effects of therapeutic levels of chronic lithium treatment on grey matter volume (Moore et al.,
2000). Patients with BAD were given lithium for 4 weeks. A baseline MRI scan was performed
while each individual was “medication free” and had been off medication for at least 2 weeks
prior to the initiation of the study. These individuals were subsequently treated with lithium for
4 weeks and upon conclusion of the treatment, a second MRI was performed. These scans were
then compared with scans taken following 4-weeks of lithium treatment. Analysis of the MRI’s
showed a significant increase (3% or approximately 24 cm3) in total grey matter volume in 8 out
of 10 patients. There was no significant change in either regional cerebral water content or brain
white matter volume. The authors postulate that the changes in grey matter volume were likely
due to neurotrophic effects and not to cell swelling or alterations in contrast medium related to
the lithium treatment (Moore et al., 2000).
NAA, an accepted neuronal marker, is localized primarily within the cytosol of mature
neurons and not found in mature glial cells, CSF, or blood (Manji, Moore, Rajkowska, & Chen,
2000; Tsai & Coyle, 1995). NAA is synthesized in the mitochondria and is related to
mitochondrial oxygen and ATP consumption. It is generally accepted as a gauge for neuronal
viability and function (Manji et al., 2000a; Tsai & Coyle, 1995). Individuals with BAD have
been found to have decreased levels of NAA bilaterally in the hippocampus and DLPFC
(Bertolino et al., 1999; Winsberg et al., 2000). Moore and colleagues conducted another study
using quantitative proton magnetic resonance spectroscopy in BAD patients undergoing lithium
treatment (Moore et al., 2000). Using an experimental design similar to the previously
mentioned (2000) study by Moore, Bebchuk, Wilds, and co-workers, the levels of NAA were
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examined following 4-weeks of lithium treatment (Moore et al., 2000). Total levels of NAA
were found to be significantly increased in all brain regions. Based on the findings, the authors
concluded that chronic lithium treatment may increase neuronal viability and function in the
human brain (Moore et al., 2000).
Neuroprotective mechanisms. The mechanisms of action for lithium’s neuroprotective
effects are mediated by several pathways and likely via multiple levels of the same pathway.
This section will detail the two pathways most accepted in the literature as being involved in
lithium-induced neuroprotection. These are lithium’s induction of the cell survival signaling
pathway and lithium’s inhibition of NMDA receptor-mediated calcium influx. Within the cell
survival signaling pathway, lithium’s effects will be discussed in relation to upstream, central,
and downstream factors. Upstream factors include BDNF and activated pathways (PI3K/Akt
and MEK/ERK). Centrally, lithium acts on GSK-3β and downstream factors include effector
systems (β-catenin, HSF-1, AP-1, and CREB), the Bcl-2 family and caspases (Rowe & Chuang,
2004).
Upstream survival events. Lithium’s role in neuroprotection begins at the cell surfacetrophic factor receptors. BDNF, a neurotrophin involved in neuronal development, survival, and
plasticity, is increased following lithium administration. BDNF activates the trophic receptor,
TrkB, inducing phosphorylation of its Tyr490. Once activated the TrkB receptor has several
receptor systems, including phospholipase Cγ (PLCγ) signaling, MEK/ERK signaling, and
PI3K/Akt signaling (Huang & Reichardt, 2001).
The importance of BDNF in lithium-induced neuroprotection is supported by two
important pieces of evidence. First, in vitro and in vivo studies have showed that treatment with
lithium increases BDNF levels. Second, lithium-induced neuroprotection is dependent on
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activation of BNDF. Indeed, in a study where TrkB activation was inhibited by either the TrkB
antagonist K252a or in BDNF knockout mice, lithium-induced neuroprotection from glutamate
toxicity was blocked (Hashimoto et al., 2002). Once BDNF binds to the TrkB receptor, the
PI3K/Akt and MEK/ERK pathways are activated. Both of these pathways are vital for lithium’s
observed neuroprotective effects.
Via the PI3K/Akt pathway, the activation of TrkB results in the phosphorylation of the
adaptor protein Shc that recruits Grb-2 to form a protein complex that initiates further downstream signaling events (Liou et al., 2003; Pearson et al., 2001). From this point the pathway can
go in one of two directions, both leading to the activation of PI3K. Once PI3K is activated, it
produces 3-phosphoinositides that in turn recruit phospholipid-dependent kinases (PDKs) that
phosphorylate Ser473 and/or Thr308 to activate Akt-1. Akt-1, also known as protein kinase B, is
a serine/threonine protein kinase that regulates anti-apoptotic activity on multiple targets
including GSK-3β, BAD (part of Bcl-2 family), CREB, some members of the forkhead family,
and procaspase-9. In vitro studies demonstrate that overexpression of Akt protects neurons
subjected to serum or growth factor withdrawal (Chen, Yuan, Jiang, Huang, & Manji, 1998;
Kermer, Klocker, Labes, & Bahr, 2000; Springer, Nottingham, McEwen, Azbill, & Jin, 2001).
The involvement of PI3K in lithium-induced Akt-1 upregulation was demonstrated in vitro by
inhibiting PI3K, thereby preventing lithium-induced increases in Akt-1 (Chalecka-Franaszek &
Chuang, 1999; Kumari, Liu, Nguyen, Zhang, & D'Mello, 2001). Glutamate excitotoxicity has
been reported to decrease levels of Akt-1. This is mediated by long-term lithium treatment.
Additionally, long-term lithium treatment was found to increase recovery of Akt-1
phosphorylation and activity (Chalecka-Franaszek & Chuang, 1999). However, these findings
do not universally apply to all cell types. Using certain cell lines, some studies were unable to
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detect changes in Akt-1, specifically, phosphor-Ser-473-Akt, following lithium treatment (De
Sarno, Li, & Jope, 2002; Zhang, Phiel, Spece, Gurvich, & Klein, 2003).
MAP kinases are another important pathway involved in preventing apoptosis and
promoting neuroprotection (Rowe & Chuang, 2004). Some of the prominent members of the
MAP kinase family include c-Jun, N-terminal kinase (JNK), p38 kinase, and ERK. The
involvement of ERK in neuroprotection has been well documented in the literature (Chang et al.,
2003; Segal & Greenberg, 1996). The ERK pathway begins with the phosphorylation of the Trk
receptor by BDNF, leading to activation of Ras (Yan, Roy, Apolloni, Lane, & Hancock, 1998).
Ras binds to Raf proteins (Raf-1 and B-Raf) that subsequently activate MEK, resulting in
phosphorylation of ERK. ERK has direct and indirect effects on effector systems, such as NFκB and ribosomal S6 kinase (RSK). These effector systems subsequently regulate CREB and
GSK-3β. The MEK/ERK pathway also has deleterious downstream effects on the Bcl-2 family,
caspases, and AP-1 transcription factor (Rowe & Chuang, 2004; Steelman et al., 2004). Using
an in vivo model, it was reported that the MEK/ERK pathway was responsible for the
neuroprotective effects of chronic lithium treatment (Einat et al., 2003). However, others have
reported that lithium blocks the MEK/ERK pathway, although differences in results appear to be
cell-type-dependent (Pardo, Andreolotti, Ramos, Picatoste, & Claro, 2003). Together these
findings indicate that lithium-induced neuroprotection is complex and not solely related to any
one particular target of the drug (Rowe & Chuang, 2004).
The stress-induced kinases p38 and JNK are typically involved in promoting apoptosis.
Activation of these two pathways begins with a cellular stressor that activates GTPases (Rho,
Rac, Cdc42). The GTPases activate sets comprised of a MAP kinase kinase kinase
(MEKK1/2/3/4), a MAP kinase kinase (MKK3/4/6/7), and a MAP kinase (JNK or p38) (Mielke
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& Herdegen, 2000; Tibbles & Woodgett, 1999). MAP kinase translocates to the nucleus and
phosphorylates, thereby activating transcription factors (e.g., AP-1 and p53) (Sionov & Haupt,
1999; Whitmarsh & Davis, 1996). Support for lithium’s involvement in this pathway comes
from neuroprotection studies where cell damage induced by glutamate-toxicity or deprivation of
trophic factors was prevented by lithium (Chen et al., 2003; Hongisto et al., 2003; Rowe &
Chuang, 2004).
The central factor. Glycogen synthase kinase-3 is a serine/threonine protein kinase that
is highly abundant systemically as well as in the brain. There are at least 2 isoforms of GSK-3.
They are GSK-3α and GSK-3β. GSK-3 is involved in the regulation of neuronal plasticity, gene
expression, and cell survival, and may be involved in the pathology of neuropsychiatric and
neurodegenerative diseases (Li, Bijur, & Jope, 2002; Martinez, Castro, Dorronsoro, & Alonso,
2002). There are several kinases that regulate GSK-3β activity including Akt, protein kinase A
(PKA), protein kinase C (PKC), MAP kinases and the Wnt signaling pathway. GSK-3 acts on
diverse substrates, including more than 40 proteins that are involved in cellular metabolic
processes, signaling, and structural functions (Jope & Johnson, 2004; Martinez et al., 2002).
Among these diverse substrates are several signaling proteins (e.g., AP-1, CREB, activated Tcells, HSF-1, β-catenin, NF-κB, c-Jun, and Myc) (Davies, Jiang, & Mason, 2001; Li et al., 2000;
Martinez et al., 2002; Rothwarf & Karin, 1999; Rowe & Chuang, 2004; Yoganathan et al.,
2000).
There are three potential mechanisms for lithium-induced regulation of GSK-3β: directly,
indirectly, and autoregulation. It is important to note that the neuroprotection afforded by
lithium treatment is likely related to action via all three mechanisms. Additionally, GSK-3α is
also affected by lithium and may have relevance to lithium-induced neuroprotection (Rowe &
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Chuang, 2004). However, lithium’s effects on GSK-3β have been more thoroughly
characterized and therefore will be the focus of the following discussion.
Direct inhibition of GSK-3β. Direct inhibition of GSK-3β by lithium is thought to be
through competitive binding to magnesium channels. It was theorized that the direct inhibition
of GSK-3β may account for the observed neuroprotective effects in animal models of stroke.
However, lithium’s inhibition of GSK-3β occurs quickly. Only one study found that a single
dose of lithium was effective in reducing neurobehavioral deficits, when administered 3 hours
after the onset of MCAO (lasting 24 hours) (Ren et al., 2003). This is in contrast to several
studies that have shown that chronic treatment is necessary for neuroprotection (Bauer, Alda,
Priller, & Young, 2003; Rowe & Chuang, 2004; Xu et al., 2003). Additionally, the IC50 for
direct inhibition of GSK-3β is between 1.5 and 2.0 mM lithium. This range is higher than doses
typically found in neuroprotective studies. Thus, it was reported by Rowe and Chuang in their
2004 review article, that neuroprotection induced by lithium treatment can occur with less than
50% inhibition of pro-apoptotic GSK-3β.
Indirect inhibition of GSK-3β. Indirectly, it is speculated that lithium regulates the
phosphorylation status of GSK-3β by increasing Ser9 phosphorylation (Klein & Melton, 1996;
Li et al., 2002). The activity of GSK-3β is regulated by the phosphorylation states of Ser9 and
Tyr216. Phosphorylation of Ser9 decreases GSK-3β activity and phosphorylation of Tyr216
increases activity. Another potential avenue for lithium’s action is through the survival signaling
pathway. On this path, lithium treatment stimulates BDNF, which in turn promotes the
PI3K/Akt and MEK/ERK pathways, leading to inhibition of GSK-3β (Li et al., 2002).
Autoregulation of GSK-3β. The third potential mechanism of action for lithium-induced
inhibition of GSK-3β is through autoregulation (Rowe & Chuang, 2004). The activity level and
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phosphorylation state of GSK-3β can be altered via autoregulation. This is mediated by the
protein phosphatase-1 / inhibitor-2 (PP-1/I-2) complex (Zhang et al., 2003). In one direction,
increased activation of GSK-3β phosphorylates I-2, and activates PP-1. Activated PP-1
dephosphorylates GSK-3β at Ser9, thereby increasing the activation of GSK-3β, which starts the
cycle again. Working in the opposite direction, inhibition of GSK-3β inhibits PP-1 by I-2. This
results in an increase in the phosphorylation of Ser9, thereby decreasing the activation of GSK3β. Lithium-induced inhibition of GSK-3β inhibits PP-1, thereby inhibiting Ser9
dephosphorylation, further reducing GSK-3β activation (Rowe & Chuang, 2004; Zhang et al.,
2003).
Downstream factors. There are numerous downstream factors that may be affected by
lithium treatment. However, for the purposes of this dissertation, rather than detail all of these
factors, only those that are well established in the literature as being involved in lithium’s
neuroprotective effects will be discussed. These factors include: β-catenin, HSF-1, AP-1, and
CREB (Rowe & Chuang, 2004).
β-Catenin. β-Catenin is a proto-oncogene produced by the canonical Wnt pathway (Yu
& Malenka, 2003). Briefly, Wnt proteins bind to extracellular receptors that are part of the
family known as Frizzleds. Frizzleds subsequently activate the intracellular protein disheveled1, which in turn inhibits GSK-3β (Moon, Bowerman, Boutros, & Perrimon, 2002). Active GSK3β forms part of a β-catenin destruction complex. This complex phosphorylates β-catenin,
resulting in its breakdown. Therefore, inhibition of GSK-3β leads to increased levels of βcatenin. Increases in β-catenin promote interactions with the transcription factor T-cell
factor/lymphoid enhancer factor (Tcf-Lef) forming the Tcf/Lef-β-catenin complex. This
complex moves into the nucleus and promotes the transcription of several genes, many of which
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are involved in preventing apoptosis (Huelsken & Behrens, 2002; Moon et al., 2002; Rowe &
Chuang, 2004; Seidensticker & Behrens, 2000; Yu & Malenka, 2003). Due to lithium-induced
inhibition of GSK-3β and subsequent activation of the Wnt pathway, lithium is expected to
influence β-catenin levels. Indeed, both in vitro and in vivo studies have found that lithium
treatment increases β-catenin levels (Gould, Chen, & Manji, 2004; Rowe & Chuang, 2004;
Stambolic, Ruel, & Woodgett, 1996).
HSF-1. As described previously in this thesis, HSF-1 is a transcription factor that when
activated initiates the chaperone protein HSP-70. HSF-1 can be suppressed by serial
phosphorylation. ERK phosphorylates HSF-1 at Ser307, which then allows GSK-3β to
phosphorylate HSF-1 at Ser303 (Chu et al., 1996). This dual activation hinders the binding of
HSF-1 to DNA, as well as its ability to facilitate transcription (Bijur et al., 2000; Rowe &
Chuang, 2004; Xavier et al., 2000). HSP-70 is known to exert neuroprotective effects related to
its interaction stabilizing Akt, thus impeding Apaf-1 by mediating cytochrome c release and
caspase activation, in addition to inhibiting activation of JNK (Beere et al., 2000; Rowe &
Chuang, 2004).
AP-1. The transcription factor AP-1 can be either neuroprotective or neurodegenerative.
It is a dimeric complex that includes members of the Jun, Fos, CREB, and ATF families. The
action of AP-1 is dependent on the molecules that form the AP-1 complex and the genes targeted
by those complexes. Stress factors and cellular signals influence what role AP-1 plays in either
neuroprotection or apoptosis. In general, the signals that activate AP-1 subsequently activate
MAP kinases (e.g., JNK and p38), resulting in AP-1 binding to an assortment of genes (Rowe &
Chuang, 2004; Shaulian & Karin, 2002; Whitmarsh & Davis, 1996). AP-1 can be modulated by
secondary factors such as GSK-3β. Increases in GSK-3β cause phosphorylation of c-Jun and
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impairs AP-1 binding activity (Boyle et al., 1991; Rowe & Chuang, 2004). Lithium has been
found to both inhibit and induce AP-1 activity. Specifically, lithium inhibits the stimulusinduced activation of AP-1 and concurrently increases the basal activity of AP-1 (Asghari,
Wang, Reiach, & Young, 1998; Hongisto et al., 2003; Ozaki & Chuang, 1997; Rowe & Chuang,
2004).
CREB. The transcription factor, cyclic adenosine monophosphate response element
binding protein (CREB), is functionally related to learning and memory formation (Silva, Kogan,
Frankland, & Kida, 1998). CREB is a nuclear protein that regulates genes that contain a CRE
promoter region. Increases in calcium levels or cyclic adenosine monophosphate (cAMP) can
initiate the phosphorylation and activation of CREB. CREB-dependent transcription is necessary
for the cellular events involved in long-term memory formation (Silva et al., 1998). CREB also
plays a role in apoptosis. The sensitivity of CREB is modulated by many pathways including
BDNF, MEK/ERK, and GSK-3β (Bonni et al., 1999; Hansen, Rehfeld, & Nielsen, 2004;
Kopnisky et al., 2003; Rowe & Chuang, 2004). CREB-induced neuroprotective effects are
dependent on the induction and increased expression of anti-apoptotic factors such as Bcl-2 and
BDNF. As stated above, CREB can be induced by BDNF. The induction of CREB by BDNF
initiates a feedback loop whereby increases in CREB upregulate BDNF expression which then
increases CREB (Kopnisky et al., 2003; Rowe & Chuang, 2004).
Glutamate and NMDA receptors. Dixon and Hokin (1998), in an effort to determine the
mechanism of action for lithium, speculated that lithium was exerting therapeutic effects via
glutamate. They discovered that acute treatment with high levels of lithium (20 – 25 mM)
increased glutamate levels by blocking the reuptake of glutamate by the presynaptic neuron.
Due to the toxic effects of lithium associated with dosages higher than 1.2 mM, it is likely that
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the elevation in glutamate is related to lithium toxicity. Alternately, chronic lithium
administration in mice at therapeutic levels resulted in a significant increase in glutamate
reuptake. The reduction of glutamate in the synaptic cleft is hypothesized to be involved in the
anti-manic effects of the drug (Shaldubina et al., 2001). Increased reuptake of glutamate may
also be involved in lithium’s neuroprotective effects.
The NMDA receptor is an ionotropic glutamate receptor involved in numerous essential
processes including development, neuroplasticity, and excitotoxicity. When activated under
normal conditions, the NMDA-receptor allows calcium and sodium into the cell. When overstimulated, the calcium influx is detrimental, as it is the primary element in glutamate
excitotoxicity (Rowe & Chuang, 2004; Sattler & Tymianski, 2001). Excessive calcium
accumulates in the mitochondria and disrupts the mitochondrial membrane potential, initiating
apoptotic pathways (Rowe & Chuang, 2004; Stout, Raphael, Kanterewicz, Klann, & Reynolds,
1998). It is generally supported that inhibiting the overflow of calcium into the cell would
mediate the excitotoxic effects and protect the cell (Hashimoto et al., 2002; Rowe & Chuang,
2004). NMDA receptor-mediated neurotoxicity is also dependent on the MAP kinases.
Glutamate-induced excitotoxicity activates apoptotic-inducing factors such as JNK, p38, p53,
and AP-1. Pre-treatment with lithium provides neuroprotection from these potentially harmful
factors (Chen et al., 2003).
The NMDA receptor is comprised of heteromeric subunits, NMDA receptor 1 (NR1) and
NMDA receptor 2 (NR2). NMDA receptors must contain at least one NR1 and two or more
NR2 subunits A – D (NR2A – D) (Rowe & Chuang, 2004). The NR1 is required for receptor
function and the NR2 regulates the receptor function. Activation of the NMDA receptor allows
the influx of calcium into the cell. The activation state of the receptor is controlled by the
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phosphorylation state of the NR2A and NR2B subunits. Growing evidence supports the
regulation of NMDA receptors by the sarcoma family of protein tyrosine kinases (Src) (Salter,
1998). Src is found throughout the CNS, particularly in neurons, and increases in Src activation
are correlated with increased LTP in the CA1 of the hippocampus (Lu et al., 1998). Based on
these findings, overstimulation of Src-mediated receptor tyrosine phosphorylation may be
responsible for the over-activation of NMDA receptors, as in the case of glutamate-induced
toxicity (Rowe & Chuang, 2004; Salter, 1998).
Calcium-induced damage is one of the primary instigators of cytochrome c release and
apoptosis. An analysis of calcium levels, via uptake studies and Fura-2 calcium imaging,
revealed that glutamate-induced toxicity increased NMDA receptor-mediated calcium influx.
Lithium pre-treatment was able to prevent this insult-dependent increase in calcium and this was
correlated with a significant decrease in NR2B phosphorylation by tyrosine (Hashimoto et al.,
2002). In a rat model, ischemic injury was produced using permanent occlusion of both
vertebral arteries (Ma & Zhang, 2003). This injury type resulted in increased NMDA receptor
activation due to increased phosphorylation of the NR2A subunit. Injury-induced elevations in
the level of postsynaptic density protein 95 kDa (PSD-95) (NMDA receptor scaffolding protein)
was found to modulate the interaction of Src and Fyn with the NR2A subunit, resulting in
increased phosphorylation of NR2A. Pre-treatment with lithium for 7 days resulted in complete
inhibition of the interactions of Src and Fyn, members of the Src family and regulated by PSD95, with NR2A. Interestingly, no difference was observed in overall protein expression of Src,
Fyn, NR2A, or PSD-95. This indicates that some of lithium’s neuroprotective effects are related
to preventing the modulation of Sch, Fyn, and NR2A by PSD-95 (Ma & Zhang, 2003).
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Lithium-induced neurogenesis and plasticity. Lithium’s neuroprotective properties
have been well established in the literature and there is compelling evidence that chronic lithium
treatment also enhances hippocampal neurogenesis (Chen, Rajkowska, Du, Seraji-Bozorgzad, &
Manji, 2000; Yan et al., 2007). Support for lithium-induced neurogenesis comes from in vitro
and in vivo studies, which show lithium promotes differentiation of hippocampal neural
progenitor cells into neurons (Chen et al., 2000; Kim et al., 2004; Yan et al., 2007). Some of the
mechanisms that are reported to be involved in lithium-induced neuroprotection are thought to
also be involved in promoting neurogenesis, such as Bcl-2 and BDNF (Chen et al., 1999;
Fukumoto, Morinobu, Okamoto, Kagaya, & Yamawaki, 2001; Hashimoto et al., 2002; Wei et al.,
2001).
Following lithium treatment, bcl-2 levels are markedly increased in the CNS, particularly
within the hippocampus (Chen et al., 1999). Bcl-2 has been found to exert neurotrophic effects,
thereby enhancing axonal regeneration, promoting neurite outgrowth, and increasing axonal
growth rate (Chen, Schneider, Martinou, & Tonegawa, 1997). Based on findings from human
MRI studies showing increased brain volume following lithium treatment, Chen et al., 2000,
examined the effects of lithium treatment on the levels of bromodeoxyuridine (5-bromo-2deoxyuridine, BrdU) expression, a measure of proliferating cells, in the hippocampus of
C56BL/6 mice. The mice were given lithium chow for 3 – 4 weeks, resulting in an average
serum level of 0.97 ± 0.20 mM lithium. BrdU was administered for the last 12 days of lithium
treatment. Neurons were also stained with Neuronal Nuclei (NeuN), an antibody that recognizes
the vertebrate nervous system and binds to neuron-specific nuclear protein (Mullen, Buck, &
Smith, 1992). Chen, (2000) found a significant increase in BrdU positive neurons in the
hippocampus, specifically in the dentate gyrus (DG) of lithium-treated animals as compared to
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controls. However, there was no difference in NeuN expression between the lithium (66%) and
control (68%) animals (Chen et al., 2000).
Vazey and Connor (2009) investigated the effect of lithium on the priming and
differentiating of neural progenitor cells (NPC) derived from the subventricular zone (SVZ).
Cells were primed using 3 mM lithium for 14 days. After the last day of priming, the
neurospheres were plated. Four weeks later, the lithium-treated cells showed a significant
increase in neuronal differentiation as compared to non-primed cultures. Using calbindin and
glutamic acid decarboxylase 67 (GAD-67) as indicators, it was determined that lithium chloride
significantly increased the generation of mature, region-specific neurons. The authors suggest
that lithium has a role in increasing the ratio of cells expressing neuronal markers while
concurrently decreasing glial progeny (Vazey & Connor, 2009).
Su, Chu, and Wu (2007) examined the effect of lithium on survival, proliferation and
differentiation of spinal cord-derived neural progenitor cells (NPC) in vitro and after
transplantation into the spinal cord of uninjured animals. NPCs from transgenic SpragueDawley rats, expressing green fluorescent expressing protein (GFP), were injected into the dorsal
funiculi of female Sprague Dawley rats. Half of the animals that received the transplanted cells
also received daily treatment with lithium chloride (85 mg/kg, ip), the others received saline. At
2 and 4 weeks post-transplantation, lithium-treated animals had significantly more GFP
expressing cells and increased neuronal differentiated cells compared to saline controls. The
authors cite several possible mechanisms for the observed increase in cell survival including
inhibition of GSK-3β and activation of TrkB receptors via upregulation of BDNF (Su et al.,
2007).
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Lithium and learning. There are conflicting reports regarding lithium’s effects on
learning and memory in both clinical and animal studies. Many older clinical studies have
reported that lithium impairs long-term and short-term verbal memory recall (Kropf & MullerOerlinghausen, 1979; Kusumo & Vaughan, 1977; Shaw, Stokes, Mann, & Manevitz, 1987).
However, some studies have found lithium treatment either had no effect on learning and
memory (Squire, Judd, Janowsky, & Huey, 1980), or that it increased recall on tests that assess
immediate and delayed memory function (Person-Data Test and 30 Face Test) (Smigan & Perris,
1983). Pachet and Wisniewski (2003) reviewed these studies and determined that the correlation
between lithium treatment and verbal memory impairment was comparatively weak and they
indicated that additional research was needed to verify the findings of the previous studies.
Some of the concerns brought up in the article were discrepancies in testing procedures, a lack of
standardized testing, and insufficient control for comorbid illnesses.
In a recent study, Senturk et al. (2007) found that euthymic BAD patients on
monotherapy with lithium had significantly impaired immediate verbal memory recall assessed
by the Logical Memory Subscale of the Wechsler Memory Scale I (WMS). Similar to previous
studies, other areas of cognitive functioning were not affected by lithium treatment. Cognitive
functioning such as psychomotor speed, working memory, and visuospatial abilities, were
assessed using subsets of the Wechsler Adult Intelligence Scale Revised (WAIS-R) and revealed
no significant impairments relative to control subjects (Senturk et al., 2007).
Preclinical studies have also reported inconsistent effects of lithium treatment on memory
tasks. The study by Al Banchaabouchi, de Ortíz, Menéndez, Ren, and Maldonado-Vlaar (2004)
investigated the effect of chronic lithium treatment, within the therapeutic range, on performance
in memory-dependent behavioral tasks. Male Long Evans rats were administered lithium
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carbonate chow for 4 weeks and were subsequently assessed for object recognition memory and
spatial discrimination learning ability, using the novel object recognition task and hole-board
spatial discrimination task respectively. No significant difference between groups was observed
in the novel object recognition task. However, lithium-treated animals showed delayed
acquisition in the hole-board task, but only on the first 2 days (out of 3) of testing. Two sessions
were performed on each of the three testing days. Similar to the acquisition data, lithium-treated
rats made more reference errors and had significantly longer search times as compared to non
lithium-treated rats in only the first two out of six test sessions. These data indicate that
treatment with lithium may selectively impair initial performance in spatial discrimination
learning tasks (Al Banchaabouchi, de Ortíz, Menéndez, Ren, & Maldonado-Vlaar, 2004).
Lithium’s effects on spatial memory and working memory under chronic stress
conditions were evaluated using the MWM and a passive avoidance task respectively
(Vasconcellos, Tabajara, Ferrari, Rocha, & Dalmaz, 2003). The animals were randomly
assigned to one of four treatment groups (control, lithium, stress, stress + lithium), and were
trained to locate a hidden platform in the MWM over a five-day period (4 trials per day). In the
training sessions, no significant difference was detected between the treatment groups. In the
recall test (probe trial), the hidden platform was removed and the swim behavior of the animals
was recorded. The authors found that lithium-treated rats showed a trend towards shorter
latencies to reach the location of the hidden platform. Additionally, lithium-treated rats had
significantly more crossings in the area of the hidden platform (Vasconcellos et al., 2003). These
data suggest that lithium may diminish stress-induced impairments in spatial memory tasks.
Eight-days later, these same animals were used in a working memory version of the MWM. In
this task, the daily location of the platform was changed; however, during the daily sessions the
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location of the platform was fixed. Lithium-treated animals did not exhibit significant
differences in performance in the reference memory task, indicating that under chronic stress,
working memory is unaffected by the selected doses of lithium (Vasconcellos et al., 2003). The
improvement observed in the reference memory portion of the MWM, a task dependent on the
hippocampus, and the lack of effect found in the working memory portion of the MWM, a task
reported to rely more heavily on the medial PFC region (O'Dell et al., 2000), suggest that the
beneficial cognitive enhancing effects of chronic lithium treatment are associated with
hippocampal functioning.
Data from Tsaltas et al., 2007, provide additional support for lithium-induced
improvements in spatial memory. Chronic lithium treatment was found to significantly enhance
spatial working memory in the T-maze, using a delayed non-matching to place rule. The authors
reported that lithium treatment did not affect spatial reference memory because there were no
differences in the acquisition of this task as compared to control animals. Lithium treatment
enhanced performance in the T-maze, as compared to saline-treated rats, when moderate
demands were placed on memory (i.e., test intervals > 30 s and < 60 s). However, when a
greater demand was placed on working memory, a test interval of 60 s, the lithium-treated
animals performed similar to saline-treated controls. The effect of lithium treatment on longterm retention was assessed using a single trial step-through passive avoidance task. Lithiumtreated rats demonstrated longer retention of the passive avoidance task as compared to salinetreated rats. Based on these data, it was suggested that lithium treatment potentiated the longterm retention of a weak conditioning trace (Tsaltas et al., 2007).
These studies combined suggest that the previously held belief that lithium impairs
memory functioning may be incorrect (Tsaltas et al., 2007; Vasconcellos et al., 2003). Due to
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the lack of consensus between studies investigating the effects of lithium treatment and cognitive
function, and the new data emerging on the neuroprotective effects of lithium, it is necessary to
further evaluate the effects of lithium as they relate to cognitive performance.
Study Rationale
Data from both in vitro and in vivo studies in animal models of various neurodegenerative
diseases and human patients with BAD indicate that chronic administration of lithium inhibits
NMDA-receptor-mediated calcium influx and induces both up-regulation of numerous survival
signaling pathways (such as Bcl-2, CREB, BDNF, PI3K/Akt and MEK/ERK pathways, Hsp70,
and β-catenin), and down-regulation of pro-apoptotic activities (e.g., p53, Bax, caspase,
cytochrome c release, beta-amyloid peptide production, and tau hyperphosphorylation), thereby
limiting neuronal cell death cascades (Rowe & Chuang, 2004; Wada, Yokoo, Yanagita, &
Kobayashi, 2005). To our knowledge, however, no data are available describing the mechanism
of action of this drug in animal models of TBI. The purpose of the present thesis is, therefore, to
provide additional rigorous evidence in support of the beneficial effects of lithium in the
treatment of TBI, to define the best dosing paradigm, and to shed more light on the potential
mechanisms of action for the observed effects in the TBI setting.
Hypotheses
The general hypothesis is that postinjury lithium treatment will significantly improve
outcome following TBI. Specifically, lithium will reduce TBI-induced deficits in
vestibulomotor, cognitive, and behavioral functioning. It is also hypothesized that lithium
treatment will reduce TBI-induced cell death in the hippocampus. Lastly, that lithium treatment
will result in reduced activation of caspase-3 and increased expression of BDNF and growth
associated protein-43 (GAP-43) within the hippocampus.
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Specific Aims
The first aim was to determine the optimal dose of lithium that, when administered
following TBI, would significantly reduce injury-associated cognitive deficits. The second aim
was evaluate the effects of lithium treatment as a therapy to ameliorate depressive-like behavior
in rats following TBI. The third aim was to use the most effective dose of lithium and determine
the therapeutic time window for administering that dose while still maintaining the observed
beneficial effects on cognition. The fourth aim was to evaluate the neuroprotective properties of
lithium as they relate to cell survival in the CA3 and hilar subregions of the hippocampus. The
fifth aim was to evaluate the effect of lithium on selected markers known to be affected by TBI
that are involved in neurogenesis, neuroprotection, and apoptosis.
General Methods
The methodologies contained within this section are common to all the experiments
described in this thesis. Methodologies specific to the individual experiments (Experiments 1 –
4) are detailed in the corresponding chapters.
Subjects
Adult male Sprague Dawley rats (Hilltop Lab Animals, Inc., Scottsdale, PA), weighing
between 300 – 370 grams were used in the present thesis. Animals were individually housed in a
vivarium, maintained at 22 °C, on a 12 hour light/dark cycle. All animals were given ad libitum
access to food and water. The procedures used in the present thesis followed the guidelines
established in the Guide for the Care and Use of Laboratory Animals (U.S. Department of
Health and Human Services) and were approved by the Institutional Animal Care and Use
Committee (IACUC).
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Experimental TBI
Surgical preparation. Each rat was initially anesthetized, in a Plexiglas bell jar, by
inhalation of 4% isoflurane gas, in a carrier gas of 70% nitrous oxide: 30% oxygen, for 4 min.
The surgical site was shaved and the animal was placed in a stereotaxic device, fitted with a
nosecone to deliver the gas anesthesia during the procedure. The optimal depth of anesthesia
was achieved with 2% isoflurane, in the same carrier gas mixture used previously. The surgical
site was prepped using gauze sponges soaked in betadine and ethanol. The scalp was sagittally
incised and a 4.8 mm diameter burr hole was performed over the right cerebral hemisphere
between the lambda and bregma craniometrical points. Two small nickel-plated screws were
placed 1 mm rostral to bregma on the ipsilateral side of the burr hole, and another 1 mm lateral to
the central suture, midway between bregma and lambda, on the contralateral side to the burr
hole. A Luer-Lok syringe hub was secured on the skull at the site of the burr hole first with αcyanoacrylate, then with dental acrylic applied around the syringe hub and two screws were
added for additional stability. The scalp was sutured and bacitracin applied to the surgical site.
Each subject was monitored for full recovery from anesthesia before being returned to their
home cage.
Fluid-percussion injury device. The fluid-percussion injury (FPI) device used to
produce experimental TBI was identical to that described in detail by Dixon et al., 1987. Figure
1 shows an image of the injury device. The device consists of a 60-cm-long and 4.5 cm diameter
Plexiglas cylinder with a rubber-covered O ring-fitted Plexiglas piston at one end and, on the
opposite end of the cylinder, a 2-cm-long metal housing mounted with an extracranial pressure
transducer (Entran Devices, Inc., Model EPN-0300*-100A). This metal housing was attached to
a 5-mm transfer tube with a 2.6 mm inner diameter that ends with a male Luer taper fitting. At
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the time of injury, an injection port with a Luer taper was used to connect the male end of the
transfer tube and the surgically implanted female Luer-Lok fitting. The entire system was then
filled with distilled water. The injury was produced by releasing a metal pendulum positioned to
strike the piston of the injury device. A small volume of distilled water was injected into the
closed cranial cavity to produce a brief displacement and deformation of brain tissue. The
magnitude of injury was controlled by varying the height from which the pendulum was
released.

Figure 1. Image of fluid percussion injury (FPI) device.
Lateral fluid-percussion injury. Twenty-four hours after surgical preparation, at the
time of injury, the rats were anesthetized by breathing 4.0% isoflurane gas, in a carrier gas of
70% nitrous oxide to 30% oxygen, for 4 min. The surgical site was exposed and the animal was
connected to the FPI device. The force of the injury administered was between 2.0 to 2.2
atmospheres of pressure (atm), which is equivalent to a moderate-level severity brain injury. The
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atm were recorded by the in-line transducer connected to a storage oscilloscope (Tektronix 5111;
Beaverton, OR). Sham-injured controls received the same surgical preparation, anesthesia, and
connection to the injury device, however, no injury was delivered. All animals were
immediately ventilated with room air until spontaneous breathing was resumed.
Postinjury neurological assessment. The injury resulted in loss of consciousness and
temporary suppression of the animal’s reflexes. Immediately following the injury, the animal
was placed supine and suppression of the righting reflex was assessed. The amount of time
required for the animal to regain this reflex after TBI is a good predictor of injury severity
(Gennarelli, 1993; Hallam et al., 2004; Hamm, 2001; Schmidt & Grady, 1995; Thompson et al.,
2005).
Drug Preparation and Administration
Lithium chloride (Sigma, St. Louis, MO) was dissolved in 0.9% sterile saline to make
1.00, 0.50, 0.25, and 0.125 mmol/kg solutions. Lithium was administered via intraperitoneal
injection, in a volume of 1 ml/kg. Vehicle treated animals were administered 1 mg/kg, 0.9%
sterile saline.
Statistical Analysis
Injury severity was evaluated by analysis of the suppression of the righting reflex. A
one-way ANOVA was used to determine if the level of injury was comparable among the groups
that received a TBI. Where appropriate, a Fisher least significant difference (LSD) post hoc
analysis was used to compare individual group differences.
Experiment 1
Study Rationale
Cognitive impairments in memory and attention can occur following even mild TBI and
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can persist for years after the traumatic event (Draper & Ponsford, 2008; Kashluba, Hanks,
Casey, & Millis, 2008; McDonald, Flashman, & Saykin, 2002). It is widely believed that these
sequelae are largely attributable to the damage caused by secondary injury events, including
ischemia, excitotoxicity, excess calcium release, and mitochondrial dysfunction that ultimately
may lead to neuronal injury or death. Findings from preclinical studies show that these
disruptions to cognitive and cellular functioning can be attenuated by the administration of
neuroprotective agents and drugs used in clinical settings for the treatment of memory and
attention deficits (Marklund, Bakshi, Castelbuono, Conte, & McIntosh, 2006). Thus,
pharmacotherapies that positively modulate neuroprotective mechanisms and/or have cognitive
enhancing effects are sought after as potential therapies for brain-injured patients.
One such drug is lithium, a therapeutic agent extensively used for over 50 years in the
treatment of BAD. The renewed interest in lithium is due to findings from preclinical studies
that have demonstrated both neuroprotective and cognitive enhancing effects following lithium
treatment. Indeed, several studies using animal models of ischemic injury and stroke have
demonstrated that lithium treatment improved cognitive outcome and prevented neuronal cell
loss (Kopnisky et al., 2003; Ren et al., 2003; Yan et al., 2007; Yan et al., 2007). Furthermore,
some recent studies have reported that lithium treatment, in non-brain-injured rodents, was found
to enhance cognitive function (Nocjar, Hammonds, & Shim, 2007; Tsaltas et al., 2007;
Vasconcellos et al., 2003).
Similar to what has been reported in clinical studies, the data from animal studies lack a
consensus regarding the benefit to vs. impairment of cognitive functioning following lithium
treatment. Despite the discord among preclinical studies, there are sufficient data to warrant
further examination of lithium-induced cognitive enhancement. Studies that support this
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assertion are briefly described here. Lithium treatment was found to block drug-induced
impairment of spatial memory retention by the protein kinase AII (PKAII) inhibitor H-89, thus
reducing the swim latencies in the MWM (Sharifzadeh et al., 2007). Rats exposed to chronic
stress demonstrate impaired performance in tasks that require reference memory abilities.
Lithium treatment negated the effect of stress on spatial learning and significantly improved
MWM performance (Vasconcellos et al., 2003). Furthermore, lithium administration to naïve
rats was found to improve performance in neurobehavioral tasks, such as delayed non-matching
to place in the T-maze, spatial memory retention in the MWM, and passive avoidance
assessments (Tsaltas et al., 2007; Vasconcellos et al., 2003).
Irrelevant of the severity level of TBI (mild, moderate, severe), individuals who have
sustained a brain injury are more likely to present with psychiatric and mood disorders, including
depression, anxiety, psychosis, and behavioral problems (e.g., poor motivation, agitation,
aggression, disinhibition) (Fleminger, 2008; Jones et al., 2008; Jorge & Starkstein, 2005; Rogers
& Read, 2007). The most commonly reported psychiatric illness following TBI is depression.
Based on the cumulative effects of depression combined with the other sequelae associated with
human TBI, it is important to evaluate potential therapies that target the psychological, in
addition to the biological, components of brain injury.
Lithium is effective as a prophylaxis and a treatment for the manic and depressive
episodes associated with BAD, and is highly effective as an adjunct antidepressant in treatmentrefractory patients (Bauer et al., 2003; Gould et al., 2008; O'Donnell & Gould, 2007; Schou,
2001). Eroğlu and Hizal (1987), using Wistar rats, showed that chronic lithium treatment, via
intraperitoneal injection, was associated with antidepressant-like effects in the forced swim test
(FST). Chronic treatment with lithium chow was found to significantly reduce the time
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immobile in a mouse model of the FST (Gould et al., 2008; O'Brien et al., 2004; Shaldubina et
al., 2006).
There are several lines of evidence from preclinical studies that indicate lithium treatment
has neuroprotective effects against insult-induced neuronal injury and that it may have memoryenhancing effects. Lithium has also been found to reduce depressive-like behavior in rodents.
The physiological and behavioral response to lithium treatment, as observed in preclinical
studies, appears to affect key aspects of the sequelae associated with TBI (i.e., neuronal cell loss,
cognitive impairment, and neuropsychiatric illness). Based on these reported findings, it seems a
logical progression to investigate the potential benefit of post-TBI lithium treatment.
Surprisingly, there is a paucity of research combining lithium treatment and TBI.
Treatment paradigm. A predominant feature of lithium-induced neuroprotection
studies is the usage of a preinjury treatment paradigm (Chuang, 2004; Chuang, 2005; Rowe &
Chuang, 2004; Wada et al., 2005; Xu et al., 2003; Yan et al., 2007). To our knowledge, there has
been only one in vivo study (Ren et al., 2003) that has evaluated the effect of post-insult lithium
treatment. Animals were subjected to MCAO for 1 hr followed by reperfusion for 23 hours.
This injury produced an extensive infarction in the cerebral cortex. Single doses of lithium
chloride (between 0.50 – 3.00 mEq/kg, sc) administered immediately after initiation of MCAO
significantly reduced the infarct volume when assessed at 24 hours post-insult (Ren et al., 2003).
A single dose of lithium, 1.00 mEq/kg, delayed up to three hours after the onset of MCAO, was
associated with a significant reduction in ischemia-induced neurological deficits at 24 hours
post-insult. Neurological deficits were assessed using tests for motor (flexion of hind limb and
forelimb, head movement, ability to walk in a straight line, circling to paralytic side, and falling
down on paralytic side), sensation (visual and proprioceptive tests), and reflex response (pinna,

68

and startle reflex) (Ren et al., 2003). Lithium treatment, administered immediately after the
onset of MCAO and continued daily for 7 days, was correlated with a significant reduction in
ischemia-induced neurological deficits on post-insult days 1 – 7. Additionally, the benefits
associated with 7-day-lithium treatment were still observed up to 14 days post-insult. These
data, taken together, support the use of an early postinjury time point for initiating lithium
treatment, that lithium must be administered over the course of several days and that the
beneficial effects of lithium treatment can continue beyond the duration of treatment.
It is well known that time is a critical factor when treating an individual with a TBI.
Secondary injury cascades are initiated immediately after sustaining a TBI and the resulting
neuronal death or dysfunction and can last from hours to weeks postinjury. To mitigate these
harmful effects, it is generally accepted that pharmacological interventions that target
neuroprotective mechanisms must be administered early after injury since treatment delays may
render the drug ineffective due to irreparable damage. Additionally, the innate mechanisms that
support neuronal plasticity and recovery are initiated within the first week after a TBI. Drugs,
such as lithium, that have been shown to affect neuronal plasticity, may require early initiation of
treatment to facilitate and maximize recovery.
Experimental TBI studies that have focused on the mechanisms associated with the acute
phase of secondary brain injury typically administer a pharmacological treatment immediately
prior to (30 – 15 min) or immediately following (10 – 30 min) injury. The time point selected
for administering the initial dose of lithium in Experiment 1, 30 min post-TBI or sham-injury, is
an approximate midpoint between the furthest time point successfully used in an animal model of
ischemia (2 hr post-MCAO) (Ren et al., 2003) and preinjury drug administration time points.
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Dose selection. The doses selected for use in the present experiment (1.00, 0.50, 0.25,
and 0.125 mmol/kg, lithium chloride) were chosen based on previous in vitro and in vivo studies.
These studies reported lithium-induced therapeutic and neuroprotective effects were observed
following treatment with doses of lithium ranging between 0.5 – 1.0 mEq/kg (mEq/kg equivalent
to mmol/kg) (Nonaka & Chuang, 1998; Ren et al., 2003; Xu et al., 2003; Yan et al., 2007). To
put these doses of lithium into perspective, the intraperitoneal dose of lithium chloride used in
rodent taste aversion studies is approximately 3.0 mmol/kg (127.20 mg/kg) (Masaki &
Nakajima, 2006; Nachman & Ashe, 1973; Nolan et al., 1997).
Neurobehavioral outcome assessment. In the present study, the neuroprotective effects
of lithium were evaluated based on the performance of the animals on neurobehavioral outcome
measures: i.e., beam walk (BW), MWM, and FST. In order to best determine the dose/doses of
lithium that would provide neuroprotective effects in the injured brain, a dose response was
carried out using the animal stroke literature as a guide in selecting the dose range.
Vestibulomotor functioning was evaluated based on performance in the BW task. This
task was selected because it is a reliable, sensitive, and valid measure of motor deficits following
TBI (Hamm, 2001). The postinjury time points that we selected for assessment on the BW (PID
1, 3, 7) were based on previous data from our laboratory showing that motor deficits produced by
lateral FPI are most pronounced between PID 1 – 3 and typically resolve by PID 7.
The MWM was selected as the primary cognitive outcome measure because it has been
extensively used with the lateral FPI model and it is known to be sensitive to hippocampal
damage, a brain region known to be vulnerable in human TBI. The MWM was selected to test
the ability of the rat to utilize reference memory for spatial learning and memory (Morris,
Garrud, Rawlins, & O'Keefe, 1982). Performance in the MWM is directly correlated with the
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functionality of the hippocampus (Morris et al., 1982). Similar to the BW, the MWM is
relatively quick and easy to learn for rats and food does not have to be withheld for the
acquisition of this task. The timeframe for assessment in the MWM (PID 10 – 14) was selected
because any motor deficits produced by the injury have subsided and TBI-induced cognitive
deficits are more pronounced, thus making any drug effects more apparent (Hamm et al., 1993).
The FST is a well-established behavioral model used to assess the efficacy of
antidepressant medications and as a measure of depressive-like behavior (Castagne, Porsolt, &
Moser, 2009; Jones et al., 2008; Lahmame, Grigoriadis, De Souza, & Armario, 1997; Porsolt,
Anton, Blavet, & Jalfre, 1978; Porsolt, Le, & Jalfre, 1977). Based on clinical data pertaining to
the incidence of depression among TBI patients and the potentially debilitating effects of this
illness, the FST was included in the present thesis to evaluate the impact of lithium on
depressive-like behavior following TBI. Lithium, on its own, has been shown to significantly
reduce the time spent immobile in the FST in both rats (Eroglu & Hizal, 1987; Tomasiewicz,
Mague, Cohen, & Carlezon, Jr., 2006) and mice (Gould et al., 2007; O'Brien et al., 2004;
Shaldubina et al., 2006). In the study by Eroğul and Hizal (1987), male Wistar rats were
administered daily injections of lithium chloride (0.5, 2.0, & 5.0 mEq/kg, ip) over a 19 day
period. On day 18 (day 1 of the FST), the animals were placed in a cylinder, filled with water
from which they could not escape, for the 15 minute (exposure) session. During the 5 minute
(recall) test session, on day 19 of lithium treatment (day 2 of the FST), the lithium-treated groups
spent significantly less time immobile as compared to saline-treated controls. These data
indicate that lithium reduced the depressive-like behavioral response to the FST (Eroglu & Hizal,
1987). In studies using rodent TBI models, only a handful have used the FST as an outcome
measure and there is a lack of consistency in these findings. Some studies report that there is no
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difference between brain-injured and sham-injured rats while others have found significant
behavioral differences after TBI, as well as dysregulation of the neuroendocrine stress response
system (Jones et al., 2008; Milman, Rosenberg, Weizman, & Pick, 2005; Tweedie et al., 2007;
Yucel et al., 2008).
Hypotheses
It is our hypothesis that treatment with lithium will reduce the cognitive and motor
deficits associated with lateral FPI. Research supporting the neuroprotective effects of lithium
treatment in animal models of brain injury and neurodegenerative diseases found that serum
concentrations of lithium at or below the levels used clinically in human patients provided the
greatest neuroprotection. All the doses of lithium selected for use in the present study fall within
this desired range. Therefore, we theorize that all the selected doses of lithium will ameliorate
postinjury deficits. We extrapolated, from a thorough review of the literature, that lower doses
of lithium, within the desired therapeutic range, provided the most benefit. Therefore, we
hypothesized that the middle and low doses of lithium (0.50, 0.25, 0.125 mmol/kg) would be
more effective (i.e., neuroprotective) as compared to the high dose (1.00 mmol/kg).
The findings from other TBI-focused laboratories, where the FST was employed as a
measure of depressive-like behavior following TBI, support the use of this assessment in rodent
models of brain injury. It is hypothesized that TBI will increase the amount of time spent
immobile in the vehicle-treated rats as compared to the other treatment groups. Based on
lithium’s mood stabilizing effects, it our hypothesis that animals receiving lithium treatment
(both injured and sham) will exhibit less time spent immobile in the FST as compared to the
TBI-Vehicle group and Sham-Vehicle group.
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Specific Aims
The first aim of this study was to identify the dose of lithium associated with the greatest
reduction in TBI-induced deficits, as measured by BW and MWM performance. The second aim
of this study was to evaluate the efficacy of lithium treatment in preventing or reducing
depressive-like behavior after brain injury, as assessed by the FST.
Methods
Information pertaining to the subjects, surgical preparation, experimental brain injury,
neurological evaluation, and drug preparation used in this experiment are identical to what was
described in Chapter 2, General Methods.
Experimental design. Animals underwent surgical preparation and lateral FPI or shaminjury. Injured animals were randomly assigned to one of five treatment groups, 1.00, 0.50, 0.25,
and 0.125 mmol/kg lithium, or vehicle (0.9% sterile saline). Sham-injury animals were
randomly assigned to one of two treatment groups, 1.0 mmol/kg lithium or vehicle. Table 1
illustrates the treatment group design for Experiment 1. Once-daily lithium- or vehicletreatment was initiated 30 min postinjury and continued through the last day of behavioral
assessment in the FST (PID 19). All drug vials were coded to prevent experimenter bias.
Animals were injected at approximately the same time each day. On the days when the animals
were behaviorally assessed, the start time for the testing was approximately 30 – 60 minutes after
lithium or vehicle was administered.
Animals were assessed on the BW on PID 1, 3, and 7. MWM assessment took place on
PID 11 – 15. Hidden platform testing in the MWM occurred on PID 11-14. The probe trial and
visible platform assessments were performed on PID 15. The FST was performed on PID 18 and
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19. The first session was a 15 min training session followed 24 hours later by the 5 min test
session. Figure 2 illustrates the treatment plan for animals in Experiment 1.

Table 1
Experimental group design for beam walk and MWM portion of Experiment 1
Treatment Groupa
TBI-Vehicleb
TBI + 1.00c
TBI + 0.50c
TBI + 0.25c
TBI + 0.125c
Sham + 1.00c
Sham-Vehicleb
Note. an = 10 for each group. bvehicle (0.9% sterile saline) injection volume
1 ml/kg. cdosage of lithium as mmol/kg, dose volume 1 ml/kg
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Figure 2. Timeline for Experiment 1. This figure provides a detailed timeline for the
neurobehavioral assessments and dosing paradigm for all treatment groups in
Experiment 1.

Drug preparation. Lithium chloride (Sigma, St. Louis, MO) was dissolved in 0.9%
sterile saline to make 1.00, 0.50, 0.25, and 0.125 mmol/kg solutions. Lithium was administered
via intraperitoneal injection, in a volume of 1 ml/kg. Vehicle treated animals were administered
1 mg/kg, 0.9% sterile saline, also called normal saline.
Lithium dose response. The doses of lithium selected for the present study correspond
to the following doses in mg/kg: 1.00 mmol/kg (42.350 mg/kg), 0.50 mmol/kg (21.175 mg/kg),
0.25 mmol/kg (10.587 mg/kg), and 0.125 mmol/kg (5.293 mg/kg). These doses were selected
based on previous in vivo studies that reported therapeutic and neuroprotective effects following
lithium treatment that produced serum levels within the therapeutic range used clinically to treat
BAD (0.60 – 1.20 mmol/kg) or below (Allagui et al., 2008; Nonaka & Chuang, 1998; Omata et
al., 2003; Ozaki & Chuang, 1997; Xu et al., 2003; Yan et al., 2007). Significant amelioration of
insult-induced deficits on behavioral and histological measures were reported following daily (23
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day) treatment with lithium chloride, 1.00 mmol/kg via intraperitoneal injection (the highest dose
selected for the present study), that produced serum levels within the therapeutic range, 0.97 ±
0.31 mM (Yan et al., 2007).
Neurobehavioral assessment. Three neurobehavioral outcome assessment measures
were selected for use in the present study: BW, MWM, and the FST. Vestibulomotor
functioning was evaluated using the BW. Cognitive ability was assessed using the MWM.
Finally, depressive-like behavior was determined by performance in the FST.
Beam walk task. The vestibulomotor functioning of each rat was assessed using the
BW, similar to that detailed by Feeney and colleagues (1982) (Feeney, Gonzalez, & Law, 1982;
Dixon, Lyeth, Povlishock, Findling, Hamm, et al., 1987). The rat must escape a bright light and
loud noise via walking along an elevated 100 cm long, 2.5 cm wide wooden beam to enter a
darkened goal box at the opposite end of the beam. The latency for the rat to reach the goal box
(not to exceed 60 s) was recorded and averaged over three trials for each assessment day. If the
rat fell off the beam, 60 s was recorded as the time for that trial. On the training day there was
no limit on the number of trials allowed for each rat. Each rat was trained on the BW until they
met criterion, traversing from one end of the beam to the goal box on three consecutive trials in
less than 10 s per trial. Rats were trained on the BW one day prior to injury or sham-injury. All
subsequent assessments following the training day consisted of three trials per day.
Morris water maze. The MWM is a large circular tank (180 cm diameter by 45 cm high)
filled to a depth of 30 cm with thermostatically controlled warm water maintained between 25 –
28 oC. Figure 3 is an image of the MWM and tracking system. For assessment, rats were given
four trials per day for 4 consecutive days on PID 11-14. For each daily block of four trials, the
rats were placed in the tank facing the wall at one of the four designated entry points. The order
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of the entry points was randomized to minimize practice effects. Each rat started the trials once
from each of the four cardinal directions (north, east, south, and west) in random order. The
hidden goal platform was positioned 45 cm from the outside wall and was not moved during the
experiment. Rats were given a maximum of 120 s to find the hidden platform. If the rat failed to
find the platform within the allotted time, it was placed on the platform by the experimenter.
Upon completion of each trial, all rats remained on the platform for 30 s before being placed in a
heated incubator between trials. The inter-trial interval for all the trials was approximately 10
min.
The Videomex Water Maze Program (Columbus Instruments, Columbus, OH) was used to track
the movement of an animal during each trial in the MWM and calculated several pieces of data
useful in interpreting the maze performance of the test subjects, such as goal latency, cumulative
distance, and proximity. Goal latency is the amount of time, in s, required for each animal to
locate the goal platform and total distance traveled is recorded in meters per second (m/s). The
swim speed is calculated by dividing the average distance traveled by the animal by the average
latency to reach the goal platform. This outcome measure can indicate whether or not the
latency to reach the platform is affected by injury-induced motor disturbances and/or druginduced alterations in motor performance.

For this experiment, the swim speed of different

groups was compared to ensure that differences in performance were not due to motor function.
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Figure 3. Schematic of Morris water maze (MWM) and tracking system.

Gallagher, Burwell, and Burchinal (1993) first described a method of calculating the
proximity based on the relative position of the animal to the center point of the goal platform.
The distance of the subject from the platform center is calculated each second, and at the end of
the trail, is summed. An “ideal” straight line, determined by the program, based on the entry
position of the animal relative to the platform, is subtracted from the actual path swum by the
animal. The resulting value is the cumulative index, a scalar value that represents how much the
subject deviated from the “ideal” path to the goal and how close the animal was to the goal
platform. The benefit of the cumulative index is that it is relatively insensitive to the starting
position of the animal and distance to the goal platform. By dividing the cumulative value by the
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latency to reach the goal platform, a proximity average value is produced. The proximity
average was originally developed as a means of direct comparison between the performance of
young, faster swimmers, and older, slower swimmers. Although the cumulative and proximity
values are nominally presented in centimeters, they are calculated based on a scalar index and as
such do not represent actual distance values. The lower the proximity score, the better the
animal matched the “ideal” path to the goal. Fast swimmers that swam directly to the target area
and then spent time exploring in the target area will commonly have negative values (Gallagher,
Burwell, & Burchinal, 1993).
Probe trial. Assessment using the probe trial was carried out on PID 15 (i.e., after the
last day of hidden platform testing). The probe trial consisted of a single 60-s trial in the MWM,
with the hidden platform removed. Animals were randomly assigned a start position (one of the
four cardinal points) and were allowed to swim freely for 60 s prior to removal from the pool by
the investigator. The data collected by the Videomex tracking system was used to determine the
proximity score. Lower proximity scores indicated that the animal took a more direct path to the
platform. This test was always performed prior to the visible platform test.
Visible platform. The visible platform test (PID 15) was used to assess the visual acuity
of each rat. The water level in the MWM was drained to 1 cm below the top of the previously
hidden platform, and a 10 cm painted black pole was attached to the platform to make the
platform more visible. For each of the 8 trials, the platform was moved to a new, randomly
selected, location, which was different from the hidden platform location. The point of entry
(one of the four cardinal directions) for each rat was randomly selected for each trial. To
adequately perform this task, each rat had to locate the platform within 15 s after placement in
the pool.
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Forced swim test. The FST procedure detailed in the 1977 article by Porsolt and
colleagues, modified by Lahmame et al., (1997), was used in the present study. The FST is a
two-day procedure that took place on PID 18 and 19 with one trial per day. Animals were
assessed between 11:00 and 16:00 hours. Each rat was placed in a clear Plexiglas cylinder
(height, 45 cm, internal diameter, 25 cm) containing water maintained at a temperature of 25˚C
and filled to a level of 30 cm. At this water level the rats cannot touch the bottom or escape.
The water was changed following each trial and the Plexiglas cylinder was wiped down using a
70% ethanol and 30% water solution. For the first exposure (PID 18), the rats were placed in the
water for 15 min. Twenty-four hours later, during the second exposure (PID 19), the animals
were placed in the water for a 5 minute test session. After completing the test period the animals
were placed in an incubator and allowed to dry before being returned to their home cage. Both
sessions were videotaped using a camera mounted on a metal pole lateral to the Plexiglas
cylinder, such that the full length of the rat’s body could be seen on the tape. The 15 minute
(exposure session) was used to train the rats that there was no escape (i.e., a model of learned
helplessness and depressive-like behavior). Both test sessions were recorded on videotape,
however, only the 5 min (recall session) tape was later evaluated by two reviewers blinded to the
treatment conditions. The recall testing session revealed how the animals responded to a
situation where there is no escape. Based on previous studies, the time to become immobile
(TTBI) and the total time immobile (TTI) were selected as outcome measures for the present
study. Immobility was operationally defined as when the rat remained motionless, or performed
minimal movements, without breaking the surface of the water and not moving all four limbs to
maintain their head/nose above the water (Lahmame et al., 1997).
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Statistical analysis. Injury severity, as assessed by the suppression of the righting reflex,
was analyzed as described in the general methods section. Statistical analyses specific to this
experiment are described in the following paragraphs.
The mean daily latency for each group to traverse the beam and reach the goal box were
calculated for PID 0, 1, 3, and 7. These data were then compared using a split-plot analysis of
variance and a Fisher LSD post hoc analysis was performed to compare specific groups of
interest. Data from the training session on the BW was not used for any statistical analysis.
The mean latency to locate the goal platform and proximity score for each treatment
group was computed daily during the hidden platform portion of the MWM testing (PID 11–14).
The average goal latencies and proximity scores were then analyzed using a separate split-plot
analysis of variance. The swim speed was averaged for each day in the MWM, and a one-way
ANOVA was performed to determine any relationship between the groups. The probe trial data
and visible platform data (PID 15) were also analyzed using a one-way ANOVA. Where
appropriate, a Fisher LSD post hoc test was performed to compare specific groups of interest.
The TTBI and the TTI from the 5 min test session on PID 19 were evaluated using a one-way
ANOVA and an independent samples t-test respectively. Where appropriate a Fisher LSD post
hoc was performed to compare groups of interest.
Results
Neurological outcome. There was no significant difference in the suppression of the
righting reflex among injured groups. A one-way ANOVA was used to compare the mean
duration of the suppression of the righting reflex, TBI-Vehicle, M = 428.00 s, TBI-1.00, M =
422.00 s, TBI-0.50, M = 560.00 s, TBI-0.25, M = 457.70 s, TBI-0.125, M = 424.80, F(4, 45) =
1.965, p = .116. The sham groups regained their righting reflex in less than 2 min from the time
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they were removed from the bell jar used to anesthetize the animals. Based on our experience in
the laboratory, this is the same amount of time an animal requires to regain the righting reflex
after anesthesia alone.
Beam walk. A split plot [7 group x 4 day] ANOVA revealed a significant group effect,
F(6, 63) = 3.585, p = .004. A Fisher LSD post hoc analysis revealed a significant reduction in
motor deficits in the TBI-1.00 (p = .021), TBI-0.25 (p = .035), Sham-Vehicle (p = .001), and
Sham-1.00 (p = .003) as compared to TBI-Vehicle. Although the TBI-0.125 group did not
significantly differ from the TBI-Vehicle group, there was a trend toward significantly shorter
latencies (p = .057). No significant difference was detected in the BW performance of the TBI1.00, TBI-0.25, TBI-0.125, Sham-Vehicle, and Sham-1.00 groups. No significant difference was
observed between the TBI-Vehicle and TBI-0.50 groups (p = .719), the two groups with the
longest latencies to reach the goal box. Figure 4 illustrates the primary groups of interest based
on performance, TBI-Vehicle, TBI-1.00, TBI-0.25, TBI-0.125, and Sham-Vehicle. A graph
comparing the average latencies to reach the goal box across all treatment groups in the BW task
is provided in Figure A1 in Appendix A.
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Figure 4. Comparison of pre- and post-TBI motor performance among treatment groups
of interest in Experiment 1. These data are expressed as the mean latency across days
± SEM, n = 10/group. A split-plot ANOVA showed that there was a significant effect of
group. Post hoc analysis of the data using the Fisher LSD test showed that the TBI1.00 and TBI-0.25 groups had significantly shorter latencies to reach the goal box as
compared to the TBI-Vehicle group. The difference between the TBI-Vehicle and TBI0.125 groups was not statistically significant; however, there was a trend indicating
shorter latencies for the TBI-0.125 group. The three injured lithium-treated groups had
statistically similar latencies to reach the goal box. All the doses of lithium are mmol/kg.
Vehicle treated animals received 0.9% sterile saline. All treatments were administered
in a volume of 1 mg/kg. Specific statistical information is provided in the text.
Comparisons are made to the Sham-Vehicle group. *** p ≤ .001.
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Morris water Maze.
Hidden platform. The hidden platform portion of the MWM revealed a significant
group effect, F(6, 63) = 9.483, p < .001. A Fisher LSD post hoc test determined that both the
0.25 and 0.125 mmol/kg doses of lithium were equally effective in reducing TBI-induced deficits
in the MWM as compared to the TBI-Vehicle group. These data are presented in Figure 5. The
0.50 and 1.00 mmol/kg doses of lithium did not significantly improve maze performance as
compared to the TBI-Vehicle treated group; however, the 1.00 mmol/kg dose did approach the
level of significance (p = .053). None of the treatment groups, including the Sham-1.00 group,
performed as well as the Sham-Vehicle group. See Figure A2 in Appendix A, for a comparison
of MWM performance across all the treatment groups.
Swim speed. A one-way ANOVA revealed that there was a significant difference in the
average swim speed of the treatment groups, F(6, 63) = 4.896, p < .001. A Fisher LSD post hoc
analysis revealed that all the TBI-Lithium groups (1.00, 0.50, 0.25, 0.125 mmol/kg lithium)
swam significantly faster as compared to the Sham-Vehicle, Sham-1.00, and TBI-Vehicle
groups. These data are illustrated in Figure 6. There was no significant difference in the swim
speeds across the TBI-Lithium groups. Additionally, there was no significant difference in the
swim speeds of the two sham- and injured-vehicle-treated groups.
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Figure 5. Comparison of MWM latency data among selected groups in Experiment 1.
This graph shows the daily average latency to reach the goal platform for each
treatment group (n = 10/group), ± SEM. A split-plot ANOVA and Fisher LSD post hoc
revealed that the TBI-Vehicle group had significantly longer latencies to reach the goal
platform as compared to the TBI-0.125, TBI-0.25, Sham-Vehicle, and Sham-1.00
groups. None of the groups performed as well as the Sham-Vehicle group. All doses of
lithium are mmol/kg. (*) indicate comparisons made to the Sham-Vehicle group. (†)
represent comparisons made to the Sham-1.00 group. (#) represents comparisons
made to the TBI-Vehicle group. * p < .05. **, ## p < .01. ***, ††† p < .001.
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Figure 6. Comparison of the overall average swim speed for each treatment group in
Experiment 1. Data are expressed as the mean ± SEM. n = 10/group (N = 70). A oneway ANOVA showed a significant difference in the overall swim speeds, F(6, 63) =
4.896, p < .001. A Fisher LSD post hoc analysis showed that all of the TBI-Lithiumtreated groups swam significantly faster as compared to both sham groups and the TBIVehicle-treated group. There was no significant difference in the swim speeds of the
Sham-Vehicle, Sham-1.00, and TBI-Vehicle groups (p > .05). No differences were
observed in the swim speeds of the TBI-Lithium-treated groups (p > .05). (*) indicates
comparisons made to the Sham-Vehicle group. (†) indicates significant differences in
treatment groups as compared to Sham-1.00. (#) indicates comparisons made to TBIVehicle. *, †, # p < .05. **, ††, ## p < .01.
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Proximity score hidden platform. The average daily proximity score was calculated for
each treatment group (n = 10/group). Lower scores indicated a more direct path to the goal
platform. A split-plot ANOVA revealed a significant main effect of treatment group, F(6, 63) =
4.459, p = .001. A Fisher LSD post hoc analysis showed that only the Sham-Vehicle (p < .001)
and Sham-1.00 (p = .003) had significantly lower proximity scores as compared to the TBIVehicle group. There was no significant difference among the proximity scores of the injuredvehicle and -lithium groups. Figure 7 illustrates data from the two most effective doses of
lithium, as determined by the analysis of the MWM latency data (i.e., TBI-0.25 and TBI-0.125),
in addition to the TBI-Vehicle and both sham groups. The scores for the Sham-Vehicle and
Sham-1.00 groups were statistically similar (p = .235). Although the Sham-Vehicle group had
significantly lower proximity scores as compared to the injured lithium-treated groups, the scores
from the two most effective doses of lithium, TBI-0.25 and TBI-0.125, did not statistically differ
from the proximity score of the Sham-1.00, p = .061 and .185 respectively. A comparison of
proximity scores during MWM across all treatment groups is provided in Figures A3 and A4 of
Appendix A.
Probe trial. The average proximity score for each treatment group during the probe trial
(PID 15) was analyzed using a one-way ANOVA. These data are illustrated in Figure 8. There
was a significant main effect of group, F(6, 59) = 3.407, p = .006. A Fisher LSD post hoc
analysis determined that the Sham-Vehicle group had a significantly lower proximity score as
compared to all the other treatment groups, p < .01. No other differences were found.
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Figure 7. Comparison of the proximity scores for the groups of interest across days
during hidden platform testing in MWM. This graph shows the daily average proximity
score for the treatment groups of interest (n = 10/group) during MWM testing, ± SEM.
All doses of lithium are in mmol/kg. A repeated measure ANOVA revealed a significant
difference among the average daily proximity scores of the treatment groups. A Fisher
LSD post hoc found that the two sham groups had significantly lower proximity scores
(indicating better performance) as compared to the TBI-Vehicle group. The two injured
groups that had significantly shorter latencies to reach the goal platform as compared to
the TBI-Vehicle group during the hidden platform testing, TBI-0.25 and TBI-0.125, had
significantly higher proximity scores as compared to the Sham-Vehicle group (i.e.,
poorer performance). However, these two injured groups did not significantly differ from
the Sham-1.00 group, suggesting that these groups took a more direct path to the goal
platform. There was no appreciable difference in the proximity scores of the TBIVehicle group and the TBI lithium-treated groups. (*) indicate comparisons to the
Sham-Vehicle group. (†) indicate comparisons made to the Sham-1.00 group. **, †† p <
.01. *** p < .001.
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Figure 8. Analysis of the proximity scores for the groups of interest during the probe
trial in Experiment 1. The data are expressed as the mean ± SEM, (n = 10/group). An
ANOVA found significant differences between the treatment groups. A Fisher LSD post
hoc revealed that the Sham-Vehicle group had a significantly lower proximity score as
compared to all other treatment groups. * p < .05. ** p < .01. *** p < .001.
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Visible platform. The mean latency, in seconds, for each group (n = 10/group) to locate
the visible platform revealed the following data, expressed as the group mean (± SEM): TBIVehicle, M = 10.87 s (± 1.07); TBI-1.00, M = 12.58 s (± 1.18), TBI-0.50, M = 13.79 s (± 2.49);
TBI-0.25, M = 10.85 s (± 1.51); TBI-0.125, M = 14.08 s (± 2.14); Sham-Vehicle, M = 10.04 s (±
2.93); Sham-1.00, M = 9.88 s (± 1.13). A one-way ANOVA revealed that there were no
significant differences between any of the treatment groups in the average latency to locate the
visible platform, F(6, 63) = 0.836, p = .547.
Forced swim test. The mean latency, in seconds, for animals in the TBI-Vehicle (n =
10), TBI-0.25 (n = 9), and Sham-Vehicle (n = 10) groups to become immobile (i.e., TTBI) are
illustrated in Figure 9. These data were analyzed using a one-way ANOVA, and no significant
difference was detected in the TTBI, F(2, 26) = 0.610, p = .551. Because the TTBI data was not
significant, we analyzed only the TBI-Vehicle and Sham-Vehicle groups for the TTI data. An
independent samples t-test was used to evaluate any difference in the TTI between the TBIVehicle (n = 10), M = 165.41 s, SD = 43.78 and Sham-Vehicle (n = 9), M = 176.30 s, SD = 36.81
groups; t(17) = -.576, p = .567. Similar to what was found with the TTBI data, the FST was not
able to detect differences between injured and sham animals.
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Figure 9. Mean latency for animals to become immobile in the forced swim test. The
time to become immobile (TTBI) was assessed on the second day in the FST (PID 19).
Data are expressed as the mean TTBI ± SEM. A one-way ANOVA showed that there
was no significant difference in the TTBI between the TBI-Vehicle (n = 10), TBI-0.25 (n
= 9), and Sham-Vehicle (n = 10) groups. Within the parameters of the present study,
the FST lacks the sensitivity to detect differences between sham and injured animals.
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Discussion
The aim of the present study was to determine the best dose or doses of lithium for
reducing TBI-induced motor and cognitive (spatial navigation and depressive-like behavior)
deficits. A dose response was used to determine the most effective doses of lithium as a therapy
to ameliorate motor and cognitive deficits associated with moderate-severity TBI. Previous
studies have shown lithium to be an effective therapy when administered prior to a traumatic
insult in vitro and when administered pre- and post-MCAO in vivo. The results from the present
study support the use of low doses of lithium as a postinjury therapy to ameliorate TBI-induced
cognitive and vestibulomotor deficits.
Beam walk task. The effects of the different doses of lithium on vestibulomotor
functioning indicate that the doses of lithium corresponding to the upper and lower end of the
clinically relevant therapeutic range were the most beneficial. Injured animals treated with 1.00,
0.25, and 0.125 mmol/kg, doses of lithium showed marked improvement in their latency to reach
the goal box on PID 1 and 3, as compared to animals that received the 0.50 mmol/kg dose.
These findings partially fit with the working hypothesis of this study that the middle and lower
doses of lithium would be more effective as compared to the high dose. Although the benefit
associated with the higher dose was unexpected, it is not uncommon for high and low doses of
drugs, particularly those used in brain injury studies, to have positive effects on performance
whereas doses falling within the middle range of this scale are associated with a lack of
improvement. Indeed, the review article by Calabrese (2008) examined multiple ischemic braininjury and TBI studies, which varied greatly in their methodologies, and found over 30 drugs that
were reported to have this same pattern of effective recovery of motor function with high and
low doses of a drug, that was not observed following administration of mid-range doses. As
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expected, by PID 7 all the injured groups had a return to near preinjury levels of performance in
the BW task.
Morris water maze.
Hidden platform. The results from the hidden platform portion of the MWM task
showed that lowest doses of lithium tested (0.25 and 0.125 mmol/kg) were the most effective in
reducing TBI-induced cognitive deficits. It was speculated that the 0.50 mmol/kg dose would
have also provided neuroprotection, however, this was not the case.
To ensure that the differences we found in the MWM performance between the treatment
groups was not affected by motor deficits, the average swim speed per group was calculated.
Although there were small differences in the overall swim speeds of the treatment groups, there
was no significant difference in the swim speeds of the sham and injured vehicle-treated animals.
Neither injury nor lithium treatment alone were sufficient to alter the average swimming speed of
the groups. However, when TBI and lithium treatment were combined, the average swim speed
of these groups (i.e., TBI-1.00, TBI-0.50, TBI-0.25, TBI-0.125) significantly increased.
Additionally, there was no appreciable difference in the swim speeds of the injured lithiumtreated groups. Based on these data, we hypothesize that there may be a combined effect of
injury and lithium treatment on motor function and that an aspect of this effect is manifest as
increase in swim speed. The differences in the group swim speeds could be a confounding
variable, however, it is unlikely that the group differences in swim speed significantly affected
the latencies to locate the hidden platform. All the injured lithium-treated groups swam faster
than the TBI-Vehicle group. The groups treated with the lower doses (0.25 & 0.125 mmol/kg)
had significantly shorter latencies to locate the hidden platform than the TBI-Vehicle, whereas
the higher doses (1.00 & 0.50 mmol/kg) had similar latencies to reach the goal platform as
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compared to the TBI-Vehicle group. A factor that could have contributed to the differences in
swim speed is the mass of the animals. However, an analysis of the average daily mass for each
treatment group did not reveal any significant between-group differences. The finding that the
mass of the animals was comparable over the course of the study supports the theory that the
differences in swim speed were due to drug effects rather than weight loss or gain.
The proximity score has been reported to be a better indication of spatial learning than
goal latency when there are differences in overall swim speeds (Gallagher et al., 1993). Analysis
of the proximity score data from the hidden platform testing in the MWM showed that none of
the injured lithium-treated groups significantly differed from TBI-Vehicle. However, relative to
the other TBI groups, the TBI-0.25 and TBI-0.125 were the only ones that performed as well as
the Sham-1.00 group (i.e., had lower proximity scores). These data parallel the latency data in
the MWM, which showed chronic postinjury treatment with the two lowest doses of lithium
(0.25 and 0.125 mmol/kg) was associated with shorter latencies to the goal platform that were
statistically similar to those observed in the Sham-1.00 group. The higher doses of lithium (1.00
and 0.50 mmol/kg) were not able to significantly reduce MWM latency relative to the low doses
of lithium and both sham groups.
Despite the differences in swim speeds, because all of the injured lithium-treated animals
swam significantly faster than sham groups, it is not likely that the swim speed is a confounding
variable. The similarity in the proximity scores of the TBI-0.25, and TBI-0.125, and Sham-1.00
groups, despite having significantly different swim speeds, provides further support for the use
of the selected dose of lithium (0.25 mmol/kg) in the subsequent experiments in this dissertation.
Probe trial. The probe trial was administered on PID 15 (day 5 in the MWM). This test
was incorporated to measure the cumulative learning of each rat for the location of the hidden
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platform. The proximity score from this assessment was compared across groups and was
expected to support the data from the hidden platform testing portion of the MWM. However,
the only difference that was detected was a significantly lower proximity score in the ShamVehicle group, indicating improved performance, as compared to all other treatment groups.
These data could indicate that the injured lithium-treated groups did not effectively learn the
location of the hidden platform. Additionally, the Sham-1.00 group had significantly higher
proximity scores, indicating poorer performance, as compared to the Sham-Vehicle group,
suggesting that lithium itself may have deleterious effects on MWM learning. Based on the
similarities in performance between the Sham-Vehicle and Sham-1.00 groups on the BW and
hidden platform portion of the MWM (i.e., latency, proximity, and swim speed), it is unusual
that the probe trial data indicated that these groups were significantly different and that the
Sham-1.00 group performance was statistically similar to all the injured groups. An alternate
explanation for the observed results in this task is that the probe trial lacks the sensitivity to
detect the injury- and drug-induced effects on MWM learning as compared to the latency and
proximity outcome measures from the hidden platform test.
Visible platform. The visible platform test was used to ensure adequate visual acuity as
well as motivation to locate the platform. Analysis of these data showed that all the animals met
the criterion established for the visible platform task (i.e., they were able to locate the hidden
platform within an average of 15 s over 8 trials). There was no significant difference between
any of the treatment groups in the average latency to locate the visible platform, thereby
excluding the possibility that the differences in overall performance between the treatment
groups was attributable to visual or motivational differences.
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Forced swim test. The FST was used to assess depressive-like behavior following TBI.
However, in the present study we did not detect any differences in either the TTBI or the TTI
between the TBI-Vehicle and Sham-Vehicle groups. Because there was no discernable effect of
injury, further use of this test with the different doses of lithium was not carried out. The lack of
an injury effect could be attributed to the animal’s prior experience in the MWM. Based on this
assumption, the prior exposure to a swimming task may have desensitized the animals to the
stress and subsequent “learned helplessness” associated with longer periods of immobility and
shorter latencies to become immobile. Behavioral assessment of depressive-like behavior using
the FST may be best suited for animals not previously subjected to assessment in the MWM.
Experiment 2
Rationale
It is well established that the therapeutic time window is critical when evaluating the
effectiveness of a treatment. According to the biphasic model of TBI, there is a sharp increase in
neuronal and metabolic activity followed by a steep decline in overall brain functioning that can
persist for some time postinjury. Drug treatments typically target either the acute or chronic
phases. Indeed, agents that are beneficial when administered during the acute postinjury phase
(e.g., mu-opioid receptor agonists and glutamate antagonists) may be ineffective or even impair
recovery when administered during the chronic postinjury phase (Hamm, O'Dell, Pike, & Lyeth,
1993; Lyeth, Jiang, Gong, Hamm, & Young, 1995). During the chronic postinjury phase,
marked by a hypofunctional state, drugs that have excitatory effects are associated with
improved outcome.
The findings from Experiment 1 showed that the lowest doses of lithium, administered 30
min postinjury, were effective in reducing cognitive and motor deficits associated with TBI.
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This finding is encouraging and it may provide further insight into mechanisms of action for
lithium as well as secondary injury processes occurring after lateral FPI. However, a 30 minute
therapeutic time window does not translate well to clinical populations. The primary difficulty
in translating successful therapies from the bench to the bedside is ensuring that the initiation of
treatment is equivalent (Marklund et al., 2006). Therapies that are effective in the acute
postinjury phase, in preclinical models, must be administered within a brief time period in
clinical trials. This can present a challenge for investigators due to the time lag between the
traumatic event, the arrival of the individual to a medical center, and obtaining informed consent
from the patient or a family member. In the present study, we determined which of two
postinjury time points (8 and 24 hr) is most effective in ameliorating the sequelae associated with
the lateral FPI model of TBI, and provide insight into the therapeutic time window for initiating
lithium treatment. The 8 and 24 hr postinjury time points were selected based on the clinical
relevance, because a longer therapeutic time window will offer the best chance for translating
these findings to clinical practice. Furthermore, delaying treatment may provide insights into the
mechanisms of action through which lithium may exert its neuroprotective effects.
The data collected from the 8 and 24 hr treatment delays was analyzed with the data
obtained from the 30 min treatment delay group that was treated with the optimal dose of lithium
(0.25 mmol/kg) from Experiment 1 (i.e., the TBI-0.25 group). The data from the TBI-0.25
group, along with the two treatment delays from the present study, were used to establish the
furthest time point from injury that chronic lithium treatment can be administered while still
offering significant protection of vestibulomotor and cognitive function.
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Hypotheses
It was hypothesized that the optimal dose (0.25 mmol/kg, ip), selected from Experiment
1, would be effective in reducing TBI-induced vestibulomotor and cognitive deficits at both
treatment delay time points (8 and 24 hr).
Specific Aims
The aim of the present study was to evaluate the effect of delayed postinjury lithium
treatment on cognitive and vestibulomotor function. Using the optimal dose from Experiment 1,
we aimed to define a therapeutic time window for lithium administration.
Methods
The subjects, surgical preparation for lateral FPI, lateral FPI, postinjury neurological
assessment, drug preparation, and neurobehavioral outcome assessment for BW and MWM, are
identical to those described in Experiment 1. Due to the lack of a detectable difference between
sham and injured animals in the FST, this test was not administered. The treatment timeline used
for this study is detailed in Figure 10.
Experimental design.
Drug treatment. Animals received daily (PID 0-19) intraperitoneal injections of either
lithium chloride or vehicle (0.9% sterile saline). Daily treatment was initiated at either 8 or 24
hours postinjury. Sham animals were randomly assigned to one of two treatment groups,
lithium-treated (0.25 mmol/kg, ip) with treatment initiated 24 hours post-sham-injury (to test for
any effects of the optimal dose of lithium in uninjured rats), or vehicle-treated (1 ml/kg, ip). See
Table 2 for treatment group design.
Statistical analysis. In Experiment 1, the selected dose of lithium (0.25 mmol/kg, ip) was
found to be effective in reducing TBI-induced cognitive and motor deficits when administered
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30 min after injury. To determine the relative efficacy of the two time delays in the present
study, the BW and MWM data from the optimal dose in Experiment 1 were included in the data
analysis of the present study.
Data from the MWM was analyzed for goal latency using a split-plot ANOVA [6
(Group) x 4 (Day)] comparing injured animals and sham-injured animals. A mean daily latency
to find the goal platform during MWM testing on day’s 11 – 14 postinjury was computed for
each group. Proximity scores and swim speed were averaged individually for each day in the
MWM, and a one-way ANOVA was performed for each outcome measure to determine the
relationship between the groups. For each of the other tasks involving the MWM (i.e., probe
trial and visible platform), a one-way ANOVA was used to determine any relationship between
the groups. Where appropriate, a post hoc analysis was performed to compare specific groups of
interest.

Figure 10. Timeline of events in Experiment 2. This figure shows the schedule for
administration of both the drug-treatment and neurobehavioral assessments used in
Experiment 2. Abbreviations: beam walk test (BW), Morris water maze (MWM),
postinjury day (PID)
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Table 2.
Experiment 2: Treatment Groups

TBI-Vehiclea

n
10

Sham-Vehiclea

10

TBI-30 minc

10

TBI-8 hrb

10

TBI-24 hrb

9

Sham-24 hrb

9

Treatment group

Note. avehicle (0.9% sterile saline, dose volume: 1 ml/kg), 30 min
postinjury or sham. b24 or 8 hr treatment delay (dosage: 0.25 mmol/kg
lithium, dose volume: 1 ml/kg). cData from the TBI-30 min group are from
the TBI-0.25 Lithium group in Experiment 1.

Results
Neurological assessment. The suppression of the righting reflex was assessed
immediately after the delivery of the TBI. The mean latency (in seconds) necessary for each
animal to recover the righting reflex was calculated for each treatment group that received a TBI.
These data are as follows (± SEM): TBI-Vehicle, M = 403.30 s (± 24.95) (n = 10); TBI-30 min,
M = 430.20 s (± 12.73) (n = 10); TBI-8 hr, M = 430.20 s (± 12.73) (n = 10); TBI-24 hr, M =
413.67 s (± 21.49) (n = 9). A one-way ANOVA failed to detect any significant differences in the
suppression of the righting reflex among the injured groups, F(3, 35) = 0.859, p = .471. This
finding indicates that all the injured animals had equivalent injury severities.
Animal mass. The mass of the animals was compared over the 21 days from the surgical
preparation for the injury (PID -1) to the final day of lithium treatment (PID 19). The ANOVA
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did not find any significant difference in the average mass of the treatment groups, F(5, 47) =
1.814, p = .128. The Sham-Vehicle and TBI-30 min data are the same that was used in the
animal mass data analysis in Experiment 1.
Beam walk. Data from the BW assessment are presented in Figures 11-12. A split-plot
ANOVA [6 (Group) x 4 (Day)] revealed significant group differences in the mean latencies to
reach the goal box, F(5, 52) = 5.012, p = .001. A Fisher LSD post hoc analysis showed that the
Sham-Vehicle (p < .001), Sham-24 hr (p < .001), TBI-8 hr (p = .019), and TBI-30 min (p = .004)
groups had significantly shorter latencies to reach the goal box as compared to the TBI-Vehicle
group. Additionally, the average BW latencies for these four groups were not significantly
different from each other (p = .125). No significant difference was observed between the TBIVehicle and TBI-24 hr group (p = .403). While the TBI-8 hr group was significantly different
from the TBI-Vehicle, it did not significantly differ from the TBI-24 hr group (p = .139).
Morris Water Maze.
Hidden platform. The mean latency for each group to locate the hidden platform was
compared across days. A split-plot ANOVA [6 (group) x 4 (day)] showed that there was a
significant difference in the latency to reach the goal platform between treatment groups, F(5,
52) = 8.042, p < .001. A Fisher LSD post hoc analysis found that the TBI-Vehicle group had
significantly longer latencies to reach the goal platform as compared to the Sham-Vehicle (p <
.001), Sham-24 hr (p < .001), TBI-30 min (p = .002), and TBI-8 hr groups (p = .002). No
difference was detected between TBI-24 hr and TBI-Vehicle groups, (p = .319). The TBI-30
min (p = .040) and TBI-8 hr (p = .037) groups had significantly shorter latencies to reach the
hidden platform as compared to the TBI-24 hr group. No significant difference was observed
between the TBI-30 min and TBI-8 hr groups (p = .967). Animals in the Sham-Vehicle group
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performed significantly better as compared to animals that received a TBI. No significant
difference in performance was detected between the Sham-Vehicle and Sham-24 hr groups (p =
.352). MWM data for the 24 hr and 8 hr treatment-delay groups are presented in Figure 13 and
14 respectively.
Swim speed. The mean swim speed across days in the MWM was calculated for each
treatment group. These data are presented in Figure 15. A one-way ANOVA found a significant
difference between the swim speeds, F(5, 52) = 2.981, p = .019. A Fisher LSD post hoc analysis
revealed that there was no appreciable difference in the average swim speeds between the ShamVehicle, TBI-Vehicle, Sham-24 hr, and TBI-24 hr groups. Additionally, both of the 24 hr
treatment delay groups (TBI-24 hr and Sham-24 hr) had statistically similar swim speeds as
compared to the TBI-8 hr or TBI-30 min groups. However, the TBI-8 hr and the TBI-30 min
groups swam significantly faster (p = .008 and .002 respectively) in the MWM as compared to
the Sham-Vehicle group (p = .571), but only the TBI-30 min group swam significantly faster
than the TBI-Vehicle group, p = .015. The average speed of the TBI-8 hr group was faster than
the TBI-Vehicle group and there was a trend toward a significant difference (p = .057) in speeds
between the two groups.
Proximity to hidden platform. The proximity score data from the hidden platform testing
was compared using a split-plot [6 (group) x 4 (day)] ANOVA and revealed a significant effect
of group, F(5, 52) = 5.379, p < .001. A Fisher LSD post hoc analysis found that the TBI-30 min
(p = .031) and TBI-8 hr (p = .03) had significantly lower proximity scores, indicating a more
direct route to the goal platform, as compared to the TBI-Vehicle group. However, the proximity
scores of the TBI-30 min and TBI-8 hr were significantly higher than the Sham-Vehicle (p =
.034 and .036 respectively) but did not differ from the Sham-24 hr group (p = .122 and .128
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respectively). Both sham groups had significantly lower proximity scores (p < .001) as
compared to the TBI-Vehicle group. The TBI-24 hr group significantly differed (p < .01) only
from the sham groups. The proximity data for the 24 hr and 8 hr treatment-delay groups are
presented in Figure 16 and 17 respectively.
Probe trial. The probe trial (60 s) was conducted in the MWM on PID 15, 24 h after the
last trial of the hidden platform testing. This test was performed with the platform removed from
the MWM. The mean proximity score was calculated for each treatment group using the data
collected by the VideoMex tracking software. The proximity score was determined by
comparing the swim path of the animal and the most efficient path to the goal, as determined by
the VideoMex program. In this analysis, a lower score is indicative of better learning for the
location of the hidden platform. Data from the 24 hr and 8 hr treatment-delay groups are
presented in Figure 18 and 19 respectively. A one-way ANOVA showed that there was a
significant effect of treatment group on the proximity score, F(5, 45) = 2.959, p =.022. A Fisher
LSD post hoc analysis revealed that the Sham-24 hr (p = .009) and Sham-Vehicle (p = .039)
were the only groups with significantly lower scores as compared to the TBI-Vehicle group. The
Sham-24 hr group also had significantly lower proximity scores as compared to the TBI-30 min
(p = .023), TBI-24 hr (p = .006); however, no difference was observed between Sham-24 hr and
TBI-8 hr (p = .257). Sham-Vehicle differed only from TBI-24 hr (p = .030). No difference was
found in the proximity score between the Sham-Vehicle and TBI-30 min (p = .07) or TBI-8 hr (p
= .314) groups.
Visible platform. The mean latency, in seconds, for each treatment group to locate the
visible platform was calculated based on the performance of each animal over 8 trials (PID 15).
The group means (± SEM) are as follows: TBI-Vehicle, M = 10.54 s (± 1.56); TBI-30 min, M =
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10.85 s (± 1.51); TBI-8 hr, M = 11.35 s (± 1.54); TBI-24 hr, M = 12.99 s (± 1.06); Sham-Vehicle,
M = 13.03 s (± 2.71); Sham-24 hr, M = 8.88 s (± 0.56). A one-way ANOVA failed to detect any
statistically significant differences among the group means, F(5, 52) = 0.862, p = .513.
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Sham-24 hr
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TBI-24 hr *** †††
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Latency to reach goal box (s)

45
40
35
30
25
20
15
10
5
0
1 (PID 0)

2 (PID 1)

3 (PID 3)

4 (PID 7)

Days tested on beam walk (postinjury day)
Figure 11. Comparison of 24 hr treatment delay on beam walk performance. These
data represent the mean latency to reach the goal box, ± SEM. TBI-Vehicle (n = 10),
TBI-24 hr (n = 9), Sham-24 hr (n = 9), Sham-Vehicle (n = 10). An ANOVA followed by a
Fisher LSD post hoc test determined that the TBI-24 hr and TBI-Vehicle group
performed significantly worse on the beam walk task as compared to both sham groups.
There was no difference in performance detected between the two injured groups and
no significant difference between the two sham groups. (*) indicates comparisons made
to the Sham-Vehicle group. (†) indicate significant differences in treatment groups as
compared to Sham-1.00. †††, ***p < .001.
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Figure 12. Comparison of 8 hr treatment delay on beam walk performance. These data
represent the mean latency to reach the goal box, ± SEM. TBI-Vehicle (n = 10), TBI-30
min (n = 10), TBI-8 hr (n = 10), and Sham-Vehicle (n = 10). The TBI-30 min group data
is identical to the TBI-0.25 from Experiment 1 and is included in the data analysis as a
basis for comparing the effectiveness of the selected dose of lithium when the initiation
of treatment is delayed. The TBI-8 hr and TBI-30 min had significantly shorter latencies
to reach the goal box as compared to the TBI-Vehicle and TBI-24 hr groups. (*) indicate
comparisons made to the Sham-Vehicle group. (#) indicate comparisons made to TBIVehicle. * p < .05. ## p < .01. *** p < .001.
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Figure 13. Effect of 24 hr treatment delay on MWM performance. Data are the mean
latency for the selected treatment groups, TBI-Vehicle (n = 10), TBI-24 hr (n = 9),
Sham-Vehicle (n = 10), and Sham-24 hr (n = 9), ± SEM. There was a significant main
effect for group. A Fisher LSD showed that the TBI-24 hr and TBI-Vehicle groups had
significantly longer latencies to reach the goal as compared to both sham groups.
There was no significant difference between the latencies of the two sham groups or the
two injured groups. (*) indicate comparisons made to the Sham-Vehicle group. (†)
indicate significant differences in treatment groups as compared to Sham-1.00. †† p <
.01. †††, *** p < .001.
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Figure 14. Effect of 8 hr treatment delay on MWM performance. Data represent the
mean latency for the selected groups (n = 10/group) to reach the hidden platform, ±
SEM. The dose of lithium used is 0.25 mmol/kg (ip). The TBI-30 min group data is the
TBI-0.25 from Experiment 1 and is included in the data analysis as a basis for
comparing the effectiveness of the selected dose of lithium when the initiation of
treatment is delayed. An ANOVA showed significant differences between the treatment
groups. A Fisher LSD post hoc analysis found that the TBI-30 min and TBI-8 hr groups
had significantly shorter latencies to reach the hidden platform as compared to the TBIVehicle group (p = .002). The Sham-Vehicle group performed significantly better in this
task as compared to the TBI-Vehicle (p < .001), TBI-30 min (p = .032), and TBI-8 hr (p =
.035) groups. (*) indicate comparisons made to the Sham-Vehicle group. (#) indicate
comparisons made to the TBI-Vehicle group. * p < .05. ## p < .01. *** p < .001.
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Figure 15. Average swim speed for each treatment group in Experiment 2. Data
represent the mean swim speed for each treatment group across days in the MWM
during hidden platform testing, ± SEM. TBI-Vehicle (n = 10), TBI-24 hr (n = 9), TBI-8 hr
(n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n = 9). The TBI-30
min group data is the TBI-0.25 from Experiment 1 and is included in the data analysis
as a basis for comparing the effectiveness of the selected dose of lithium when the
initiation of treatment is delayed. The swim speed is calculated by dividing the distance
traveled by the latency to reach the goal platform (cm/s). A significant difference in
swim speed was found for the TBI-30 min and TBI-8 hr groups as compared to all other
treatment groups. Initial comparisons were made to the Sham-Vehicle group (*).
Additional significant between-group comparisons are indicated by braces. *p < .05.
**p < .01.
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Figure 16. Comparison of 24 hr treatment delay on proximity to the goal platform during
MWM testing. Data represent the proximity score obtained during hidden platform
testing in the MWM for the TBI-Vehicle (n = 10), TBI-24 hr (n = 9), Sham-Vehicle (n =
10), and Sham-24 hr (n = 9) groups, ± SEM. Lower scores indicate the animal took a
more direct path the hidden platform (i.e., improved performance). Both sham groups
had significantly lower proximity scores relative to the two injured groups. No
statistically significant difference was observed between the proximity scores of the two
sham groups or the two injured groups. (*) indicate comparisons made to the ShamVehicle group. (†) indicate significant differences as compared to Sham-1.00. ††p < .01.
†††,
***p < .001.
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Figure 17. Comparison of 8 hr treatment delay on proximity to the goal platform during
MWM testing. Data represent the mean proximity score for each treatment group (n =
10/group), ± SEM. The TBI-30 min group data is the TBI-0.25 from Experiment 1 and is
included in the data analysis as a basis for comparing the effectiveness of the selected
dose of lithium when the initiation of treatment is delayed. An ANOVA, followed by a
Fisher LSD post hoc analysis found that the Sham-Vehicle group performed significantly
better (i.e., lower scores) as compared to the selected injured groups. (*) indicate
comparisons made to the Sham-Vehicle group. (#) indicate significant differences as
compared to TBI-Vehicle. *, #p < .05. ††p < .01. †††, ***p < .001.
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Figure 18. Comparison of 24 hr treatment delay on the proximity score from the probe
trial on PID 15. The bars represent the mean proximity score for each treatment group,
TBI-Vehicle (n = 10), TBI-24 hr (n = 9), Sham-Vehicle (n = 10), Sham-24 hr (n = 9), ±
SEM. Proximity score is based on a 60 s probe trial (no platform in MWM) on postinjury
day (PID) 15. A Fisher LSD post hoc analysis revealed that the Sham-Vehicle (p =
.039) and Sham-24 hr (p = .009) groups had significantly lower scores (i.e., took the
most direct route and remained closest to the location of the hidden goal platform) as
compared to the TBI-Vehicle group. (*) indicate direct comparisons made to the ShamVehicle group. Other statistically significant group differences are indicated by braces.
**p < .01.
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Figure 19. Comparison of 8 hr treatment delay on proximity score from the probe trial
on PID 15. The TBI-30 min group data is from the TBI-0.25 group in Experiment 1. The
mean proximity score for each treatment group, obtained from the 60 s probe trial (no
platform in MWM) on postinjury day (PID) 15. The bars represent the mean proximity
score for each treatment group (n = 10/group), ± SEM. The TBI-30 min group data is
the TBI-0.25 from Experiment 1 and is included in the data analysis as a basis for
comparing the effectiveness of the selected dose of lithium when the initiation of
treatment is delayed. An ANOVA followed by a Fisher LSD post hoc analysis revealed
that the Sham-Vehicle and TBI-8 hr groups had significantly lower proximity scores (i.e.,
took the most direct route and remained closest to the location of the hidden goal
platform) as compared to the TBI-Vehicle group. The proximity score for the TBI-30 min
group was significantly higher as compared to Sham-Vehicle and did not statistically
differ from TBI-Vehicle. (*) indicate direct comparisons made to the Sham-Vehicle
group. Other significant group differences are indicated with braces. *p < .05. **p <
.01.
112

Discussion
In the present study we examined the therapeutic time window for administering the
selected dose of lithium from Experiment 1. Lithium treatment was delayed for either 8 or 24
hours postinjury. We selected the 8 and 24 hr time delays for initiating treatment because they
are clinically relevant, i.e., they would allow sufficient time for the treatment to be administered,
taking into account time for transportation and obtaining informed consent. The current
investigations into the therapeutic window for the optimal dose of lithium, selected from
Experiment 1, revealed that lithium treatment can be delayed up to 8 hours postinjury and still
provide significant neuroprotection as evidenced by improved motor and cognitive performance
postinjury.
Beam walk. The TBI-8 hr group showed a significant reduction in the latency to traverse
the beam in the days following the TBI and performed similarly to the TBI-30 min group from
Experiment 1. The beneficial effects observed following the 8 hr delay did not carry over for the
TBI-24 hr group. In fact, the latter group performed comparably to the TBI-Vehicle treated
group. These data indicate that lithium may mediate posttraumatic vestibulomotor impairment.
Morris Water Maze.
Hidden platform. Analysis of the hidden platform data revealed similar findings to those
observed in the BW. The TBI-8 hr group exhibited significantly shorter latencies to reach the
goal platform as compared to the TBI-Vehicle group. Delaying treatment with lithium for up to
8 hr postinjury appears to maintain the cognitive protective effects observed after the 30 min
treatment delay in Experiment 1. All benefit associated with this dose of lithium (0.25 mmol/kg,
ip) was lost when treatment was delayed for 24 hr. In fact, a comparison of latency between
TBI-Vehicle and TBI-24 hr groups was statistically indistinguishable. Although the 24 hr
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treatment delay, using the selected dose of lithium, was not protective, the findings from the 8 hr
treatment delay are very encouraging.
Similar to the findings from the previous study, there was no difference in swim speed
between the Sham-Lithium, Sham-Vehicle and TBI-Vehicle groups. However, the hypothesized
interaction between TBI and lithium on swimming speed did not carry over into this experiment.
There was no appreciable difference in the swim speed of the TBI-24 hr relative to any treatment
group. The TBI-8 hr group swam significantly faster than the Sham-Vehicle group but did not
statistically differ from the swim speed of the TBI-Vehicle group. At this time, it is unclear what
is producing these group differences in swim speed.
Dissimilarities in group swim speeds can represent a confounding variable, leading
Gallagher et al. (1993) to develop the proximity score, which is a measure of spatial memory that
is not affected by swim speed or entry position in the maze. This score provided additional
information about the spatial distribution of the rat’s search, and was designed to supplement
existing measures frequently used in assessing MWM performance (e.g., latency, path length,
swim speed) (Gallagher et al., 1993). The results from our analysis of the daily proximity score
data from the hidden platform assessment are congruent with the corresponding latency data.
The proximity score data indicates that both the TBI-30 min and TBI-8 hr groups had learned,
more efficiently, the location of the hidden platform as compared to the TBI-Vehicle group.
Although the TBI-30 min and TBI-8 hr groups did not perform as well as Sham-Vehicle, there
was no difference in performance as compared to the Sham-24 hr group.
Probe trial. The single probe trial was performed on PID 15, after the last day of hidden
platform testing. This assessment shows the spatial bias of the animals search pattern (Gallagher
et al., 1993) and was included to assess the cumulative learning of each rat for the location of the
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hidden platform. The only difference that we observed was between the Sham-Vehicle group
and the other treatment groups. The homogeneity of the scores from the other treatment groups
suggests that this measure is not sensitive enough to detect small between-group differences.
Visible platform. The visible platform was used to assess the visual acuity of the animals
and ensured that any differences detected in the latency to reach the goal platform were not due
to the inability of the rat to see the external maze cues. There were no differences observed in
the latency to locate the visual platform across treatment groups.
Experiment 3
Study Rationale
The hippocampus, a brain structure critical for learning and memory, is known to be
vulnerable to TBI (Dixon et al., 1987; Hicks et al., 1996; Lowenstein, Thomas, Smith, &
McIntosh, 1992). Lateral fluid percussion injury has been shown to produce cell loss within the
CA3, hilus, and DG of the hippocampus (Dietrich, Alonso, & Halley, 1994; Hicks et al., 1996;
McIntosh et al., 1989). The time course and regional variability for neuronal loss in the
hippocampus was evaluated following lateral FPI in rats (Sato, Chang, Igarashi, & Noble, 2001).
Injured animals were evaluated at the following time points postinjury: 3 hr, 1, 3, 7 and 28 days.
Affected cells were identified using Fluoro-Jade, a marker of irreversible cell damage that stains
the axon, cell body, and processes of apoptotic and necrotic cells (Hornfelt, Edstrom, & Ekstrom,
1999; Schmued, Albertson, & Slikker, Jr., 1997); silver staining, used to detect degenerating
neurons; and terminal deoxynucleotidyl transferase nick-end labeling (TUNEL), used to identify
irreversibly damaged neurons by labeling fragmented DNA. Quantification of cell loss was
evaluated from three adjacent slices directly beneath the site of injury. Pyramidal neurons in the
hippocampus, CA1, CA2, and CA3, exhibited Fluoro-Jade staining at 3 hours, and on PID 1
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through 7, with the most intense staining observed on PID 1 in the CA1 region. The relative
number of Fluoro-Jade postitive structures on PID 7 was significantly reduced as compared to
PID 1 and was nonexistent on PID 14. Brain slices adjacent to those used for Fluoro-Jade were
processed using silver stain and TUNEL in the brains of animals from the 3 hour and 1 day time
points. These adjacent slices exhibited silver staining and TUNEL-positive cells that
corresponded to the same regions that were marked by the Fluoro-Jade (Sato et al., 2001). The
study by Sato did not perform histological examination of the dentate hilar region of the
hippocampus; however, in a different study that also used the lateral FPI model, a marked
increase in Fluoro-Jade B positive cells was detected in the ipsilateral hilus at 6 and 12 hours
postinjury. Analysis of this region at 24 hours postinjury found a significant decline in FluoroJade B positive cells, suggesting that by 24 hours significant cell death has occurred (Lee &
Agoston, 2009).
The Giemsa stain is a hematoxylin and eosin stain that is useful for histology because of
the high-quality staining of chromatin and the nuclear membrane, the metachromasia of some
cellular components, and the different qualities of cytoplasmic staining depending on the cell
type (Barcia, 2007). This stain is composed of methylene blue, azure B, and eosin. Methylene
blue and azure B, basic dyes, bind to acidic cellular components (e.g., DNA, RNA, neutrophilspecific granule matrices, platelets, and ribosome-rich cytoplasm). Eosin, the acidic part of the
stain, binds to basic cellular components (e.g., hemoglobin, eosinophilic granual contents, and
basic cellular proteins) (Woronzoff-Dashkoff, 2002). Differentiation of neuronal types within
the hippocampus is determined by color. Neurons within the CA3 and hilus stain violet in color
and neurons within the DG stain a blue or dark blue color.
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Previous studies that have examined post-TBI cell survival in the hippocampus found that
7 days postinjury was sufficient for significant cell loss to have occurred. Following this time
point there is little evidence for further significant cell death (Sato et al., 2001). The analysis of
neuronal survival within the CA3 and hilus may correlate with alterations in MWM performance
following lateral FPI. To evaluate this potential interaction, animals were treated daily for 7
days postinjury. To address this question, hippocampal neurons within the CA3 and hilar
regions were counted using unbiased stereological methods, optical dissector and fractionators
sampling (West, Slomianka, & Gundersen, 1991).
Hypotheses
Injured vehicle-treated rats will have significantly fewer healthy neurons in both the
CA3 and hilus, as compared to sham animals. It is also hypothesized that injured lithium-treated
rats will have more surviving neurons in these subregions of the hippocampus as compared to
injured vehicle-treated rats.
Specific Aims
The aim of the present study is to evaluate the effect of lithium treatment on cell survival
in the ipsilateral CA3 and hilar regions of the hippocampus.
Methods
Animals underwent surgical preparation identical to that described in Chapter 2, General
Methods. Twenty-four hours after surgical preparation, on the day of injury, animals were
randomly assigned to one of three treatment groups: TBI-Vehicle (n = 4), TBI-Lithium (n = 4),
and Sham-Vehicle (n = 4). Postinjury neurological assessment and preparation/administration of
the 0.25 mmol/kg dose of lithium was identical to that described in Experiment 1. Treatment
with either lithium chloride (0.25 mmol/kg) or 0.9% saline was initiated 30 min post- TBI or
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sham injury. Both the lithium and saline were administered via intraperitoneal injection, in a
volume of 1 ml/kg. Injections with lithium or saline were continued daily for 7 days. The same
animals were used to obtain the cell counts from the CA3 and hilus.
Tissue preparation. On PID 7, animals were sacrificed by an overdose of sodium
pentobarbital (200 mg/kg, ip) to effect and subsequently underwent transcardial perfusion with
500 ml of 0.9% saline, followed by 500 ml of 4% paraformaldehyde in 0.1M phosphate-buffered
saline (PBS). After completing the perfusion process the brain was excised and placed in 4%
paraformaldehyde for 24 – 48 hr and then stored in PBS solution. Coronal slices of brain tissue,
60 μm thick, were cut using a vibratome (Leica VT1000s). Sections of cortex were collected
from bregma -2.30 mm through -4.16 mm, based on stereotaxic coordinates obtained from a rat
atlas (Paxinos & Watson, 1982), including the area beneath the injury site. The tissue was
mounted on microscope slides (Superfrost/Plus) and allowed to air-dry overnight prior to Giemsa
staining.
Giemsa cell staining. 10% Giemsa solution was prepared fresh and heated in an oven to
60 °C. Slides were placed in a staining dish placed indirectly under tepid running tap water and
allowed to soak for 3 min. The slides were then placed into the pre-heated Giemsa staining
solution, in a 60 °C oven, for 30 min. The slides were then removed from the oven and soaked
in tepid indirect running tap water for 2 min. The slides were then differentiated in 0.5% Acetic
acid for 1 - 2 min, at which point the intensity of the stain was assessed by visual inspection
under a microscope. Once the desired stain intensity was reached, the slides were quickly rinsed
in dH2O and placed in 95% alcohol for 1 min. This was followed by two, 1 min immersions in
100% alcohol and then two 5 min immersions in Xylene. Separate glass staining dishes were
used for each solution. Slides were then coverslipped using permount and allowed to dry.
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Hippocampal cell counts. The number of neurons in the hippocampal subregions, CA3
and hilus, was determined by using unbiased stereological methods, optical dissector and
fractionators sampling, with the Olympus image system CAST program. Every third coronal
hippocampal section for a total of 10 sections per brain was examined. This ensured that 120 μm
would separate the slices used for counting and thereby prevented counting the same cell twice.
The dissector was set to count cells within the range of -3 μm to -15 μm and the step size across
each section was fixed at 175 μm. The sampling areas were outlined under a 10X objective
while cell counting was done under a 64X oil immersion lens. Giemsa stained neurons (dark
blue/violet) in the CA3 and hilus region were counted. Neurons were identified by their distinct
morphological features; only those cells with a clearly defined nucleolus within a defined nuclear
membrane were included in the counts. Additionally, a cell was counted only when the
nucleolus of that cell first came into focus within the specified depth (12 μm) of the dissector
frame, and part or all of the soma was within the frame of the counting box but not touching the
bottom or left sides of the frame and/or the extensions of these lines. Due to the scarcity of
neurons within the hilar region, all cells with a neuronal phenotype were counted to ensure
accurate cell counts. Alternately, within the CA3 region, due to the high density of cells,
counting frames, randomly selected by the CAST software, representing 12% of the sampling
area samples was used in establishing the cell counts for this region. The 12% parameter used
for the CA3 region yielded cell counts above 150 cells per brain in injured vehicle-treated rats,
the group that is expected to have the greatest hippocampal cell loss. Based on the article by
West and colleagues, counting 100 – 200 cells per brain ensures the accuracy of the results (West
et al., 1991).
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CA3. The CA3 region of the hippocampus, or regio inferior, consists of roughly half of
the pyramidal cell layer, the other half is the CA1, or regio superior. The CA3 region contains
pyramidal cells that are larger in size as compared to those found in the CA1. The border
between CA2 and CA3 served as one of the anatomical markers that were used when delineating
the CA3 region of interest. CA2 is the narrow zone of pyramidal neurons that forms the
transition between CA3 and CA1, distinguishable by the mixing of neurons with large and small
cell bodies. The other boundary was represented by an imaginary plane, perpendicular to the
suprapyramidal and infrapyramidal blades of the DG. This imaginary plane marks the transition
of CA3 neurons from a tightly packed grouping of cell bodies, roughly 4 – 5 cells deep, to a
distinctly less organized, loosely packed formation (West et al., 1991).
Hilus. The hilus was defined as the crescent-shaped area between the C-shaped blades of
the DG, excluding the loosely packed cells of the CA3 that extend into this area. This region
contains large, lightly packed polymorphic cells with a uniform distribution (West et al., 1991).
There are several neuronal types found within the hilus, including mossy cells, granule cells,
basket cells, multipolar cells and fusiform cells. Only those cells with a pyramidal shape were
included in the cell counts in this study (i.e., no granular cells).
Statistical analysis. A one-way ANOVA was performed to determine the relationship
between treatment groups and neuronal survival within the CA3 and hilus. Where appropriate, a
Fisher LSD test was performed to compare specific groups of interest.
Results
CA3 cell counts. The number of healthy cells in the CA3 was calculated using unbiased
stereological methods. These data are presented in Figure 20. A one-way ANOVA revealed a
significant difference between treatment groups F(2,9) = 11.727, p .003. A Fisher LSD post hoc
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analysis revealed a significant effect of injury. Animals in the TBI-Vehicle group had
significantly greater (p = .001) cell loss in the CA3 region as compared to animals in the ShamVehicle group. Daily treatment with lithium following TBI significantly ameliorated injuryinduced cell loss in the CA3 region of the hippocampus (p = .022). Additionally, there was no
significant difference detected between the Sham-Vehicle and TBI-Lithium groups (p = .07).
Hilus cell counts. The graph in Figure 21 shows the group differences in cell survival in
the ipsilateral hilus. The comparison of the mean cell counts (± SEM) for each group revealed a
large difference between the Sham-Vehicle, M = 5782 (± 917) and injury groups, TBI-Vehicle,
M = 2275 (± 191) and TBI-Lithium, M = 3462 (± 386). A one-way ANOVA revealed a
significant difference in the hilar cell counts of the treatment groups, F(2, 9) = 9.302, p =.006. A
Fisher LSD post hoc analysis showed that the Sham-Vehicle group had significantly more cells
in the ipsilateral hilus as compared to both the TBI-Vehicle (p = .002) and TBI-Lithium (p =
.021) groups. No significant difference in hilar cell counts was detected between the TBIVehicle and TBI-Lithium groups (p = .185).
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Figure 20. Effect of post-TBI daily lithium treatment on cell survival in the ipsilateral
CA3 subregion of the hippocampus. The number of surviving cells was quantified using
stereological technique 7 days after injury or sham in the ipsilateral hippocampus.
Groups were treated with either vehicle (0.9% sterile saline) or lithium (0.25
mmol·kg·day), initiated 30 min postinjury (n = 4/group). Data are expressed as mean, ±
SEM. A one-way ANOVA indicated a significant group difference (p < .05) when
comparing the average cell counts for each group. Further comparisons using a Fisher
LSD post hoc analysis revealed significantly more healthy neurons in the CA3 region of
TBI-Lithium and Sham-Lithium groups as compared to the number of healthy CA3
neurons in the TBI-Vehicle group. No significant difference in cell survival was
observed between the TBI-Lithium and Sham-Vehicle groups. (*) indicate significant
group differences relative to Sham-Vehicle, additional between group comparisons are
indicated by braces. *p < .05. **p < .01.
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Figure 21. Effect of post-TBI daily lithium treatment on cell survival in the ipsilateral
hilar subregion of the hippocampus. The number of surviving cells in the hilus was
assessed 7 days after injury or sham, using stereological technique. Treatment groups
(n = 4/group) received daily injections with either vehicle (0.9% sterile saline, ip) or
lithium (0.25 mmol·kg·day, ip), initiated 30 min postinjury. Data are expressed as mean,
± SEM, of the total cell counts (x1000) for the ipsilateral hilar region. A one-way
ANOVA showed an effect of group. A Fisher LSD post hoc analysis determined that
there was a significant effect of injury on neuronal survival in the ipsilateral hilus. The
Sham-Vehicle group had a significantly larger number of neurons within the hilus as
compared to the TBI-Vehicle and TBI-Lithium groups. There was no appreciable
difference in number of cells within the ipsilateral hilar regions of the two injury groups.
(*) indicate comparisons made to the Sham-Vehicle group. *p < .05. **p < .01.
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Discussion
The CA3 and hilus are known to be selectively vulnerable to lateral FPI and are also
brain regions that are commonly affected following TBI in humans. Neuroprotective therapies
that can prevent secondary injury-induced cell loss or facilitate the repair of injured neurons are
hypothesized to mitigate vestibulomotor and cognitive sequelae associated with TBI. The
reported protective effect of lithium treatment against the induction of apoptosis in vitro as well
as in models of acute brain injury (e.g., MCAO, transient global ischemia) (Nonaka et al., 1998;
Ren et al., 2003; Rowe & Chuang, 2004) was the basis for our interest in the potential benefits to
cell survival following lithium administration in our injury model.
Cell loss in the CA3 and hilus regions of the hippocampus following lateral FPI has been
correlated with poorer performance in cognitive tasks such as the MWM. In accordance with
the findings of previous studies, the CA3 and hilus of animals in the TBI-Vehicle group showed
significant cell loss as compared to animals in the Sham-Vehicle group (Cortez et al., 1989;
Hicks et al., 1993; Sato et al., 2001; Smith et al., 1991). It was hypothesized that lithium
treatment would enhance cell survival in the CA3 and hilus regions of the hippocampus. The
data obtained from the ipsilateral CA3 region cell counts support the working hypothesis. Not
only did lithium treatment significantly increase cell survival as compared to the TBI-Vehicle
group, there was no significant difference found between the Sham-Vehicle and TBI-Lithium
groups. Based on these findings, we expected the same neuroprotective effects observed in the
CA3 would also be seen in the hilus. We were surprised to find that lithium treatment did not
show any benefit to cell survival in the hilus. Both the TBI-Vehicle and, to a lesser extent, TBILithium groups had significant cell loss as compared to the Sham-Vehicle group. Taken
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together, these data indicate that 7-day lithium treatment, initiated 30 min post-TBI, offers
significant protection to cells in the CA3 region but not the hilus.
A possible explanation for this observation is that the cells within the hilus are more
vulnerable to TBI-induced pathology as compared to those in the CA3 region, thus requiring
greater neuroprotection than that provided by the selected dose of lithium. This assumption is
supported by data from Lowenstein and colleagues, who found that, following lateral FPI, a
significant reduction in the number of healthy cells occurs bilaterally within the hilus, while no
significant changes are detectable in the number of surviving neurons within the CA3 region of
the hippocampus (Lowenstein et al., 1992), although this region has been shown in previous
research (Cortez et al., 1989; Hicks et al., 1993; Sato et al., 2001; Smith et al., 1991) as well as in
the present study, to be also selectively vulnerable to FPI. Additional insight into the regional
pattern of neuroprotection that we have observed is discussed in the article by Toth and
colleagues (1997), which identifies the existence of a temporal pattern of cell death in the hilus
following lateral FPI. In particular, these authors have reported that the primary damage to
neurons within the hilus occur at the moment of the fluid pulse and not as a result of delayed,
secondary injury processes. The authors showed this by means of the Gallyas silver stain, used
to detect injury to neuronal processes in a rapid fashion after an insult (Toth, Hollrigel, Gorcs, &
Soltesz, 1997). This silver stain accumulates in injured neurons presumably as a result of the
interaction of silver with charged monomers derived from the breakdown of polymeric
cytoskeletal elements, in a fashion similar to the intensification process occurring during
photography (Gallyas, Zoltay, & Dames, 1992; Toth et al., 1997). Thus, it is possible that the
damage to cells within the hilus occurs prior to the initiation of treatment with lithium.
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In a recent clinical study, brain tissue samples from 21 individuals, obtained surgically
during temporal lobectomies to alleviate temporal lobe epilepsy that developed after these
individuals sustained head trauma, were used for histopathological analysis of neuronal
organization and number in addition to other neurological inflammatory changes, and chronic
gliosis (Swartz et al., 2006). The individuals included in this study had no other risk factors for
epilepsy, defined by the authors as “family history, perinatal distress, prolonged febrile
convulsion, history of significant substance abuse, history of CNS infection, and history of other
CNS pathology”. Of the 21 neocortical specimens, 15 included hippocampal tissue and, of these,
11 were processed with cresyl violet (a stain used to identify nissl substance) and NeuN (used to
identify neurons). All 11 brains showed some degree of cell loss in the hilus, however, only
those samples with moderate to severe cell loss in the hilus, based on visual pathologic
examination, also had damage to other hippocampal regions (Swartz et al., 2006). Although the
samples from this clinical study were obtained from individuals with epilepsy, a neurological
disease that is associated with cell loss in the hippocampus even when it is not preceded by brain
injury, it does demonstrate an ordered progression of cell death in the hippocampus that starts
with the hilus.
Experiment 4
Study Rationale
At this time, the exact mechanisms of action through which lithium treatment protects the
brain are not clear. One reason for this is the widespread effect of lithium on multiple
neuroprotective targets and pathways, sometimes acting at several points within the same
pathway (Rowe & Chuang, 2004). Based on the known actions of lithium in the brain, it is
possible that lithium may protect against both the acute and chronic phases of secondary brain
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injury. The neuroprotective effects of this drug against excitotoxic insults and cell death,
detailed in the previous sections of this dissertation, suggest to us that lithium treatment may
reduce neuronal damage by acting on targets associated with the acute (excitotoxic) phase of
secondary injury. Additionally, lithium treatment is reported to promote neuronal reorganization
and plasticity, suggesting that this drug could facilitate functional recovery during the chronic
(hypofunctional) postinjury phase.
Long-term treatment with lithium has been shown to protect neurons against apoptosis,
prolong cell survival, and promote regeneration of axons in the mammalian brain (Chen et al.,
2000; Shaldubina et al., 2001). To elucidate further the potential mechanisms involved in
lithium-induced neuroprotection, we selected three markers: GAP-43, a measure of postinjury
structural reorganization; BDNF, an indicator of neuronal plasticity and neuroprotection; and
caspase-3, to evaluate apoptotic cell death. These markers are described in detail in the
following sections.
GAP-43. GAP-43 levels are widely accepted as a good marker for synaptic plasticity in
the adult CNS (Benowitz & Routtenberg, 1997; Christman, Salvant, Jr., Walker, & Povlishock,
1997; Emery et al., 2000; Hulsebosch, DeWitt, Jenkins, & Prough, 1998). This phosphoprotein,
specific to the central nervous system, is a primary constituent of growth cones that head the
extension of growing axons. GAP-43 is also known as protein F1, neuromodulin, neural
phosphoprotein B-50, axonal membrane protein GAP-43, calmodulin-binding protein P-57,
nerve growth-related peptide GAP43, neuron growth-associated protein 43, and PP46 (Kosik et
al., 1988). For the purposes of this thesis, and from this point onward, it will be referred to as
GAP-43. GAP-43 expression and axonal transport are only found in young animals and in
neurons undergoing reorganization (e.g., following brain injury) (Karns, Ng, Freeman, &
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Fishman, 1987; Skene, 1989). The function of GAP-43 is to regulate the interactions between
the membrane skeleton/cytoskeleton components and plasma membrane (Meiri & GordonWeeks, 1990; Meiri, Pfenninger, & Willard, 1986). The activity of this protein is shaped by
extracellular signals such as phosphorylation (e.g., PKC), calmodulin (CaM) binding, and
calcium-dependent proteolysis (Apel, Byford, Au, Walsh, & Storm, 1990; Apel & Storm, 1992).
When GAP-43 is phosphorylated it is associated with growing axons whereas unphosphorylated
GAP-43 is associated with retracting axons. Previous literature showed increases in GAP-43
levels as early as 48 hours following TBI (Emery et al., 2000; Hulsebosch et al., 1998) and
continuing for up to 28 days postinjury (Christman et al., 1997; Hulsebosch et al., 1998).
Several studies, using a variety of injury models, have reported increased GAP-43
messenger and protein expression. The involvement of GAP-43 in structural remodeling,
neurogenesis, and induction of LTP have lead to a general consensus that increased expression
postinjury is indicative of a period of enhanced plasticity (Christman et al., 1997; Emery, Royo,
Fischer, Saatman, & McIntosh, 2003; Hulsebosch et al., 1998). Following axotomy in the CNS,
GAP-43 is upregulated and rapidly transports to distal parts of the axon (Tetzlaff, Alexander,
Miller, & Bisby, 1991). In a previous study, using the central FPI model, GAP-43 protein
expression was significantly increased in the hippocampus and cortex of injured animals
(Hulsebosch et al., 1998). Another study, using the same injury model in cats, found that injured
axons expressed increased levels of GAP-43 protein for up to 28 days postinjury (Christman et
al., 1997). Following lateral FPI, in a rat model, GAP-43 levels were increased in the
hippocampus of injured animals as compared to sham animals. This increased expression was
observed at 48 and 72 hr postinjury in several hippocampal subregions, but decreased over time
(Emery et al., 2000). These aforementioned effects of FPI-induced injury on GAP-43 expression
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were observed following moderate-severity brain injuries. However, following severe brain
injury, produced by CCI, there was no change in GAP-43 protein expression in either the
hippocampus or cortex (Thompson, Gibson, Thompson, Deng, & Hall, 2006). These data taken
together suggest that there is a negative correlation between injury severity and postinjury GAP43 expression. This indicates that the degree to which the injured brain is able to modulate
mechanisms involved in neuroplasticity is linked to the severity of the injury.
BDNF. Brain derived neurotrophic factor (BDNF) is a neurotrophic factor that is
important in the survival, growth, and plasticity of several neuronal types, including dorsal root
ganglion, hippocampal, and cortical neurons (Binder & Scharfman, 2004; Fukumoto et al., 2001;
Huang & Reichardt, 2001; Mai, Jope, & Li, 2002). Strong support exists for the role of BDNF in
LTP in multiple brain regions, including the hippocampus (Binder & Scharfman, 2004; Mai et
al., 2002). The effects of BDNF are mediated by the TrkB receptor, part of a family of tyrosine
kinases that act as receptors for several other neurotrophins. Activation of the TrkB receptor is
important for initiating multiple signaling cascades such as the PI3K/Akt and MEK/ERK
pathways, regulating transcription factors, and controlling gene expression. This receptor is also
necessary for the induction of LTP in the hippocampus. (Barnabe-Heider & Miller, 2003; Binder
& Scharfman, 2004).
To determine a potential mechanism of action for lithium’s reported neuroprotective
effects, Fukumoto et al. (2001) investigated the effect of lithium treatment on several
neurotrophic factors, including BDNF. Male Wistar rats were fed a 2% lithium-carbonate diet
for 1, 7, 14, and 28 days. BDNF levels in the hippocampus, temporal cortex, and frontal cortex
were measured by ELISA. There were no differences in BDNF levels on treatment day 1
between the lithium-chow and regular-chow fed rats. However, 14 and 28 days of treatment
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significantly increased BDNF expression in both the hippocampus and temporal cortex. In the
PFC of lithium-treated rats, expression was significantly increased at 14 days, with a trend
towards significance on day 28 (Fukumoto et al., 2001). In contrast, a study by Angelucci and
colleagues (2003) determined that chronic (6 week) lithium treatment did not significantly
increase BDNF levels in the hippocampus as determined by ELISA (Angelucci, Aloe, JiménezVasquez, & Mathé, 2003). However, there were several differences in the methodologies
employed in the Angelucci study as compared to the Fukumoto study. These differences include
the estimated serum concentration of lithium (0.5 mEq/L vs. 1.02 ± 0.04 and 0.80 ± 0.02
mEq/L), duration of treatment (6 weeks vs. 2 and 4 weeks), and strain of rat used (Flinders
Sensitive Line and Flinders Resistant Line vs. Wistar) (Angelucci et al., 2003; Fukumoto et al.,
2001).
Lithium alone has been shown to increase the expression of BDNF in the hippocampus
and cortex of rats (Fukumoto et al., 2001) as well as the overall brain expression of BDNF
mRNA (Nibuya, Morinobu, & Duman, 1995). Increases in BDNF expression have been
observed in specific regions of the hippocampus as early as 30 min following mild- and
moderate-severity FPI (Hicks et al., 1999; Hicks, Zhang, Dhillon, Prasad, & Seroogy, 1998;
Truettner et al., 1999). A significant increase in BDNF mRNA expression in the DG of the
hippocampus was reported at 1 hr and remained elevated for up to 72 hr following lateral FPI.
Within the CA3 region, significant increases in BDNF mRNA expression was observed between
1 – 6 hours postinjury. However, at 24 hr postinjury, expression levels had returned to sham
values. These alterations in BDNF expression indicate that these increases are related to
neuroprotection and plasticity (Hicks, Numan, Dhillon, Prasad, & Seroogy, 1997; Hicks et al.,
1998).
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A recent clinical study using serum acquired by immunoaffinity capillary electrophoresis,
reported a negative correlation between neurotrophin levels (BDNF, CNTF, NT-3, NT-4, betaNGF) and severity of head injury. Specifically, the serum concentration of BDNF among
patients with severe brain injuries was 93% lower as compared to the BDNF concentration found
in mild brain-injured patients (Kalish & Phillips, 2009). BDNF expression has been also
associated with improved outcome following spinal cord injury when infused continuously after
treatment with the drug methylprednisolone (Kim & Jahng, 2004).
Caspase-3. Cysteinyl aspartate-specific proteinase-3 (caspase-3) was selected as a
marker for apoptosis. Several studies have investigated the neuroprotective effects of lithium
against a variety of insults and have correlated activated caspase-3 inhibition with improved
outcome (Xu et al., 2003). Additionally, the inhibition of pro-apoptotic caspases following TBI
is speculated to improve outcome by preventing secondary injury-induced cell loss.
Caspases are part of a family of cysteine proteases that are involved in the initiation of
apoptosis. So far, there are 14 identified mammalian caspases (Nicholson & Thornberry, 1997).
They are synthesized as pro-enzymes that subsequently undergo proteolysis and activation by
other caspases in a sequential fashion. Based on function, caspases can be categorized into three
classes. The first two are initiator and effector caspases and are involved in apoptosis. The third
class is related to cytokine maturation. Only the initiator and effector caspases (i.e., those
involved in apoptosis) will be discussed further.
Initiator caspases include caspase-2, -9, -8, -10, and CED-3. These caspases have a long
prodomain (e.g., DED or caspase recruitment domain) that allows the interaction between the
caspases and the complexes that activate them. This interaction results in the cleavage and
thereby activation of the initiator caspase, allowing it to activate an effector caspase. Effector
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caspases include caspase-3, -6 and -7. These caspases have a short prodomain that is removed
by cleavage following activation, leaving a large and small subunit (Lawen, 2003). All cleavage
occurs after aspartate (Asp) residues. Effector caspases are also known as executioner caspases
because once they are activated, cell death is imminent.
The proform, or inactive form of caspase-3, is a 32-kDa protein synthesized in the
cytoplasm until it is cleaved, thereby activating the 17-kDa active form of caspase-3. Based on
previous findings from Tseng and Lin-Shiau (2002), 24 hr pre-incubation with lithium did not
afford any neuroprotection to cultured neurons. Additionally, following a 3 day pre-incubation
period, lithium was able to only partially protect neurons; significant neuroprotection was not
observed until 6 or more days of pre-incubation (Tseng & Lin-Shiau, 2002). However, Ren et al.
(2003), using an in vivo model of ischemia (MCAO), found that a single dose of lithium
effectively reduced neurobehavioral deficits and infarct size 24 hr post-insult. Neurobehavioral
deficits were assessed using ten different tests for motor, sensation, and reflex abnormalities.
This study also reported that daily treatment with lithium for 7 days, initiated 3 hours post-insult,
was able to minimize caspase-3 activation and DNA damage, as determined by a significant
reduction in TUNEL staining (Ren et al., 2003).
Hypotheses
GAP-43. The TBI-Lithium group will have elevated GAP-43 levels as compared to TBIVehicle and Sham-Vehicle groups. Both injured groups will have increased GAP-43 protein as
compared to the Sham-Vehicle group on PID 7. The relative abundance of GAP-43 protein in
the TBI-Lithium group will be higher as compared to the TBI-Vehicle group on PID 1 and 7. By
PID 21 we expect that all treatment groups will have similar levels of GAP-43 protein.
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BDNF. It is hypothesized that relative abundance of BDNF protein within the ipsilateral
hippocampus of animals in the TBI-Lithium group will be significantly increased as compared to
the other treatment groups on PID 1. The TBI-Lithium group will have higher levels of BDNF
protein as compared to both the TBI-Vehicle and Sham-Vehicle groups on PID 21.
Caspase-3. In Experiment 3, we found significant cell loss in the CA3 region of the
hippocampus among animals in the TBI-Vehicle group as compared to both the TBI-Lithium and
Sham-Vehicle groups. Based on these data, in addition to the reported antiapoptotic effects of
pre-insult lithium treatment in other models of brain injury, we hypothesize that lithium
treatment after lateral FPI will significantly ameliorate TBI-induced increases in apoptosis via
the inhibition of activated caspase-3, on PID 1 and 7. We also theorize that animals in the TBILithium group will have significantly higher levels of proform caspase-3 expression as compared
to TBI-Vehicle. Additionally, animals in the TBI-Vehicle group, as compared to Sham-Vehicle,
are expected to have significantly greater levels of activated caspase-3 protein with a
concomitant reduction in the expression of proform caspase-3 at both postinjury time points. We
do not expect to find significant differences between the TBI-Lithium and Sham-Vehicle groups.
Specific Aims
The aim of this experiment was to evaluate, in the ipsilateral hippocampus, potential
mechanisms of action for the observed neuroprotective effects of lithium treatment. Expression
levels of GAP-43 protein were used to assess structural remodeling on PID 1, 7, and 21.
Neuronal plasticity was assessed by analysis of BDNF protein expression on PID 1, 7, and 21.
Lastly, caspase-3 levels were evaluated to determine the impact of postinjury lithium treatment
on apoptosis.
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Methods
Four animals per treatment group (i.e., TBI-Vehicle, TBI-Lithium, Sham-Vehicle) per
time point (i.e., PID 1, 7, 21) were used for the protein analysis using a western blot technique (N
= 36). Each rat was anesthetized using 4% isoflurane gas, in a carrier gas of 70% (nitrous
oxide):30% (oxygen), for 4 min. The anesthetized animal was immediately decapitated and the
brain quickly removed from the skull. The hippocampus was bilaterally dissected on an ice-cold
glass plate and was quickly transferred to a centrifuge tube containing 125µl RIPA lysis buffer
(1x RIPA, Upstate; 1 tablet Complete Protease Inhibitor, Roche). Samples were homogenized
and centrifuged at 14,000g for 20 min at 4 ºC. Aliquots of the supernatant were transferred into
tubes and stored at -80 °C.
Western blot. Total protein concentrations in each sample were assessed using a
FLUOStar microplate reader and BCA Protein Assay Kit (Pierce, 23227). Samples were diluted
1:20 and the final amount of protein loaded into each lane was 20μg. Sample buffer (7.5 µl) and
reducing agent (1.5 µl) were added to each tube prior to heating the samples for 5 min at 95 ºC.
After heating, the samples were loaded onto SDS-PAGE precast gels (12% Bis-Tris Criterion
XT, Bio-Rad), and were run using 1x MES Running Buffer (Bio-Rad) at 150 V for 1 hour. Once
competed the separated gels were then transferred to PVDF membranes (Bio-Rad, 100V, 1 hour)
using Transfer Buffer (1x Tris/Glycine Buffer [Bio-Rad] + methanol). After the transfer was
complete, the gels were removed and stained with Coumassie Brilliant Blue to ensure complete
transfer to the membranes. The PVDF membranes were washed two times in nanopure water
and once in phosphate-buffered saline before blocking in 0.5% non-fat dry milk + 0.05% Tween
20 (milk TBS-T), for one hour on a shaker. After blocking, the PVDF membranes were
incubated at 4 ºC, overnight in milk TBS-T and the appropriate dilution of primary antibody.
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The following antibodies and dilutions were used: mouse monoclonal anti-GAP-43 (1:1000)
(Invitrogen, 7B10), rabbit polyclonal BDNF (1:300) (Santa Cruz Biotechnology, Inc., sc-546),
and rabbit monoclonal caspase-3 (1:1000) (Cell Signaling, MA, 9665). Mouse monoclonal antiβ-actin (1:1000) (Sigma Aldrich, A1978) was used as a control to ensure equal loading of the
protein. Membranes were washed six times in milk TBS-T, and incubated for 1 hour in milk
TBS-T with the appropriate dilution of the secondary antibody. Goat anti-mouse secondary
antibody conjugated to horseradish peroxidase (1:20,000, Rockland) was used for GAP-43 and
β-actin; goat anti-rabbit secondary antibody conjugated to horseradish peroxidase (1:20,000,
Rockland) was used for BDNF and caspase-3. Each membrane was thoroughly washed in TBST and developed for 5 min with Dura SuperSignal (Pierce). The blots were then imaged using
GeneSnap and GeneTools software (Syngene). Negative controls were used to verify the
absence of nonspecific binding of the secondary antibody. These blots received identical
treatment with the exception of omitting the primary antibody, see Figure 18.
Western strip and re-probe. The GAP-43 blots corresponding to PID 1 and 7 were
stripped and re-probed using the caspase-3 antibody. These blots were selected for re-probing
because the bands of interest for the two antibodies, GAP-43 (45-kDa) and caspase-3 (17-kDa &
32-kDa), do not overlap. Additionally, the specificity of the GAP-43 antibody (a solitary band at
45-kDa) removed any question regarding the authenticity of the bands observed after using the
caspase-3 specific antibody. All of the blots were stripped and re-probed for β-actin, used as a
load control. Each PVDF blot was stripped and re-probed no more than three times, including βactin.
Positive control. A positive control for activated caspase-3 was used to confirm the
ability of the selected antibody to detect both the 32-kDa, proform and 17-kDa, activated form of
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the pro-apoptotic marker caspase-3. Samples containing staurosporine in cell lysate were
obtained from Cell Signaling Technologies, MA. Three levels (low, medium, high) of
staurosporine + cell lysate and cell lysate alone were loaded onto a SDS-PAGE precast gel (12 %
Bis-Tris Criterion XT, Bio-Rad) along with 3 samples each from TBI-Vehicle, TBI-Lithium, and
Sham-Vehicle groups from PID 1, selected for comparison. All samples were prepared using the
same protocol detailed in the western blot section of the methods. The PID 1 time point was
selected based on the findings from previous studies that showed the highest levels of activated
caspase-3 expression in the hippocampus occurred between 24 – 48 hr post-TBI (Conti,
Raghupathi, Trojanowski, & McIntosh, 1998; Knoblach et al., 2002; Newcomb, Zhao, Pike, &
Hayes, 1999).
Statistical analysis. The relative abundance of the proteins of interest for TBI-Vehicle,
TBI-Lithium, and Sham-Vehicle treatment groups were standardized to, and reported as, the
percent of Sham-Vehicle. The raw value from the relative optical density from each subject was
divided by the average optical density of the corresponding Sham-Vehicle group and converted
into a percent. Each antibody, at each postinjury time point, was evaluated separately using a
one-way ANOVA. Additional comparisons were made to assess the change in protein
expression over time for each treatment group. A Fisher LSD post hoc analysis was performed
where appropriate.
Results
The following sections detail the results obtained from the quantification and statistical
analysis of the abundance of GAP-43, BDNF, caspase-3, and β-actin (used as a loading control)
protein in the ipsilateral hippocampus at the specified postinjury time points. Figures 22 and 23
show images of the blots used for the negative control. Figure 24 shows representative samples
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from each blot. The primary aim of this experiment is to evaluate if postinjury lithium-treatment
alters the relative abundance of the specified proteins of interest as compared to the TBI-Vehicle
and Sham-Vehicle groups. Although we did run and analyze samples taken from animals in the
Sham-Lithium group, to evaluate the actions of lithium alone on these proteins, these data do not
directly pertain to the specific aims of this experiment and as such the analysis of the ShamLithium group data will not be discussed in this chapter. A separate analysis of the relative
abundance of GAP-43, BDNF, and caspase-3 between the two sham-injured groups are
presented in Tables C1 – C3. The comparison of the two sham groups revealed that lithiumtreatment alone may have an effect on β-actin, a commonly used loading control. These data are
provided in Figure C1 in Appendix C. Additional analyses using an ANOVA and Fisher LSD
post hoc test where appropriate were performed on all four treatment groups (TBI-Vehicle, TBILithium, Sham-Vehicle, Sham-Lithium). These analyses compare the raw data (relative optical
density) and the raw data normalized to the load control β-actin, see Tables C4 – C6 in Appendix
C.
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Figure 22. Negative control for secondary antibody used with GAP-43 and caspase-3.
Protein from one animal per treatment group was run twice on a gel. The resulting
PVDF membrane was cut into strips, lanes 2 – 5 were incubated with the primary
antibody (1°) followed by the secondary antibody. This strip, labeled as +1°, shows that
the primary antibody is able to detect the 45 kilodalton (45 kDa) band corresponding to
the molecular weight of GAP-43 protein. The strip that contains lanes 7 – 9 was
incubated with the secondary antibody only. No bands were detected in lanes 7 or 8,
showing that there was no nonspecific binding associated with the secondary antibody.
Lanes 5 and 9 contain the standard MagicMark (MM), the molecular weights
corresponding to these bands are presented on the right of the minus primary (-1°) blot.
These blots clearly show that there was no nonspecific binding associated with the
secondary antibody.
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Figure 23. Negative control for secondary antibody used with BDNF. Protein from one
animal/treatment group was run twice on a gel. The resulting PVDF membrane was cut
into strips, lanes 2 – 5 were incubated with the primary antibody (1°) followed by the
secondary antibody. This strip, labeled as +1°, shows that the primary antibody is able
to detect the 14 kDa band corresponding to the molecular weight of BDNF protein. The
strip that contains lanes 7 – 10 was incubated with the secondary antibody only. No
bands were detected in lanes 7 – 9, showing that there was no nonspecific binding
associated with the secondary antibody. Lanes 5 and 10 contain the standard
MagicMark (MM), the molecular weights corresponding to these bands are presented
on the right of the minus primary (-1°) blot. These blots clearly show that there was no
nonspecific binding associated with the secondary antibody.
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45 kDa

14 kDa

35 kDa

Figure 24. Representative images from western blot analysis of GAP-43, BDNF,
caspase-3. This figure illustrates the relative abundance of protein for GAP-43, BDNF,
and caspase-3 for each treatment group, at each analyzed time point. The molecular
weight of each protein is indicated to the right of the images. There was no significant
difference in the relative abundance of β-Actin (43 kDa), used as a loading control,
across any of the blots.

GAP-43. This section contains the results from the statistical analysis of the betweengroup differences in the relative abundance of GAP-43 protein in the ipsilateral hippocampus for
each postinjury time point (PID 1, 7, 21). Additionally, the temporal changes in GAP-43 protein
expression were assessed for each treatment group.
PID 1 (GAP-43). Figure 25 illustrates the relative abundance of GAP-43 protein levels
in the ipsilateral hippocampus on PID 1 and analyzed as the percent of Sham-Vehicle. An oneway ANOVA revealed no significant difference in the relative abundance of GAP-43 protein on
PID 1, F(2, 9) = 2.047, p = .185.
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PID 7 (GAP-43). The relative abundance of GAP-43 protein on PID 7 among the three
treatment groups of interest are presented in Figure 26. A one-way ANOVA showed a
significant difference in GAP-43 protein levels on PID 7, F(2, 8) = 6.440, p = .022. A Fisher
LSD post hoc analysis revealed significantly greater abundance of GAP-43 protein in the TBILithium (p = .019) and Sham-Vehicle (p = .013) groups as compared to the TBI-Vehicle group.
There was no statistically significant difference between the TBI-Lithium and Sham-Vehicle
groups.
PID 21 (GAP-43). A one-way ANOVA was used to compare GAP-43 expression on
PID 21 and revealed significant between-group differences, F(2, 9) = 7.731, p = .011. Further
analysis using the Fisher LSD post hoc test showed that the TBI-Lithium group had appreciably
lower GAP-43 protein levels as compared to the Sham-Vehicle (p = .004) and TBI-Vehicle (p =
.037) groups. There was no significant difference between the TBI-Vehicle and Sham-Vehicle
groups. These data are presented in Figure 27.
Temporal changes in the relative expression of GAP-43.
TBI-Vehicle. The change in GAP-43 expression for each treatment group over time
revealed that there was no significant difference between groups in GAP-43 expression across
the postinjury time points, F(2, 9) = 0.743, p = .503.
TBI-Lithium. The analysis of the relative abundance of GAP-43 protein across days,
within the TBI-Lithium group, revealed that lithium treatment significantly altered the temporal
expression of this protein, F(2, 8) = 12.875, p = .003. A Fisher LSD post hoc analysis found that
GAP-43 protein expression on PID 1 was significantly elevated as compared to PID 7 (p = .05)
and PID 21 (p = .001). Additionally, GAP-43 protein levels on PID 7 were significantly

141

increased as compared to PID 21 (p = .044). The temporal changes in the relative expression of
GAP-43 across groups are illustrated in Figure 28.
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Figure 25. Western blot quantification of relative abundance of GAP-43 protein in
ipsilateral hippocampus on PID 1. The raw data are expressed as the mean percent of
Sham-Vehicle, ± SEM, (n = 4/group). An one-way ANOVA failed to detect any
significant between-group difference, F(2, 9) = 2.047, p = .185. We did notice a trend
towards elevated GAP-43 levels in the TBI-Lithium group as compared to the TBIVehicle group.
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Figure 26. Relative abundance of GAP-43 protein in the ipsilateral hippocampus on
postinjury day (PID) 7. TBI-Vehicle (n = 4), TBI-Lithium (n = 3), Sham-Vehicle (n = 4).
The raw data are expressed as the mean percent of Sham-Vehicle, ± SEM. An ANOVA
was used to compare the raw data and revealed a significant difference between
treatment groups. GAP-43 protein levels in the TBI-Vehicle group were significantly
lower as compared to the TBI-Lithium (p = .019) and Sham-Lithium groups (p = .013).
No difference was found between the Sham-Vehicle and TBI-Lithium groups.
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Figure 27. Relative abundance of GAP-43 protein in the ipsilateral hippocampus on PID
21. The raw data are expressed as the mean percent of Sham-Vehicle, ± SEM, (n =
4/group). An ANOVA revealed a significant effect of group. A Fisher LSD post hoc
analysis showed that the TBI-Lithium group had significantly lower GAP-43 expression
as compared to both the Sham-Vehicle and TBI-Vehicle groups. No difference was
detected between the TBI-Vehicle and Sham-Vehicle groups. Initial comparisons were
made to Sham-Vehicle, indicated by an asterisk(s); subsequent between-group
comparisons are indicated by a brace. *p < .05. **p < .01.
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Figure 28. Changes in the relative abundance of GAP-43 protein across days. The
graphs show the average optical density for each group compared relative to ShamVehicle, ± SEM. Separate ANOVAs were performed to compare changes in GAP-43
expression within the individual treatment groups across time, PID 1, 7, 21. There was
no significant change in GAP-43 protein levels in the TBI-Vehicle animals across the
three time points, p > .05. The TBI-Lithium group was the only group to show significant
changes in GAP-43 expression over time, p = .003. A Fisher LSD post hoc showed that
GAP-43 levels on PID 1 were significantly higher as compared to levels on PID 21 (p =
.001) and showed a trend suggesting higher levels of GAP-43 as compared to PID 21 (p
= .068). GAP-43 expression on PID 7 was significantly higher as compared to PID 21
(p = .033). Initial comparisons were made to PID 1; subsequent between-group
differences are indicated by a brace. Trends in the data are indicated by a brace with a
dashed line. *p < .05. ***p < .001.
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BDNF. This section contains the results from the statistical analysis of the betweengroup differences in the relative abundance of BDNF protein in the ipsilateral hippocampus for
each postinjury time point (PID 1, 7, 21). Additionally, the temporal changes in BDNF protein
expression were assessed for each treatment group.
PID 1 (BDNF). Figure 29 shows the raw data from the analysis of BDNF protein levels
on PID 1. The relative abundance of BDNF protein was assessed in the ipsilateral hippocampus
on PID 1 and analyzed as the percent of Sham-Vehicle. A one-way ANOVA showed there was
no significant difference in BDNF expression across groups on PID 1, F(2, 9) = 3.012, p = .10.
PID 7 (BDNF). The average percent change in BDNF protein levels on PID 7 was
analyzed using a one-way ANOVA. There was no significant difference in the relative
abundance of BDNF protein detected among the groups, F(2, 9) = 1.766, p = .225. However,
there was a trend toward elevated BDNF levels in the TBI-Lithium group as compared to the
TBI-Vehicle and Sham-Vehicle. These data are shown in Figure 30.
PID 21 (BDNF). The relative abundance of BDNF protein in the ipsilateral
hippocampus on PID 21 was evaluated across treatment groups. These data are presented in
Figure 31. A one-way ANOVA revealed a significant difference in BDNF levels between the
treatment groups, F(2, 9) = 17.579, p = .001. A Fisher LSD post hoc analysis of the data
revealed a significant decrease in the amount of BDNF protein detected in the TBI-Vehicle (p <
.001) and the TBI-Lithium (p = .004) groups relative to Sham-Vehicle. Additionally, we
observed a trend suggesting an increase in BDNF protein in the TBI-Lithium group as compared
to the TBI-Vehicle group (p = .081).
Temporal changes in the relative expression of BDNF. The temporal changes in BDNF
protein expression were evaluated for each of the treatment groups across the postinjury time
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points (PID 1, 7, 21). Figure 32 illustrates the raw data for each treatment group at each time
point, expressed as the percent change relative to the Sham-Vehicle. In the following
paragraphs, only the data from the TBI-Vehicle and TBI-Lithium groups will be discussed. The
reason for this is that the Sham-Vehicle group is the basis of comparison for all the treatment
groups, including itself. The statistical value of the F test is always equal to zero, and the p value
is always 1.00.
TBI-Vehicle. BDNF protein levels from each postinjury time point were analyzed using a
one-way ANOVA. A significant effect of time was observed, F(2, 9) = 24.402, p < .001. A
Fisher LSD post hoc analysis revealed that BDNF expression on PID 1 and PID 7 was
significantly higher as compared to expression levels on PID 21, p = .001 and p < .001
respectively. There was no significant difference in the relative abundance of BDNF protein
between PID 1 and PID 7, p = .170.
TBI-Lithium. The TBI-Lithium group showed significant changes in protein levels over
the three postinjury time points, F(2, 9) = 5.874, p = .023. A Fisher LSD post hoc test revealed
that BDNF expression was significantly higher on PID 1 (p = .01) and PID 7 (p = .033) as
compared to PID 21. No statistically significant difference was found between the PID 1 and
PID 7 time points (p = .474).
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Figure 29. Comparison of the relative abundance of BDNF protein levels in the
ipsilateral hippocampus on PID 1. These data are expressed as the percent of ShamVehicle ± SEM, (n = 4/group). No significant difference in BDNF protein amount was
detected among the treatment groups. However, there appears to be an increase in
BDNF protein levels in the TBI-Lithium group relative to the other groups.
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Figure 30. Comparison of the relative abundance of BDNF protein on PID 7.
These data are expressed as the percent of Sham-Vehicle ± SEM. No significant
difference in BDNF protein amount was detected among the treatment groups.
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Figure 31. Comparison of the relative abundance of BDNF protein on PID 21. Values
are expressed as percent of Sham-Vehicle ± SEM, (n = 4/group). A significant
difference was found between the Sham-Vehicle group and both injured groups. A
trend was observed suggesting that the relative abundance of BDNF in the TBI-Lithium
group was higher as compared to TBI-Vehicle. Initial comparisons were made to ShamVehicle. Trends in the data are indicated by a brace with a dashed line. **p < .01. ***p
< .001.
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Figure 32. Comparison of BDNF levels among individual treatment groups across time.
Values are expressed as percent of Sham-Vehicle ± SEM. Individual ANOVAs were
performed for each treatment group. A Fisher LSD post hoc analysis found significant
decreases in BDNF protein levels on PID 21 in both the TBI-Vehicle and TBI-Lithium
groups relative to the levels on PID 1 and 7. Significant between-group comparisons
are indicated using braces. *p < .05. **p ≤ .01. ***p ≤ .001.
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Caspase-3. Data from the statistical analysis of the relative abundance of the proform of
caspase-3 protein levels, at the two specified postinjury time points (PID 1, 7), are presented in
the following paragraphs. TBI-induced increases in activated caspase-3 protein levels have been
reported during the early postinjury phase (within 1 week of injury); therefore, we did not
examine the levels of this protein (activated or proform) on PID 21. The temporal changes in the
detected levels of proform caspase-3 within the TBI-Vehicle and TBI-Lithium groups are also
illustrated. We were not able to detect any activated caspase-3 in any of our samples.
Caspase-3 (PID 1). The proform of caspase-3 protein was evaluated across the treatment
groups as the percent of Sham-Vehicle. A one-way ANOVA revealed that there was no
significant difference in proform caspase-3 protein expression between the treatment groups,
F(2, 9) = 1.929, p = .201. These data are presented in Figure 33.
Caspase-3 (PID 7). We further investigated the potential neuroprotective effects of postTBI lithium treatment on apoptotic activity by analysis of the relative abundance of proform
caspase-3 protein in the ipsilateral hippocampus on PID 7. There was no significant difference
in proform caspase-3 expression across groups on PID 7, F(2, 8) = 1.594, p = .261. These data
are illustrated in Figure 34.
Temporal change in relative amount of proform caspase-3. The raw data showing the
relative change of proform caspase-3 levels for each treatment group are displayed in Figure 35.
These data show an apparent injury-induced increase in the detected levels of proform caspase-3
protein within the ipsilateral hippocampus from PID 1 to 7. There was no evidence of activated
caspase-3 in our samples. However, the trend towards elevated proform caspase-3 over time in
the TBI-Vehicle group suggests that activated caspase-3 plays a role during early postinjury time
points.
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TBI-Vehicle. The difference in proform caspase-3 levels for the TBI-Vehicle groups on
PID 1 and 7 were compared using an independent samples t-test, t(6) = -2.234, p = .067.
Although there was no significant difference detected between the two time points, there appears
to be a trend indicating increased proform caspase-3 levels on PID 7.
TBI-Lithium. The TBI-Lithium group did not exhibit significant alterations in the relative
abundance of proform caspase-3 protein between PID 1 and PID 7, t(5) = -1.428, p = .213.
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Figure 33. Comparison of proform caspase-3 levels on PID 1 across treatment groups.
Data from each treatment group (n = 4/group) are expressed as the percent of ShamVehicle ± SEM. An ANOVA failed to detect any significant differences between the
treatment groups. However, the TBI-Lithium group appears to have an increase in the
detected levels of proform caspase-3 protein as compared to the TBI-Vehicle group.
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Figure 34. Comparison of proform caspase-3 levels on PID 7 across treatment groups.
Data are expressed as the percent of Sham-Vehicle ± SEM. TBI-Vehicle (n = 4), TBILithium (n = 3), Sham-Vehicle (n = 4). No significant difference was detected in the
levels of proform caspase-3 across all treatment groups.
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Figure 35. Changes in proform caspase-3 protein levels over time. Data are presented
as the mean, ± SEM. Analysis of the raw data showed a trend for increased proform
caspase-3 on PID 7 as compared to PID 1 in the TBI-Vehicle group. No significant
difference was found between PID 1 and 7 in the TBI-Lithium group. Trends in the data
are indicated by a brace with a dashed line.
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Caspase-3 positive control. It was hypothesized that lithium was exerting
neuroprotective effects by preventing the activation of caspase-3. However, on the blots from
PID 1 and 7 there was an absence of the 17-kDa band corresponding to the activated caspase-3
protein. The positive control, using pre-prepared samples (Cell Signaling Technology, Inc.,
Boston, MA) clearly showed a band corresponding to the 17-kDa, activated caspase-3 protein, in
the lanes containing the normal cell lysate (NCL) + staurosporine only, see Figure 36. These
data confirm that the absence of a protein band for activated caspase-3 on the PID 1 and 7 blots
is legitimately due to the absence of detectable levels of this protein in our experimental samples,
thus confirming the accuracy of our findings from the both the PID 1 and 7 blots.

Figure 36. Image of positive control immunoblot used to detect activated caspase-3.
Image taken of the western blot that was used to evaluate the specificity of the caspase3 antibody for activated caspase-3 (17 kDa). The numbers on the right side correspond
to the molecular weights of the MagicMark (MM) protein standard. Normal cell lysate
(NCL) was used as a control (lane 7) and no activated caspase-3 was detected in this
lane. Low (L), medium (M) and high (H) indicate the relative level of apoptosis-inducing
staurosporine + NCL. Higher levels of staurosporine resulted in increased levels of
activated caspase-3, as evidenced by the dark band corresponding to the 17 kDa
activated caspase-3, in lanes 1, 3, and to a lesser extent lane 5. The analysis of the
positive control confirms the lack of activated caspase-3 in our samples.
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Discussion
We evaluated potential mechanisms of action for the observed lithium-induced
neuroprotective effects found in Experiments 1 – 3. Previously, we showed that chronic,
postinjury treatment with the selected dose of lithium chloride (0.25 mmol/kg, ip) was effective
in reducing TBI-induced cognitive and motor deficits. In addition, this dose was found to
significantly enhance neuronal survival in the ipsilateral CA3 region of the hippocampus
following lateral FPI. In the present study, the western blot technique was used to measure the
levels of GAP-43, indicative of axonal sprouting, to characterize the effect of lateral FPI and
postinjury lithium-treatment on this marker of plasticity. Additionally, the abundance of BDNF
protein, a neurotrophin that is reported to be involved in neuronal plasticity and neuroprotection,
was evaluated. The pro-apoptotic marker, caspase-3 was used to evaluate the effect of our injury
model and postinjury lithium treatment on TBI-induced apoptosis.
GAP-43. The relative optical density, used to quantify the abundance of GAP-43 protein
in the ipsilateral hippocampus, showed that there was no significant difference in the GAP-43
protein levels across the treatment groups on PID 1. This finding is in accordance with the
studies by Emery et al. (2000) and Hulsebosch et al. (1998), which reported that, 24 hr following
FPI, GAP-43 levels in the hippocampus were not significantly different from sham controls.
However, in another study, GAP-43 protein levels were significantly elevated in the ipsilateral
hippocampus at both 24 and 48 hr post-TBI (Thompson et al., 2006). The apparent disparity
between the findings from these studies are likely due to experimental differences; Hulsebosch
(1998) and Emery (2000) used the central and lateral FPI model respectively, whereas Thompson
(2006) used CCI. Additionally, there were differences in the postinjury time points selected for
evaluating GAP-43. With these factors taken together, their data collectively show increased
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levels of GAP-43 between 24 – 36 hr postinjury that decrease to baseline values or lower by 7
days postinjury (Emery et al., 2000; Hulsebosch et al., 1998; Thompson et al., 2006). This is
similar to what we observed in our study.
The analysis of the relative optical density of GAP-43 protein on PID 7 indicate that the
Sham-Vehicle and TBI-Lithium groups had statistically similar levels of GAP-43 protein and
that both groups had significantly higher levels of GAP-43 as compared to the TBI-Vehicle
group. Our finding that the TBI-Vehicle group had significantly lower levels of GAP-43 is
contrary to Emory et al. (2000), who reported no significant difference in GAP-43 protein levels
between injured- and sham-vehicle treated animals. Additionally, the in vitro study by Chen et
al. (2003) investigated the effects of 1 mmol/L lithium treatment on that healthy (i.e., uninjured)
hippocampal cells, treated for 7-days with lithium. They found that lithium-treatment resulted in
a slight increase in GAP-43 expression; however, it did not reach the level of significance (Chen,
Wang, Sun, & Young, 2003).
We hypothesized that on PID 7, GAP-43 protein levels would be increased in both TBI
groups relative to Sham-Vehicle and that the TBI-Lithium group would have increased GAP-43
protein levels relative to the TBI-Vehicle group. Our data, however, support a very different
outcome. Animals in the TBI-Vehicle group showed a significant decline in the relative
abundance of GAP-43 relative to TBI-Lithium and Sham-Vehicle groups. Furthermore, postTBI lithium treatment was able to completely reverse the injury-induced decrease in GAP-43
protein, returning it to sham levels. These data provide support for the role of GAP-43 as a
potential mechanism of action for lithium-induced neuroprotection in our injury model. The
significant increase in the relative abundance of GAP-43 protein levels on PID 7 in the TBILithium group relative to TBI-Vehicle could suggest that postinjury lithium-treatment supports
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neurite outgrowth, remodeling, and reorganization. Additional studies will be needed to evaluate
this hypothesis.
The final postinjury time point (PID 21) that we assessed for evidence of lithium-induced
axonal sprouting and remodeling by analysis of GAP-43 protein expression revealed a significant
decrease in GAP-43 levels in the TBI-Lithium group relative to the other treatment groups. This
finding was unexpected, but might indicate decline in structural remodeling several weeks after
injury in animals treated with lithium.
No changes were detected in the total amount of GAP-43 protein in the TBI-Vehicle
group across the three postinjury time points. However, the effect of postinjury lithiumtreatment did reveal a significant change in protein expression across the three time points. The
highest levels were observed on PID 1 and declined in a stepwise fashion over the remaining two
time points. These findings are contrary to previous studies that indicated that lithium treatment
had no significant effect on GAP-43 expression at 7-days in hippocampal neurons (Chen et al.,
2003). Taken together, these data suggest that post-TBI treatment with lithium may facilitate
structural remodeling in the ipsilateral hippocampus via modulation of growth cone activity.
BDNF. This neurotrophic factor was selected as a measure of neuroprotection and
neuroplasticity. During development of the nervous system, BDNF plays an important role in
neuronal survival and differentiation. In the adult brain, it is associated with neurogenesis,
neuroprotection, and plasticity (Gustafsson, Lindvall, & Kokaia, 2003). Downstream effects of
BDNF activation, such as those on synapsin 1 and CREB are linked to the regulation of synaptic
vesicles and, in so doing, neurotransmitter release and the induction of LTP respectively are also
linked to cognitive enhancing processes (Griesbach, Hovda, & Gomez-Pinilla, 2009; Silva et al.,
1998). Several studies have reported that BDNF alone administered prior to brain injury or
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insult is protective against injury-induced neuronal cell loss and cognitive deficits (Almli et al.,
2000). Additionally, a recent study by Griesbach (2009) showed that following lateral FPI,
exercise-induced increases in BDNF expression were correlated with markedly improved
performance in the MWM over injured-vehicle treated animals. The improvement in MWM
performance was blocked in animals treated with TrkB-IgG, an immunoadhesin chimera of the
TrkB receptor that prevented activation of this receptor by BDNF (Griesbach et al., 2009) . Our
hypothesis that BDNF might underlie the protective effect of lithium was based on the
observation chronic lithium administration is associated with significant increases in BDNF
expression in the rat hippocampus (Fukumoto et al., 2001).
Both injury- and lithium-treatment have each been shown to increase levels of BDNF
mRNA and protein in several brain regions, including the hippocampus (Hicks et al., 1996;
Hicks et al., 1999). In a previous study, using the lateral FPI model, significant increases in
BDNF mRNA levels were detected bilaterally in the DG (1 hr – 3 day) and CA3 (1 – 6 hr)
regions of the hippocampus (Hicks et al., 1997). Injury-induced changes in BDNF mRNA occur
within hours of the injury (Hicks et al., 1999) whereas it takes several days to detect significant
changes in hippocampal BDNF protein levels (Griesbach, Hovda, Molteni, & Gomez-Pinilla,
2002). Our data show that BDNF protein levels on PID 1 were not significantly altered
following lateral FPI. The delay between the expression of BDNF mRNA and the appearance of
BDNF protein may account for the lack of a significant increase in the relative abundance of
BDNF protein in the TBI-Vehicle and TBI-Lithium groups on PID 1.
On PID 7, both the TBI-groups showed a modest but non-significant increase in the
relative abundance of BDNF protein compared with Sham-Vehicle. The delayed increase in
BDNF protein, relative to the early increases in BDNF mRNA seen during the early postinjury
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period (Hicks et al., 1997), in both TBI groups could be indicative of the innate plasticity
response of the brain to injury. Following brain injury induced by intracerebroventricular
administration of kainic acid, Shetty, Rao, Hattiangady, Zaman and Shetty (2004) reported an
injury-induced increase in BDNF levels in the hippocampus 4-days postinjury.
In the present study, we found that the relative abundance of BDNF protein in the
ipsilateral hippocampus was significantly reduced in both injured groups relative to sham. Our
hypothesis that BDNF protein levels in the TBI-Vehicle group would be significantly decreased
relative to Sham-Vehicle on PID 21 is supported by our findings. Further support for the
observed TBI-induced reductions in BDNF protein on PID 21 comes from a previous study that
showed BDNF mRNA levels were significantly reduced in the ipsilateral hippocampus on PID
21 following CCI (Griesbach, Sutton, Hovda, Ying, & Gomez-Pinilla, 2009). Fukumoto (2001),
had reported that chronic lithium-treatment, for 14 and 28 days, resulted in a significant increase
in hippocampal BDNF expression. We hypothesized that increased BDNF levels associated with
chronic lithium treatment (Fukumoto et al., 2001) would outweigh the TBI-induced deficits in
BDNF expression (Griesbach et al., 2009). Based on our data, chronic post-TBI lithium was
associated with a trend suggesting increased BDNF protein levels over TBI-Vehicle. However,
the amount of BDNF protein detected in the TBI-Lithium group was significantly less than
Sham-Vehicle. It is interesting that on PID 7 and PID 21, both TBI groups showed similar
trends in the relative abundance of BDNF protein that was detected. Specifically, in both injured
groups the levels of this protein were elevated on PID 7 and significantly decreased on PID 21.
The parallel effects on these days could reflect neurochemical alterations in this neurotrophic
factor that are purely the result of injury-induced processes and not an effect of lithium
treatment. However, due to the sample size in our treatment groups and the large volume of
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tissue (whole hippocampus) used for the western blot analysis, subtle changes in BDNF protein
levels may have been masked. Additional studies with increased sample sizes in addition to
immunohistochemistry techniques would be needed to confirm the observed effects of post-TBI
lithium administration on BDNF levels in the hippocampus.
Caspase-3. One of the reported mechanisms through which lithium exerts
neuroprotective effects is the prevention of apoptosis by blocking the activation of caspase-3.
However, there was no detectable expression of the activated form of caspase-3 on either PID 1
or 7. Expression of the proform of caspase-3 was detectable in all the treatment groups at both
postinjury time points; however, there was no significant difference in proform caspase-3 levels
between any of the treatment groups on either PID 1 or PID 7. These findings do not support our
hypothesis that activated caspase-3 expression will be increased on PID 1 and 7 in the TBIVehicle groups.
The presence of apoptotic cells following TBI was reported in the DG and CA3 regions
of the hippocampus 24 hr after mild or moderate severity lateral FPI, in vehicle-treated rats (Rink
et al., 1995). Additionally, significant increases in caspase-3 have been reported following CCI
in rats (Clark et al., 2000; Springer, 2002; Tweedie et al., 2007). In contrast to these studies, the
17-kDa band, corresponding to the activated caspase-3 protein, was absent in our TBI groups.
To rule out any technical problems, we used a positive control that contained normal cell lysate,
with and without staurosporine, and ran them on a separate blot with selected samples from PID
1. Analysis of these data confirmed the presence of activated caspase-3 in the positive control
samples only, thus supporting our initial findings that there was no activated caspase-3 in our
experimental samples.
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The findings from the present study do not support the hypothesis that activated caspase3 would be elevated in the ipsilateral hippocampus following injury. A possible explanation is
that activated caspase-3 levels had peaked and declined by the time the animals were sacrificed.
Indeed, Rink et al. (1995) reported that cells undergoing necrosis and apoptosis can be
eliminated within a few hours. Conti et al. (1998) reported prominent, but non-significant,
increase in the number of cells with apoptotic morphologies in the ipsilateral hippocampus at 12
and 48 hr following lateral FPI. The increase in apoptosis reported by Conti (1998) temporally
coincides with the decrease in proform caspase-3 on PID 1 observed in the TBI-Vehicle group,
relative to the TBI-Lithium and Sham-Vehicle groups, in the present study. The decrease in
proform caspase-3 could be attributed to its conversion to an activated state. Alternately, it is
possible that that the cell death in the ipsilateral hilus and CA3 regions of the hippocampus,
observed in injured rats from Experiment 3, was primarily due to necrosis.
Another possibility is that the hippocampal subregions affected by apoptosis at the
selected postinjury time points were disproportionally small, and when compared to the entire
hippocampus, the presence of this protein was masked. It was reported that following lateral
FPI, the presence of apoptotic cells was not localized to any one area of the hippocampus.
Instead, these cells were scattered throughout the structure (Conti et al., 1998). Furthermore,
Conti (1998) identified larger numbers of cells with apoptotic appearance in the cortex. It is
possible that the lithium-induced neuroprotective effects that were observed in Experiments 1 &
2 were produced, in part, by lithium’s effects in other brain regions. Further study is needed to
evaluate the effects of post-TBI lithium-treatment on other brain regions, particularly those
regions important in learning and memory that are also known to be vulnerable to TBI-induced
pathology (e.g., prelimbic cortex).
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General Discussion
Our experiments have provided strong evidence to support the neuroprotective effects of
lithium and its use as a therapeutic agent in the treatment of the sequelae associated with TBI.
The present study indicates that (i) low doses of lithium chloride initiated 30 min after lateral FPI
and administered daily are effective in reducing TBI-induced deficits in vestibulomotor and
cognitive function; (ii) treatment with the selected dose of lithium can be delayed up to 8 hr postTBI and still provide similar beneficial effects associated with the 30 min treatment; (iii) chronic
low-dose lithium is associated with significant cell survival in the CA3 but not in the hilar region
of the hippocampus of the injured rats.
Dose of lithium and time window for neuroprotection after TBI
Previous research in animal models of stroke have shown that pre- or post-injury
administration of lithium, at doses equal to or below those used in the clinical setting for the
treatment of BAD, achieves neuroprotection (Nonaka & Chuang, 1998; Ren et al., 2003; Xu et
al., 2003; Yan et al., 2007; Yan et al., 2007). The current study, which assessed the effect of
postinjury administration of lithium in a rat model of lateral FPI, provides further evidence in
support of the neuroprotective role of this agent. Among the four doses of lithium that we tested
(1.00, 0.50, 0.25, 0.125 mmol/kg, ip), only the 0.125 and 0.25 mmol/kg doses, administered 30
min after injury, significantly ameliorated TBI-induced cognitive deficits, as assessed by
performance in the MWM. To date, only one other study, employing a rat model of ischemic
injury, has reported on the beneficial effects of postinjury administration of lithium (Ren et al.,
2003). The aforementioned study focused on the lithium-promoted recovery of neurological
functioning, assessed by performance on tests evaluating motor, sensory, and reflex abilities.
The authors of the study found that lithium treatment with doses ranging from 0.50 – 3.00
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mmol/kg, initiated up to 3 hr after the onset of MCAO, significantly improved
injury/reperfusion-induced neurological deficits, evaluated at 24 hr, 7 and 14 days post-ischemic
injury (Ren et al., 2003). Similarly, in our study we detected improvements in the motor
performance on the BW task (PID 1, 3, 7) of our injured-lithium treated animals. However, we
observed that the 1.00, 0.25 and 0.125 mmol/kg doses improved BW performance whereas the
0.50 mmol/kg dose did not. This phenomenon of varying physiologic response to different
dosages of a neuroprotective agent has been previously described in various models of brain
injury (Calabrese, 2008). Dawson et al. (2001) found that the most effective dose for reducing
infarct volume in a MCAO mouse model for ischemic injury did not always improve motor
performance, and in some cases significantly impaired it (Dawson, Wadsworth, & Palmer,
2001).
In Experiment 1, the two most effective doses were 0.25 and 0.125 mmol/kg. Although
both doses improved MWM performance in TBI-Lithium animals over the TBI-Vehicle treated
group, the 0.25 mmol/kg dose was selected for use in Experiment 2, as the degree of cognitive
improvement achieved with this dose was higher (although not significantly) than that observed
with the lower 0.125 mmol/kg dose.
Based on the results from Experiment 2, lithium appears to provide neuroprotection even
when its administration is delayed up to 8 hr (but not 24 hr), postinjury. This finding makes
lithium a good candidate for evaluation in TBI clinical trials, as the elapsed time between the
occurrence of a traumatic event and the administration of a test drug in humans is estimated to be
4 hours, which takes into account the arrival of the patient at the hospital and the subsequent
acquisition of an informed consent for study enrollment.
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Mechanism of the neuroprotective effects of lithium
In vitro studies have shown that lithium is effective in preventing cell death induced by a
variety of cellular insults (Chen et al., 2003; Hennion et al., 2002; Hongisto et al., 2003; Nonaka
et al., 1998; Rametti, Esclaire, Yardin, Cogne, & Terro, 2008; Senatorov, Ren, Kanai, Wei, &
Chuang, 2004). Similarly, cell death reduction with lithium treatment has been documented by
in vivo studies showing decreased infarct volume following ischemic brain injury (Ren et al.,
2003; Yan et al., 2007; Yan et al., 2007), and reduced TUNEL staining following exposure to
neurotoxins (Ghribi, Herman, Spaulding, & Savory, 2002) or radiation (Yazlovitskaya et al.,
2006).
In the present study, we sought to investigate potential mechanisms of action for the
observed lithium-induced neuroprotective effects observed in Experiments 1 – 3. Specifically,
we assessed the neuroprotective properties of lithium by means of western blot analysis of the
relative abundance of the proteins GAP-43 and BDNF, selected as measures of postinjury
structural reorganization and plasticity (Hashimoto et al., 2002) , and by measurement of
proform and activated caspase 3, markers of apoptosis.
BDNF expression has been associated with improved outcome in TBI (Griesbach et al.,
2009) and previous research has shown that lithium alone increases the expression of BDNF in
the hippocampus and cortex of rats, as well as the overall brain expression of BDNF mRNA. In
particular, lithium-induced neuroprotection has been correlated, in several models of injury, with
increased expression of BDNF and its primary receptor TrkB, and a study by Hashimoto et al.
(2002) provides strong evidence in support of this interaction. These authors demonstrated that
the protective effects of lithium-treatment against glutamate induced neurotoxicity in cortical
cells could be blocked by treatment with either an inhibitor of the TrkB receptor or a neutralizing
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antibody specific to BDNF. Additionally, cortical neurons from BDNF knockout mice were not
protected by lithium, thus further supporting the important role of BDNF-TrkB interactions in
lithium-induced neuroprotection (Hashimoto et al., 2002).
Results from our Experiment 4 indicate that the amount of BDNF protein, assessed by
western blot analysis, was appreciably higher in TBI-Lithium animals on PID 1. This increase,
however, was only transient, and on PID 21 BDNF levels were significantly decreased as
compared to Sham-Vehicle. This finding was unexpected, given the plethora of data in the
literature pointing at the significance of the BDNF-TrkB interaction in mediating the
neuroprotective effects associated with lithium (Chuang, 2004; Chuang, 2005; D'Mello et al.,
1994; Ghribi et al., 2002; Manji & Duman, 2001; Mora et al., 1999; Xu et al., 2003). It must be
noted, however, that our study is the first to investigate the effects of this drug in an experimental
model of TBI.
We also performed analysis of GAP-43, a neural-specific calmodulin binding protein,
which is a major protein kinase C substrate found in developing and regenerating neurons. We
found that on PID 1, the relative abundance of GAP-43 was noticeably elevated in the TBILithium group as compared to the TBI-Vehicle group. This suggests that post-TBI lithiumtreatment not only protects against the observed injury-induced decrease in GAP-43, it elevates
levels of this protein relative to Sham-Vehicle. The small sample size and greater variability in
the relative abundance of GAP-43 protein levels among animals in the TBI-Vehicle and ShamVehicle groups on PID 1 could have masked the effect of postinjury lithium treatment on GAP43. In addition to increasing the sample size, immunohistochemical analysis the levels of GAP43 protein in specific regions of the hippocampus or quantification of mRNA using ELISA
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would provide additional, more specific, information regarding the effects of post-TBI lithium
administration on GAP-43 levels in the hippocampus.
On PID 7 we found that the relative abundance of GAP-43 was significantly decreased in
the TBI-Vehicle group as compared to both the Sham-Vehicle and TBI-Lithium groups. This
finding suggests that, relative to the Sham-Vehicle group, the abundance of GAP-43 protein in
animals in the TBI-Vehicle is lessened on PID 1 and significantly reduced on PID 7.
Additionally, these data indicate that, in the injured brain, lithium-treatment continues to protect
against TBI-induced decline in GAP-43 for up to 7 days postinjury, maintaining the relative
abundance of this protein at Sham-Vehicle levels. However, by PID 21, we observed that the
levels of GAP-43 in the TBI-lithium group significantly rebounded to Sham-Vehicle levels. This
is in contrast to the significant decrease in the relative abundance of GAP-43 protein in the TBILithium group as compared to both the Sham-Vehicle and TBI-Vehicle groups. Based on the
study by Emery et al. (2000) the postinjury timeframe associated with increased GAP-43 levels
is between 48 -72 hrs; later postinjury assessment time points including 1, 2, and 4 weeks
postinjury were not associated with changes in GAP-43 abundance relative to sham controls
(Emery et al., 2000; Hulsebosch et al., 1998). We interpret these data to indicate that the most
likely timeframe for postinjury lithium-induced effects on neuronal remodeling most likely occur
within the first 7-days after injury.
It is believed that the inhibition of post-TBI activation of pro-apoptotic caspases
improves outcome by preventing secondary injury-induced cell loss. In agreement with this,
several studies have linked the neuroprotective effects of chronic lithium treatment with the
inhibition of apoptotic pathways. Specifically, it has been shown that lithium treatment prevents
injury-triggered pro-apoptotic events such as cytochrome c translocation, decreases in anti-
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apoptotic Bcl-2, and increases in pro-apoptotic Bax, GSK-3β, and tau (Chen et al., 1999;
D'Mello et al., 1994; Ghribi, Herman, & Savory, 2003; Li et al., 2002; Manji et al., 1999; Manji,
Moore, & Chen, 2000b; Mora et al., 1999; Rametti et al., 2008; Xu et al., 2003). Nevertheless,
the results of our western blot analysis indicate that only the proform of caspase-3 was present at
PID 1 and 7, with no significant between-group differences in protein expression. Activated
caspase-3 was not present in any of the experimental groups.
Taken together, our findings indicate that postinjury lithium treatment is significantly
effective in reducing injury-induced motor and cognitive deficits, and that this treatment is
effective in reducing post injury cognitive and motor dysfunction even when delayed up to 8hours following TBI. Treatment with this drug is also associated with a marked reduction in cell
death in the CA3 region of the hippocampus, a structure that is critical to memory formation and
retrieval. Although lithium has a very narrow therapeutic range, the dose that was most effective
in our study is well within that limit. These encouraging findings support further testing of
lithium in clinical TBI studies.
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Figure A1. Comparison of motor performance pre- and post-TBI. Lines represent the
mean latency for each treatment group (n = 10/group) across days, ± SEM. A split-plot
ANOVA showed that there was a significant effect of group. A Fisher LSD analysis
revealed that the two sham groups had significantly shorter latencies to reach the goal
box as compared to the TBI-0.50 and TBI-Vehicle groups. There was no significant
difference between the sham groups and the TBI-1.00, TBI-0.25, and TBI-0.125 groups.
All the doses of lithium are mmol/kg. Vehicle treated animals received 0.9% sterile
saline. All treatments were administered in a volume of 1 mg/kg. (*) indicate significant
differences as compared to Sham-Vehicle. (†) indicate comparisons made to the Sham1.00 group. *p ≤ .05. **,†† p ≤ .01. ***p ≤ .001. Specific statistical information is
provided in the text.
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Figure A2. MWM data from Experiment 1. This graph shows the daily average latency
to reach the goal platform for each treatment group (n = 10/group), ± SEM. A split-plot
ANOVA and Fisher LSD post hoc revealed that the TBI-Vehicle group had significantly
longer latencies to reach the goal platform as compared to the TBI-0.125, TBI-0.25,
Sham-Vehicle, and Sham-1.00 groups. None of the groups performed as well as the
Sham-Vehicle group. All doses of lithium are in mmol/kg. (*) indicate comparisons to
Sham-Vehicle. (†) indicate comparisons to Sham-1.00. (‡) show comparisons made to
TBI-30 min. (•) indicate comparisons to TBI-8 hr. *p < .05. **, ††, ‡‡, ••p < .01. ***, †††p <
.001.
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Figure A3. Proximity score from MWM hidden platform testing in Experiment 1. This
graph shows the daily average proximity score for all treatment groups (n = 10/group)
during MWM testing, ± SEM. All doses of lithium are in mmol/kg. Vertical lines
represent SEM. A repeated measure ANOVA revealed a significant difference among
the average daily proximity scores of the treatment groups. A Fisher LSD post hoc
found that the two sham groups had significantly lower proximity scores (indicating
better performance) as compared to the TBI-Vehicle group. The two injured groups that
had significantly shorter latencies to reach the goal platform as compared to the TBIVehicle group during the hidden platform testing, TBI-0.25 and TBI-0.125, had
significantly higher proximity scores as compared to the Sham-Vehicle group, however,
they did not significantly differ from the Sham-1.00 group. There was no appreciable
difference in the proximity scores of the TBI-Vehicle group and the TBI lithium-treated
groups. (*) indicate comparisons to the Sham-Vehicle group. (†) indicate comparisons
made to the Sham-1.00 group. **, ††p < .01. ***p < .001.
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Figure A4. Analysis of the proximity score for each group during the probe trial in
Experiment 1. The data are expressed as the mean, ± SEM. An ANOVA found
significant differences between the treatment groups. A Fisher LSD post hoc revealed
that the Sham-Vehicle group had a significantly lower proximity score as compared to
all other treatment groups. *p < .05. **p < .01. ***p < .001.
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Appendix B
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Figure B1. Comparison of performance on beam walk task across groups in
Experiment 2. These data represent the mean latency to reach the goal box, ± SEM.
TBI-Vehicle (n = 10), TBI-30 min (n = 10), TBI-8 hr (n = 10), TBI-24 hr (n = 9), Sham-24
hr (n = 9), Sham-Vehicle (n = 10). The TBI-30 min group data is the TBI-0.25 from
Experiment 1 and is included in the data analysis as a basis for comparing the
effectiveness of the selected dose of lithium when the initiation of treatment is delayed.
The TBI-8 hr and TBI-30 min had significantly shorter latencies to reach the goal box as
compared to the TBI-Vehicle and TBI-24 hr groups. (*) indicate comparisons to ShamVehicle. (†) indicate comparisons to Sham-1.00. (‡) compare to TBI-30 min. (•) indicate
comparisons to the TBI-8 hr. ‡,• p < .05. **, ††, ‡‡ p < .01. ***, †††p < .001.
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Figure B2. Comparison of MWM performance across groups in Experiment 2. Data are
the mean latency for each treatment group, TBI-Vehicle (n = 10), TBI-24 hr (n = 9), TBI8 hr (n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n = 9), ± SEM.
The TBI-30 min group data is identical to the TBI-0.25 from Experiment 1 and is
included in the data analysis as a basis for comparing the effectiveness of the selected
dose of lithium when the initiation of treatment is delayed. An ANOVA, followed by a
Fisher LSD post hoc analysis, showed that the Sham-Vehicle, Sham-24 hr, TBI-8 hr and
TBI-30 min groups had significantly faster latencies to reach the goal as compared to
the TBI-Vehicle andTBI-24 hr groups. The TBI-8 hr and TBI-30 min groups had longer
latencies to the goal platform as compared to the Sham-Vehicle group. There was no
significant difference in MWM performance between the two sham groups. (*) indicate
comparisons to Sham-Vehicle. (†) indicate comparisons to Sham-24 hr. (‡) denote
comparisons to the TBI-30 min group. (•) indicate comparisons to the TBI-8 hr. *, ‡, •p <
.05. **, ††, ‡‡p < .01. ***, †††p < .001.
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Figure B3. Proximity score during hidden platform testing in the MWM from Experiment
2. The average proximity score for each treatment group TBI-Vehicle (n = 10), TBI-24
hr (n = 9), TBI-8 hr (n = 10), TBI-30 min (n = 10), Sham-Vehicle (n = 10), Sham-24 hr (n
= 9) over the four days in the MWM was compared using a split-plot [6 (group) x 4 (day)]
ANOVA. A Fisher LSD was used to compare individual differences among the groups.
The TBI-30 min group data is the TBI-0.25 from Experiment 1 and is included in the
data analysis as a basis for comparing the effectiveness of the selected dose of lithium
when the initiation of treatment is delayed. The TBI-30 min (p = .031), TBI-8 hr (p =
.03), Sham-Vehicle and Sham-24 hr (p < .001) groups had significantly lower proximity
scores, indicating a more direct route to the hidden platform location, as compared to
the TBI-Vehicle group. The TBI-24 hr group had significantly higher proximity scores as
compared to the Sham-Vehicle (p = .001) and Sham-24 hr (p = .008) groups. The
proximity scores for the TBI-30 min and TBI-8 hr groups were significantly higher than
Sham-Vehicle (p = .034 and .036 respectively) but did not differ from the Sham-24 hr
group (p = .122 and .128 respectively). (*) indicate comparisons made to the ShamVehicle group. (†) indicate comparisons made to the Sham-24 hr group. (#) indicate
comparisons made to the TBI-Vehicle group. *, #p < .05. ††p < .01. ***, †††p < .001.
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Figure B4. Proximity score from probe trial in Experiment 2. The mean proximity score
for each treatment group, obtained from the 60 s probe trial (no platform in MWM) on
postinjury day (PID) 15. The TBI-30 min group data is the TBI-0.25 from Experiment 1
and is included in the data analysis as a basis for comparing the effectiveness of the
selected dose of lithium when the initiation of treatment is delayed. The bars represent
the mean ± SEM. A Fisher LSD post hoc analysis revealed that the Sham-Vehicle (p =
.039) and Sham-24 hr (p = .009) groups had significantly lower scores (i.e., took the
most direct route and remained closest to the previous location of the hidden goal
platform) as compared to the TBI-Vehicle group. Neither the TBI-30 min (p = .07) nor
the TBI-8 hr (p = .314) significantly differed from the Sham-Vehicle group. (*) indicate
comparisons made to Sham-Vehicle. (†) indicate comparisons made to the Sham-24 hr
group, *, †p < .05. ††p < .01.
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Appendix C

The Sham-Lithium group was included in the western blots to determine if lithium alone had any
effect on the relative abundance levels of the proteins of interest, GAP-43, BDNF, and caspase-3.
The raw values from the relative optical density from each subject were divided by the
corresponding value from the analysis the β-actin, and the resulting value was converted to the
percent of Sham-Vehicle.
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Sham-Lithium
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Figure C1. Comparison of β-actin levels between sham groups. Lithium is associated
with a relative abundance of β-actin at multiple time points after injury. Data are
expressed as mean ± SEM. The analysis of the β-actin protein levels were not
consistent across all treatment groups and blots, indicating that there were differences
in the total concentration of proteins loaded on the gel. However, β-actin, a cytoskeletal
protein, appears to be differentially affected by lithium-treatment and injury. The levels
of β-actin protein in the Sham-Lithium group show a significant increase in this protein
as compared to other treatment groups, suggesting that lithium treatment may affect βactin. *p < .05. ***p < .001.
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Table C1.
Comparison of GAP-43 levels between Sham-Vehicle and Sham-Lithium groups in the
ipsilateral hippocampus for each postinjury time point

Note. An independent samples t-test was used to compare the raw data (relative
optical density) and data normalized to β-actin between Sham-Vehicle and ShamLithium groups at each postinjury time point. All data are expressed as the % ShamVehicle. PID = postinjury day.

211

Table C2.
Comparison of BDNF levels between Sham-Vehicle and Sham-Lithium groups in the
ipsilateral hippocampus at each postinjury time point

Note. An independent samples t-test was used to compare the raw data (relative
optical density) and data normalized to β-actin between Sham-Vehicle and ShamLithium groups at each postinjury time point. All data are expressed as the % ShamVehicle. PID = postinjury day.
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Table C3.
Comparison of proform caspase-3 levels between Sham-Vehicle and Sham-Lithium
groups in the ipsilateral hippocampus at each postinjury time point.

Note. An independent samples t-test was used to compare the raw data (relative
optical density) and data normalized to β-actin between Sham-Vehicle and ShamLithium groups on PID 1 & 7. All data are expressed as the % Sham-Vehicle. PID =
postinjury day.
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